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ABSTRACT 
 
Dengue fever, a mosquito-borne viral disease has become a major
 
worldwide public 
health problem with a dramatic expansion in
 
recent years. Similarly, Japanese encephalitis 
(JE) is one of the leading causes of acute
 
encephalopathy affecting children
 
and adolescents 
in the tropics. There is neither an antiviral therapy nor any effective vaccine available for 
dengue. Early diagnosis plays a crucial role to forecast an early warning of epidemic and to 
undertake effective vector control measures for dengue and Japanese encephalitis. Envelope 
domain III (EDIII) protein is involved in binding to host receptors and it contains speciﬁc 
epitopes that elicit virus neutralizing antibodies.  
The objective of the present work is to develop high yield and scalable production 
process for recombinant dengue and Japanese encephalitis envelope domain III proteins in 
Escherichia coli, purification process to achieve high purity and biologically active protein as 
well as their characterization for use as diagnostic reagent in enzyme linked immunosorbent 
assay (ELISA) and possible vaccine candidate molecule. Expression of EDIII proteins of JE 
and Dengue viruses was carried out in recombinant Escherichia coli. Developments of cost 
effective and simple culture media as well as appropriate culture conditions are generally 
favorable for large scale production of recombinant proteins. Optimization of culture media 
was carried out for enhanced production of EDIII protein in E. coli. Laboratory scale batch 
fermentation process in E. coli was developed using optimized media and culture conditions. 
Furthermore, fed-batch fermentation process was also developed in optimized medium. 
Expression of this protein in E. coli was induced with isopropyl β-D-thiogalactoside. The 
protein was overexpressed in the form of insoluble inclusion bodies (IBs). Cells were 
disrupted using sonicator or agitator bead mill and IBs were purified. For diagnostic studies, 
the protein was purified under denaturing conditions using affinity chromatography. The 
affinity chromatography purified protein was used as an antigen to develop enzyme linked 
immunosorbent assay (ELISA) to detect antibodies in infected serum and CSF samples. 
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In order to take this vaccine candidate for further studies, recombinant EDIII protein 
was produced employing a pilot scale fermentation process.  Recombinant EDIII protein 
expressed as inclusion bodies was solubilized in the presence of urea and renatured by on-
column refolding protocol in the presence of glycerol. A three-step purification process 
comprising of on-column refolding with affinity chromatography, ion-exchange 
chromatography (IEX) based on salt, and IEX based on pH was developed. The purity of the 
recombinant EDIII protein was checked by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis analysis, and reactivity of this protein was determined by Western blotting 
and ELISA. Biological function of the refolded and purified EDIII protein was confirmed by 
their ability to generate EDIII-specific antibodies in mice that could neutralize the virus. 
These findings suggest that recombinant EDIII protein is highly immunogenic and elicit 
high-titer neutralizing antibodies. These results establish the application of these proteins to 
be used for the diagnosis of JE and Dengue virus infection or for further studies in vaccine 
development. This process may also be suitable for the high-yield production of other 
recombinant viral proteins.  
Keywords: Dengue. Japanese Encephalitis. Domain III protein. Escherichia coli. 
Media optimization. Bioreactor. Batch fermentation. Fed-batch process. Centrifugation. Cell 
disruption. Purification. Affinity chromatography. Antibodies. ELISA. Scale up. Pilot scale 
fermentation. Ultrafiltration. Ion-exchange chromatography. Vaccine.   
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INTRODUCTION 
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1.1 GENERAL BACKGROUND 
Dengue is a mosquito-borne viral disease and has become a major
 
worldwide public 
health problem. In India, Dengue cases have accelerated enormously with high morbidity and 
mortality rate in the last two decades (Chaturvedi and Nagar, 2008). As dengue virus has four 
serotypes, infection with one-serotype results in lifelong immunity to it but there is no cross-
protection against the others. Thus, a vaccine must be tetravalent and capable of 
simultaneously inducing a high level of long-lasting immunity to all four serotypes (Block et 
al., 2010; Guzman et al., 2010). There is neither a therapeutics nor any effective vaccines 
available for dengue infection till date. Similarly, Japanese encephalitis (JE) is a major public 
health problem in Southeast Asia and Western pacific including India. The diagnosis of JE 
infection is primarily based on symptomatic evaluation of the patients as there is a lack of 
suitable test for JE infection (Shrivastva et al., 2008; Robinson et al., 2010). The available 
vaccine for JE is based on inactivated native viral culture which may produce biohazard 
(Alka et al., 2007; Li et al., 2009). As majority of JE virus infected patients report in rural
 
hospitals with limited facilities, there is a need for a simple
 
and reliable diagnostic test, 
appropriate for such settings.  
Due to unavailability of effective vaccine or therapeutics, early diagnosis plays a 
crucial role in an early warning of an epidemic, undertake effective vector control measures 
and patient management also (Abhyankar et al., 2006; Blacksell et al., 2006). Most of the 
recombinant DNA-based strategies focus on the envelope (E) and nonstructural (NS1) 
proteins of dengue and JE viruses (Wu et al., 2003; Zhang et al., 2007). The E protein is 
organized into distinct domains designated as I, II and III. Of these, domain III, stabilized by 
a single disulfide bond, is particularly important from the viewpoint of diagnostic and 
vaccine development (Hapugoda et al., 2007; Tan and Ng, 2010). NS1 protein can also be 
used for early diagnosis of JE and Dengue infections (Lin et al., 2008; Konishi et al., 2009). 
Recent developments and success in recombinant subunit protein vaccine for several viral 
diseases opened new opportunities in dengue and JE vaccine research. Keeping in view of 
the present scenario of severity and spread of dengue and JE, studies on process development 
and evaluation of new candidate recombinant antigens for possible diagnostic and vaccine 
development is the need of the hour. Therefore, in the present work we intend to develop a 
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process for high yield production and to evaluate the diagnostic and vaccine potential of JE 
and dengue virus envelope domain III proteins. 
Recent developments in biochemical engineering and biotechnology involve 
production of biologicals like vaccines, recombinant proteins, monoclonal antibodies, etc. 
Demand for these biological products has increased because they are being used in 
therapeutic, prophylactic and diagnostic purposes (Panda, 2004; Huang et al., 2012). The key 
component of the commercial success of any biopharmaceutical product is the ability to 
achieve large-scale production (Buckland, 2005; Huang et al., 2012). The ultimate goal of 
fermentation research is the cost effective production of desired recombinant protein by 
maximizing the volumetric productivity (Manderson et al., 2006). Escherichia coli is the 
most commonly used host for heterologous protein production because it is a well-
characterized organism in term of genetics, physiology and culture conditions (Shiloach and 
Fass, 2005). Protein expression level depends on culture conditions, such as medium 
composition, induction time and inducer concentration, which can be optimized for over-
expression of recombinant proteins. Recombinant E. coli can be grown to high densities in 
complex media, semi-defined and defined media (Manderson et al., 2006; Khamduang et al., 
2009; Babaeipour et al., 2010). The composition of the growth media is crucial for enhancing 
product formation (Bhuvanesh et al., 2010). Small scale expression is widely used for 
optimizing conditions for a large-scale production of recombinant proteins (Mazumdar et al., 
2010).  
The scale up process of recombinant proteins production may be performed by 
replacing commonly used shake flasks to lab scale batch or fed-batch fermentations and pilot 
scale batch fermentations (Bell et al., 2009; Mazumdar et al., 2010). To facilitate the 
purification of recombinant proteins, the proteins are commonly produced as a fusion 
proteins that comprise of the protein fused with an affinity tag, such as the hexahistidine tag 
(Wang et al., 2009; Bhuvanesh et al., 2010). High-level expression of recombinant proteins 
in E. coli often accumulates as insoluble aggregates in the form of inclusion bodies. To 
recover active protein, inclusion bodies must be solubilized and refolded (Fahnert et al., 
2004; Khalilzadeh et al., 2008). Recombinant protein purification using the minimum 
possible steps is crucial to meet the required level of purity. Immobilized metal ion afﬁnity 
chromatography (IMAC) has become a well-established and versatile technique for both 
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analytical and large scale of protein separations. Chemical chaotropes have been traditionally 
used to solubilize proteins from inclusion bodies (Fahnert et al., 2004). Refolding is usually 
achieved by removing the chaotrope via buffer exchange after solubilizing the inclusion 
bodies, using dilution, dialysis or diaﬁltration. Protein refolding by liquid chromatography is 
an alternative to the dilution refolding and has been put much highlight in recent years 
(Wang et al., 2009). IMAC has the potential to perform protein refolding with high recovery 
of purified recombinant proteins. After the preliminary purification using affinity 
chromatography, the purity level of these proteins can be further enhanced by ion exchange 
or size exclusion chromatography. Biologically active and purified protein can be used for 
evaluation of diagnostic and vaccine potential for dengue and Japanese Encephalitis.  
1.2 ORIGIN OF THE PROBLEM 
Dengue is an endemic viral disease affecting tropical and subtropical
 
regions around 
the world. The World Health Organization estimates that there may
 
be 50 million to 100 
million cases of dengue virus infections
 
worldwide every year, which result in 250,000 to 
500,000 cases
 
of Dengue hemorrhagic fever (DHF) and 24,000 deaths. In India, Dengue 
hemorrhagic fever and Dengue shock syndrome (DSS) cases have accelerated enormously 
with high morbidity and mortality rate in the last two decades indicating a serious resurgence 
of dengue virus infection. There is no suitable treatment for dengue infection and no effective 
dengue vaccines till date. 
Japanese encephalitis (JE) is a major viral encephalitis problem in Southeast Asia 
with around 50,000 cases and 10, 000 deaths every year affecting mostly children in rural 
area. The laboratory diagnosis of Japanese encephalitis infection is complicated due to non 
availability of suitable immunological assays in these areas. Though an inactivated vaccine is 
available, however its efficacy and coverage is not yet complete. 
There is currently a need for developing cost-effective, safe and simple diagnostic test 
that combines high sensitivity and specificity which may be applicable in both laboratory as 
well as field conditions. This could as well be used for vaccine studies to control Dengue and 
JE virus infections. Envelope protein of dengue and JE virus may be very attractive 
diagnostic and vaccine candidate. The recombinant proteins are to be produced with high 
yield, by optimization of fermentation conditions. Production of these proteins obviates 
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expensive and time-consuming virus production in cell culture and the associated biohazard 
risk. It may be stated that the recombinant protein based kits will be cost effective and 
surpass other serodiagnostic tests with its applicability in laboratory as well as in field 
conditions with comparable sensitivity and specificity. Further, large amount of purified 
protein produced by optimized process may be used in vaccine studies.  
1.3 OUTLINE OF THE PRESENT WORK 
 The present study mainly deals with the production and purification of recombinant 
proteins of JE and dengue viruses and their characterization for use as a diagnostic reagent to 
develop detection system for JE and dengue. The outline of this study is: 
 Expression of domain III protein of dengue viruses and Japanese Encephalitis 
(JE) virus domain III and nonstructural 1 (NS1) protein in E. coli. 
 Optimization of media for production of domain III protein of JE and Dengue 
virus as well as NS1 protein of JE virus. 
 Batch and fed batch fermentation for production of domain III and NS1 
proteins in E. coli. 
 Scale-up of fermentation processes to 100 liters for domain III proteins. 
 Development of purification strategy to achieve high purity and biologically 
active  domain III proteins.  
 Evaluation of above proteins as a diagnostic intermediate employing ELISA 
in diagnosis of Dengue and JE infections. 
 Determination of biological activity of domain III protein of JE virus for their 
possible vaccine potential.  
1.4 ORGANIZATION OF THE THESIS  
 This thesis contains ten chapters. The present chapter, chapter 1 is an introductory 
chapter. In chapter 2, a detailed review of the literature pertinent to the previous works done 
in this field has been listed.  Chapter 3 presents the materials selection for the experiments, 
methods for the production, purification and characterization of recombinant proteins. In 
chapter 4, production of recombinant JE virus envelope domain III protein by batch and fed-
batch fermentation as well as its diagnostic potential is summarized. Chapter 5 presents the 
21 
 
result of pilot scale production, refolding with purification and vaccine potential of 
recombinant JE virus envelope domain III protein. Chapter 6 presents production, 
purification and evaluation of diagnostic potential of recombinant JE virus nonstructural 1 
protein.  In chapter 7, production of recombinant dengue virus type 3 envelope domain III 
protein by batch and fed-batch fermentation as well as its diagnostic potential is summarized. 
Chapter 8 presents the result of pilot scale production, refolding with purification and vaccine 
potential of recombinant dengue virus type 3 envelope domain III protein. In chapter 9, 
process development for production of recombinant dengue virus serotype 1, 2 and 4 
envelope domain III protein is described. The use of tetravalent dengue virus envelope 
domain III protein as a diagnostic reagent in ELISA is also presented in chapter 9. Finally, in 
chapter 10, the conclusions drawn from the above studies are described. There is also a brief 
note on the scope for further study in this field. 
 
*** 
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2.1 RECOMBINANT PROTEIN PRODUCTION 
 Biotechnology  is  defined  by  the  United  Nations  as  ―any  technological  
application  that  uses biological  systems,  living  organisms  or  derivatives  thereof,  to  
make  or  modify  products  or processes for specific use‖. The demand for therapeutic 
recombinant proteins is set to see a significant increase over the next few years. As a 
consequence, the processes used to produce these proteins must be able to meet market 
requirements (Huang et al., 2010). Recombinant proteins have gained enormous importance 
for clinical applications. Nearly 30% of currently approved recombinant therapeutic proteins 
are produced in Escherichia coli (Huang et al., 2012). The  production  of  recombinant  
proteins  has become  a  huge  global  industry  with an  annual  market  volume  exceeding  
$50  billion (Schmidt, 2004). The global biologics market valued at an estimated $149 billion 
in 2010 and is expected to reach $239 billion by 2015 (http://www.scribd.com/doc/ 
90133606/Biologic-Therapeutic-Drugs-Technologies-and-Global-Markets).  
 Molecular biology offers technologies whereby proteins can be produced and purified 
easily and more efficiently than ever before. Using recombinant DNA techniques such as 
gene fusion it is possible to generate chimeric proteins, which are novel in structure and 
function. The protein engineering has become a powerful tool in molecular biology to 
investigate protein function, in addition to production and purification of useful proteins 
(Sassenfeld, 1990; Sahdev et al., 2008). The main applications of recombinant proteins 
obtained  by  genetic  engineering  are  in  the medical therapeutic fields (e.g., production of 
recombinant vaccines, and therapeutic proteins for  human  diseases),  and  medical  
diagnosis (e.g., antigen engineering for poly and monoclonal  antibody  production  used  in  
disease testing). Other areas where recombinant proteins are commonly utilized include 
enzymes for food and fiber production, testing food for microbial contamination and 
veterinary medicine (Nilsson et al., 1992; Huang et al., 2012). Most proteins are expressed in 
infinitesimal amounts in their native cells and tissues, and it is only by recombinant 
techniques that it is possible to produce amounts great enough for basic research or for 
practical uses. Therefore, the expression of engineered proteins in efficient heterologous 
protein expression system is integral to the production, and purification of many proteins of 
interest.  
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2.2 RECOMBINANT PROTEIN PRODUCTION IN E. COLI 
 Demands  of  the  expanding  biotechnology  industry  have  driven  to  different  
improvements  in protein expression technology, which have been translated into the 
production of a spectrum of recombinant  proteins  in  different  systems  for  a  wide  variety  
of  purposes.  Most of the recombinant proteins are now-a-days produced either in bacteria, 
yeasts, engineered animal cell lines, hybridoma cells or even human cells. However, research 
continues on the development of alternative production systems, particularly in the use of 
transgenic animals or plants (Walsh, 2005; Desai et al., 2010). In the recent years, 
baculovirus and mammalian cell cultures have gained importance for the production of 
biopharmaceuticals due to the increasing needs of complex proteins and antibodies.  An  
alternative  to  baculovirus  or  mammalian expression  systems  are  yeasts, especially  when  
large  amounts  of secreted  protein  are  required (Porro et al., 2011). If the product contains 
post-translational modifications, Saccharomyces cerevisiae or Pichia pastoris may offer an 
economic alternative because they can grow to high cell densities using minimal media 
(Mattanovich et al., 2012), but the use of yeasts is limited due to their inability to modify 
proteins with human glycosylation structures for the production of therapeutic glycoproteins 
(Porro et al., 2011). The use of transgenic plants and animals as production vehicles may also 
play a role in applications requiring exceptional product volumes, but regulatory issues still 
remain to be addressed.   
 Even  though  the  choice  of  expression  system  is  progressively  widening, E.  coli 
is  still  the dominant host for recombinant protein production. It is used in many industry 
fields to produce high value intermediates, detergents, nutraceuticals and pharmaceuticals, 
amongst others. It is the most popular choice when simple proteins are required, and 
significant advances have been also  made  to  overexpress  complex  proteins,  hormones,  
interferons  and  interleukins  in  it (Walsh, 2005; Tripathi et al., 2009). The  production  of  
heterologous  proteins  or  parts  thereof  in  cytoplasmic compartments of Escherichia coli 
offers multiple  applications,  for  example,  in diagnostics and vaccine  development (Panda, 
2004; Huang et al., 2012).  Thus bacterial expression systems are the preferred choice for 
production of many recombinant proteins. The reasons for this lie in the cost-effectiveness of 
bacteria, their well-characterized genetics, and the availability of many different bacterial 
expression systems. As a host for recombinant expression, E. coli is especially valued 
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because of its rapid growth rate, capacity for continuous fermentation, low media costs and 
achievable high expression levels (Yin et al., 2007; Kamionka, 2011). Foreign proteins can 
be produced in E. coli in large amounts (5-50% of total protein). The major drawbacks of 
using E. coli for recombinant protein production are its lack of secretion systems for efficient 
release of proteins to the growth medium, limited ability to facilitate extensive disulfide-bond 
formation and othe posttranslational modifications, inefficient cleavage of the amino terminal 
methionine which can result in lowered protein stability and increased immunogenicity, and 
occasional poor folding due to lack of specific molecular chaperones (Yin et al. 2007; 
Berkmen, 2012). Even though E. coli may not be useful for all foreign protein production, it 
has been successfully utilized to produce many functional human proteins such as human 
growth hormone, proinsulin, interferon-gamma and antibody fragments (Schmidt, 2004; 
Tripathi et al., 2009). Important bioproducts produced in E. coli are listed in table 2.1. 
Table 2.1. List of bioproducts in E. coli with their manufactures. 
Product  Host Company  
Asparaginase  E. coli Merck  
r Cholera toxin B subunit E. coli SBL vaccine 
rh B-type natriuretic peptide  E. coli Scios/Johnson & Johnson 
Tissue plasminogen acticator E. coli Roche 
rh Insulin E. coli Eli Lilly, Aventis 
rh Growth hormone E. coli Genentech, Eli Lilly 
h Parathyroid hormone  E. coli Eli Lilly 
rh Interferon α-2a and 2b E. coli Hoffmann-LaRoche, Schering 
Interferon alfacon-1 E. coli Valent  
r IL-2 diptheria toxin fusion E. coli Seragen/Ligand 
rh IL-1 receptor antagonist E. coli Amgen  
r IL-2 E. coli Chiron 
r Interferon β-1b E. coli Schering AG, Chiron 
r Interferon γ-1b E. coli Genentec  
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2.2.1 Escherichia coli as a Host 
 Escherichia coli (Figure 2.1) is a Gram-negative, facultative anaerobe and non-
sporulating bacterium that is commonly found in the lower intestine of warm-blooded 
animals. The morphology of cells is rod-shaped, about 2 micrometers long and 0.5 
micrometers in diameter. Most of the E. coli  strains  are  harmless, but others can cause  
serious damage to humans. The harmless strains are part of the normal flora of the 
gastrointestinal tract, and can benefit their hosts  by  producing vitamin K2 and by  
preventing the establishment of pathogenic bacteria within the intestine (Bentley and 
Meganathan, 1982). However, E. coli can be easily grown outside the intestine as well, and it 
has become a model organism in biotechnology because of the simplicity of its genetics and 
manipulation.   
 
Figure 2.1. Escherichia coli cells electron micrograph (magnified 10.000 times). 
 Unlike  eukaryotes,  the  bacterial  chromosome  is  not  enclosed  inside  of  a  
membrane-bound nucleus but instead resides inside the bacterial cytoplasm. In there, the 
chromosome exists as a compact (usually circular) supercoiled structure which can be easily 
modified. To date, the most popular target for genetic manipulation in E.  coli has  been  the  
modification  of  host  cell metabolism to reduce acetate formation (Eiteman and Altman, 
2005). Other   genetic manipulations  have  been  focused  on  improved  protein  folding  
(which  may  be  achieved  by overexpression  of  intracellular  chaperones),  or  efficient  
disulfide  bond  formation (Berkmen, 2012). All these modifications have driven to the 
27 
 
existence of various strains of Escherichia coli with different genotypes (genetic 
constitution) which are used as expression systems. In particular, E. coli K12 and E. coli B 
(e.g. BL21 or BLR) and their many derivatives are the most commonly used hosts (Sahdev et 
al., 2008; Tegel et al., 2010).   
 All these features allow E. coli to be one of the most competitive hosts for rapid and 
economical production of simple recombinant proteins, amino acid and metabolite 
production when compared to other hosts. Commercial products mainly include recombinant 
proteins which are considered low-volume high-value products (Riesenberg et al., 1990). 
However, recent advancements in metabolic engineering made it possible to use E. coli as a 
platform to produce high-volume low-value products. In all these processes, high cell density 
and high volumetric yields are essential for economical feasibility. Capital investment and 
operation costs are reduced due to size reduction of fermentation equipment, upstream 
utilities, downstream units, etc. In this sense, process development plays an important role to 
maximise target product yields and to minimise production costs.    
2.2.2 Expression Systems for Escherichia coli  
 Various E. coli expression systems are available commercially and in the public 
domain, which is shared within the scientific community.  Each system offers different 
benefits for protein expression, detection, and purification, and should be considered 
according to the specific criteria and requirements each protein poses. In the industry, the 
selection of the host cell will be strongly influenced by the type and use of the product, as 
well as economic or intellectual property issues. The most popular commercial expression 
system for E. coli is the Novagen pET expression system based on the T7 promoter (Studier 
et al., 1990; Li et al., 2011). Systems using the λpL promoter/cI repressor (e.g., Invitrogen 
pLEX), Trc, Tac promoter (e.g., GE pTrc, pGEX), araBAD promoter (e.g., Invitrogen pBAD) 
and hybrid lac/T5 (e.g., Qiagen pQE) promoters are common (Graumann and Premstaller, 
2006). The selection and design of the expression plasmids influence synthesis rates, plasmid 
copy number, the segregational plasmid stability and therefore productivity and regulatory 
issues. For industrial applications, selective pressure by antibiotics is mainly maintained in 
pre-cultures, main cultures are usually grown without selective pressure. The ideal 
expression vector combines medium to high copy numbers with tight regulation of gene 
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expression to achieve rapid cell growth to high densities before the induction phase (Jana and 
Deb, 2005; Sahdev et al., 2008).  
2.3 CELL GROWTH AND FERMENTATION  
 When using E. coli as expression system, high cell density cultures are usually carried 
out to increase target protein yields.  Main factors which affect high density growth of E. coli  
are solubility  of  solid  and  gaseous  substrates  in  water  (limitation/inhibition  of  
substrates  with respect to growth may occur), accumulation of products or metabolic by-
products to inhibitory levels, high evolution rates of CO2 and heat as well as increasing 
viscosity of the medium (Riesenberg, 1991; Shiloach and Fass, 2005). Since this work was 
developed at bench and pilot scale, neither heat transfer or high power consumption due to 
high viscosity of the medium nor the utilisation of pure oxygen were problems, but E. coli 
growth can be also limited/inhibited by nutritional requirements including carbon, nitrogen, 
phosphorus, sulphur, magnesium, potassium, iron, manganese, zinc, copper and other growth 
factors (Tripathi et al., 2009). For high cell density cultures, the nutritional requirements can 
not be added initially to the basal media, since most media ingredients become inhibitory to 
E. coli when added at high concentrations.  Another problem is the precipitation of media 
components that can hamper adequate supply, interfere with the fermentation process and 
monitoring devices and affect downstream recovery and purification processes. Therefore, a 
well designed media and feeding strategy are essential to achieve high cell density cultures.  
Another   motivation   to   develop   different   feeding   strategies   was   to   decrease   
acetate accumulation.  Acetate accumulation can be avoided in stirred tank reactors by means 
of culture medium design and methods for carbon source feeding (Eiteman and Altman, 
2005).  
To  produce  recombinant  proteins  in  large  quantities,  fermentation technology is 
generally applied  to  increase cell density  and  protein  productivity.  Fermentation provides 
control over key chemical, physical and biological parameters that affect cell growth, as well 
as recombinant protein production. These include, but are not limited to, temperature, 
dissolved oxygen (DO) level, pH and nutrient supply. Fermentation can be classified into 
three groups: batch, fed batch, and continuous (Yee and Blanch, 1992; Stanbury et al., 1999).  
These methods can achieve cell concentrations about 100 g/l of dry cell weight and can 
provide cost-effective production of recombinant proteins. The development and design of 
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fermentation process itself play a key role for achieving productivity and robustness at scale 
(Schmidt, 2005). A robust large scale fermentation process would also need to consider the 
composition and cost of the media, feeding strategies and scale-up process.  
2.3.1 Batch Fermentation 
 Batch fermentation is an easy way to culture cells to reach high cell density in a very 
short time (Bhuvanesh et al., 2010). However, due to its low productivity compared to fed-
batch culture, it is usually used to produce protein for the purposes of protein characterization 
or toxicology study.  If a therapeutic protein is to be used in a low-dose therapy or is an 
orphan drug, a batch process is a good choice to ensure efficient and reliable production 
(Huang et al., 2012).  
2.3.2 High Cell Density Fed-batch Fermentation 
 High cell density culture (HCDC) techniques for culturing E. coil have been 
developed to improve productivity, and also to provide advantages such as reduced culture 
volume, enhanced downstream processing, reduced waste water, lower production costs and 
reduced investment in equipment. High cell-density culture systems also suffer from several 
drawbacks, including limited availability of dissolved oxygen, carbon dioxide levels which 
can decrease growth rates and stimulate acetate formation, reduction in the mixing efficiency 
of the fermentor, and heat generation (Lee, 1996; Panda, 2003). The reduction in acetate 
accumulation caused a significant improvement in the production of recombinant protein. 
Mutant strains of E. coli that are deficient in other enzymes have also been developed and 
shown to produce less acetate and higher levels of recombinant proteins.  In high cell density 
fermentation, maximizing cell concentration helps in increasing the volumetric productivity 
of recombinant proteins (Fong and Wood, 2010). It is also essential that cell growth be 
achieved in optimal time period to improve the overall production of the recombinant 
protein. Toxicity of acetate, slow growth rate, instability of plasmid, depletion of amino acid 
pools to sustain high rate of protein synthesis affect the specific cellular yield of recombinant 
protein at high cell concentration (Babu et al., 2000; Manderson et al., 2006; Tripathi et al., 
2009). It is expected that by analyzing all these parameters during high cell density fed- batch 
growth of E. coli will lead to high volumetric production of the desired protein.  
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2.4 IMPORTANT PARAMETERS AFFECTING FERMENTATION 
PROCESS  
 The operating condition such as pH, temperature and more importantly O2 supply is 
very very essential for supporting high cell growth. Solubility of oxygen in medium is very 
low and with increase in cell concentration during fed-batch growth, the solubility is reduced. 
At very high cell concentration use of air does not suffice the respiratory demand of the 
rapidly growing E. coli cells (De Leon et al., 2003). Increasing aeration rate, feeding O2 rich 
air, decreasing temperature, increasing partial pressure of the culture vessel are some of the 
method employed to maintain aerobic condition during cell growth. It has been widely 
documented that oxygen not only influences the cell growth but also has effect on gene 
expression by influencing the oxidative status of many enzymes (Castan and Enfors, 2000). 
Hence it‘s essential that along with proper feeding of nutrients, supply of oxygen should be at 
optimal level to support good growth and provide oxidizing environment for quality protein 
synthesis (Chen et al., 1995; De Mare et al., 2005). Composition of medium, physical 
parameters during growth and operating conditions are the most important factor that 
influences the cell growth. Limitation and or inhibition of substrates, limited capacity of 
oxygen supply, formation of metabolic byproducts and instability of plasmid during long 
hours of cultivation are most of the problems encountered during high cell density growth of 
E. coli (Schmidt, 2005; Tripathi et al., 2009). These, most of the times depends on host 
strain, vector and strength of promoter. Dense culture requires large amounts of O2 to support 
good growth and thus necessitates unconventional aeration strategy to maintain dissolved 
oxygen concentration at a suitable level throught out the growth period.  In most of the cases 
of E. coli being used as a host for recombinant protein, the production phases start after 
induction with suitable inducer (Panda, 2003; Fong and Wood, 2010). Thus in principle, 
growth phase and production phase can be delineated in the same vessel for the high 
volumetric yield of the recombinant protein. However, many times operation of reactor 
during cell growth influence the specific yield of the recombinant proteins. Thus while 
developing fed-batch operation to increase unit cell growth in the reactor it is equally 
essential to take care of the factors which affect the specific yield of the recombinant protein.  
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2.4.1 Development of Growth Media 
 The composition of the cell growth medium must be carefully formulated and 
monitored, because it may have significant metabolic effects on both the cells and protein 
production. For example, the translation of different mRNAs is differentially affected by 
temperature as well as changes in the culture medium. Among the three types of media 
defined, complex and semi-defined; defined media are generally used to obtain high cell-
density and can be controlled during culture (Berger et al., 2011). However, semi-defined or 
complex media are sometimes necessary to boost product formation. Chemically defined 
media are generally known to produce slower growth and low protein titres than complex 
media (Zanette et al., 1998). Nonetheless, use of complex media in producing recombinant 
proteins is a common practice because these media attain more consistent titres, allow easier 
process control and monitoring, and simplify downstream recovery of the target protein 
(Manderson et al., 2006; Bhuvanesh et al., 2010). Some nutrients, including carbon and 
nitrogen sources, can inhibit cell growth when they are present above a certain concentration. 
This explains why just increasing the concentrations of nutrients in batch culture media does 
not yield high cell-density.  
Optimization of medium components for enhanced production of recombinant protein 
is also a common practice in industry. One simple way to accomplish this goal is to modify 
the published media recipes, when high cell growth and protein expressions have been 
demonstrated (Huang et al., 2012).  To grow cells in a high density, it is necessary to design a 
balanced nutrient medium that contains all the necessary components in supporting cell 
growth avoiding inhibition. It is desirable to make the feed-solution as simple as possible by 
including sufficient non-carbon and non-nitrogen nutrients in the starting medium (Volonte 
et al., 2010). One of the essential requirements during fed-batch operation is to supply 
nutrients to promote cell growth (Khalilzadeh et al., 2004). To limit their toxicity to the 
growing cells nutrients such as glucose, glycerol, ammonia, salt are fed approximating their 
requirement. Accumulation of nutrients at high concentration inhibits growth and 
recombinant protein expression. High glucose causes Crabtree effect and leads to 
accumulation of acetate which is inhibitory to cell growth (Panda, 2003). In general most of 
the medium used for high cell growth of E. coli have carbon source mostly glucose or 
glycerol, major salts like phosphate, sodium, potassium, magnesium, ammonia and sulphates, 
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iron, minor trace elements and complex nitrogenous. High-density growth in general is 
initiated with low concentration of most required substrate and the nutrients are added later in 
the growth period (Fahnert et al., 2004; Babaeipour et al., 2008). Ideally components should 
be added to the fermentor at the same rate at which they are consumed so that it prevents the 
nutrient accumulation in toxic level while promoting good growth. Another factor which 
needs attention during medium formulation is the solubility of many components particularly 
while making concentrated solution for fed-batch addition. High concentration of glycerol, 
glucose, yeast extract and trace elements needs careful composition to avoid precipitation.  
It has been observed that addition of yeast extract with glycerol not only help in 
reducing secretion of acetic acid during growth of E. coli  but also help in utilization of acetic 
acid during carbon limitation. Apart from this, organic nitrogen source like yeast extract and 
soybean hydrolysate have been reported to enhance the specific cellular yield of the 
expressed protein particularly during high cell density fermentation where the demand of 
nitrogenous source become very high following induction (Panda, 2003; Mazumdar et al., 
2010). Presence of yeast extract in the medium also help in lowering the inhibitory effect of 
acetic acid and also work as a better physiological buffer in comparison to the minimal 
medium (Manderson et al., 2006). Therefore, its use in the feeding medium along with 
glycerol or glucose helped in avoiding the need of complex genetic manipulation to lower the 
acetic acid secretion. This indicated that with the use of yeast extract in the feeding medium 
not only the specific yields of protein can be maintained in high cell density fermentation but 
also the duration of the process can be reduced resulting in high volumetric productivity of 
the expressed protein (Zhang et al., 2010).  
2.4.2 Feeding Strategy during Fermentation Process 
 Feeding of nutrient is critical to the success of fed-batch process, as it not only affects 
the maximum attainable cell concentration, but also cell productivity. The use of fed-batch 
cultures has been shown to significantly increase the cell-density and specific protein 
production by overcoming inhibitory substrate concentrations encountered in batch culture 
(Chen et al., 1995). Various strategies exist for controlled feeding of fed-batch cultures. From 
a process engineering point of view, there are two principal strategies for the control of 
nutrient feed: the open-loop and the closed-loop (feedback) control. The choice of the 
nutrient feeding strategy has been done depending on the expression system, since no any 
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strategy is suitable in this case. Process optimization performed in present work required the  
development  of  different  nutrient  feeding  strategies  depending  on  both  the  expression 
system and target protein which were considered.  
 A pH-stat feeding system monitors the pH of the fermentation for indications of 
acetic acid production. The feed rate is increased until the maximum growth rate is reached 
as indicated by a metabolic overflow causing production of acid and a consequent decrease in 
pH. The DO-stat operation relies on the fact that specific oxygen uptake reaches a maximum 
at the maximum growth rate.  Changes in oxygen uptake rate following a pulse of feed are 
used to determine whether the microorganism is at its maximum growth rate. Exponential 
feeding makes use of an empirical model of growth, to regulate the feed rate (Lee, 1996; 
Manderson et al., 2006; Mazumdar et al., 2010). One of the essential requirements to obtain 
good cell growth during cultivation is to supply nutrients in a manner that is desirable. 
Ideally, by providing proper nutrient and operating conditions, exponential growth of E. coli 
can be maintained so that high cell concentration is achieved in less time. Oxygen supply, 
saturation of the oxidative capacity of cells at high glucose concentration, build-up of acetate 
to toxic level, plasmid instability and low productivity associated with cell growth at high 
specific growth rate has led to the development of different feeding strategy to achieve high 
cell growth at reasonable time (Babaepour et al., 2008). Direct feedback control is also 
possible by measuring on-line concentration of the growth-limiting substrate in the culture 
broth and adjusting the concentration to the preset value by automatic feeding. The feeding 
solution is added either simply in a constant way or by an exponential feeding programme. 
Two points are important to guarantee a good yield: (a) the flow of the feed solution must be 
low enough to allow carbon source limitation in the fermenter; (b) the flow of the feed 
solution must be regulated in a way that the specific growth rate does not decrease below 0.1 
h
–1
 until the point of induction. 
2.4.3 Induction Strategy and Effect of Oxygen during Fermentation Process 
 Along  with  chromosomal  DNA,  most  bacteria  also  contain  small  independent  
pieces  of  DNA called plasmids which are capable of replicating independently of the 
chromosome (Figure 2.2). Plasmids  (or  expression  vectors)  often  encode  for  genes  that  
are  advantageous  but  not essential to their bacterial host, and can be easily gained, lost or 
transferred by cells. These properties make them basic tools in biotechnology: they are used 
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to multiply particular genes or to make large amounts of proteins. In the latter case, bacteria 
containing a plasmid harbouring the gene of interest are grown and, then, transcription of the 
inserted gene can be induced to produce the target protein. 
 
Figure 2.2. Plasmid replication scheme. 
  In order to control recombinant protein expression in E. coli, several inducible 
promoters have been developed. When using them, induction of the target gene transcription 
is controlled by a signal which will depend on the type of promoter.  Idealistically, the 
promoter should not allow expression before induction, and should allow adjustable 
induction of protein expression. The most commonly used inducer for T7 promoter systems 
is isopropyl-β-D-thiogalactopyranoside (IPTG) (Figure 2.3). This synthetic inducer is 
expensive and may interfere with cell growth at high concentration. Owing the cost of IPTG, 
it would be advantageous to use less inducer to obtain the same level of transcription 
(Hansen et al., 1998).  
 
 
Figure 2.3. Isopropyl-β-D-thiogalactopyranoside molecule. 
Expression systems used in this work contained vectors with T7 and T5 promoters. 
Hence, IPTG was used as inducer. Cellular responses to induction depend on a number of 
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interacting factors including the host/vector system and properties of the expressed protein. 
Therefore, the timing of induction of new recombinants needs to be empirically determined 
for each new clone (Manderson, 2006; Tripathi et al., 2009). Inducer concentration trials 
required since IPTG inducer is expensive. The concentration of IPTG required for complete 
induction is known to vary widely along with various clones expressing different proteins. 
The induction strategy needs optimization to maintain specific cellular protein yield during 
high cell density fed-batch fermentation. In fed-batch culture separation of the two phases 
can be achieved by delaying induction of the culture until the culture has completed its 
growth to the required high densities. Considering these aspects, it is essential to decide the 
induction time so that both cell growth and protein yield are maximized.  
In recent times the secondary role of oxygen on maintenance of cell physiology and 
quality of the recombinant protein has been a major concern for the high volumetric yield of 
recombinant protein from E. coli.  Fluctuations in oxygen contents during high productive 
fermentation process can cause oxidative stress within the cells leading to limitation in amino 
acid production, plasmid instability and more importantly oxidation of proteins (Lee, 1996; 
Panda, 2003).  These effects altogether may affect the quality of the final product. Oxygen 
often becomes limiting in HCDCs owing to its low solubility. The saturated dissolved 
oxygen (DO) concentration in water at 25°C is ~7 mg/l but oxygen supply can be increased 
by increasing the aeration rate or agitation speed (Lee, 1996). Oxygen-enriched air or pure 
oxygen has also been used to prevent oxygen limitation as for example in high yield 
production of recombinant malaria antigen and human interferon (Yazdani et al., 2004; 
Babaeipour et al., 2008). However, pure oxygen is expensive and increases production costs 
when used in large quantities. As oxygen consumption increases with growth rate, the 
oxygen demand of cells can be reduced by lowering the growth rate.  
2.4.4 Scale up of Fermentation Process 
 For commercial production of recombinant proteins, the fermentation usually starts in 
a laboratory scale bioreactor (e.g., 5–30 l) to identify suitable growth and protein expression 
conditions.  The  process  then  transfers  to  pilot  level (e.g., 40–600 l) to establish optimal 
operating parameters and  finally  to  manufacturing  scale  (e.g.,  over  2,000 l)  to reach high 
productivity. The scale-up process for any recombinant protein should aim for high 
productivity with consistency in the protein quality and specific yield (Ravi et al., 2008; Bell 
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et al., 2009). However, as the scale increases important biological, chemical and physical 
parameters affecting cell growth, as well as protein expression, will also change. This makes 
the scale-up process a challenging task. The common problems associated with scale-up 
originate from poor mixing, which increases circulation time and creates stagnant regions. 
This leads to imbalanced and zonal distribution of oxygen, nutrients, pH, heat and 
metabolites inside the bioreactor (Schmidt, 2005; Lee, 2009). Therefore, several strategies 
have been used as principles to scale up E. coli fermentation to minimize the differences  
between  scales  by  keeping  one  or  more  parameters constant  from  laboratory  to  pilot 
and plant scale  bioreactors. These  parameters  include  power  input  per  liquid  volume 
(P/V),  oxygen  transfer  rate  (OTR),  oxygen  mass  transfer coeffcient  (kLa),  impeller  tip  
speed,  mixing  time  and impeller Reynold‘s number (NRe) (Junker, 2004; Garcia-Ochoa and 
Gomez, 2009). Traditionally, the constant P/V has been shown to be a successful scale-up 
criterion for large scale fungal and mammalian cell fermentation, but may be limited to 
recombinant E. coli culture because of its high energy requirement (Huang et al., 2012).  
 Development of sensors for DO measurement attributed that scaling up based on 
constant DO concentration is the most appropriate approach for microorganisms, such as E. 
coli growing under aerobic conditions,  and  other  studies  have  shown that it is indeed the 
most applied scale-up parameter (Junker, 2004; Garcia-Ochoa and Gomez, 2009). The kLa is 
directly related to a bioreactor‘s configuration and can be modulated by manipulating the 
bioreactor‘s agitation speed, impeller design and air/O2 flow rate.  In a large-scale and high-
performance E. coli fermentation where power input and mixing are not an issue, a similar 
OTR and heat transfer rate will normally be used to ensure high productivity (Schmidt, 
2005). Scale-up based on  a  constant  mixing  time  or  tip  speed  usually  has  a higher 
success rate when the scale-up factor is small (4–40 l, scale-up factor 10)  (Wu et al., 2009; 
Huang et al., 2012). In practice, however, the important scale-up parameters for each product 
may be different because of process differences and the operation limitations imposed by 
manufacturing facilities (Tripathi et al., 2009).  Therefore, a detailed and comprehensive 
process characterization must be carried out in advance to identify  critical  parameters  
influencing  protein  yield  and quality.  Those parameters then should be kept constant 
during the scale-up processes.  The  knowledge  gained  is  then  used  to  optimize  the 
fermentation  processes  to improve  the  robustness  of  the  process  in  a  scale-up  practice.   
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2.5 PURIFICATION STRATEGIES FOR RECOMBINANT PROTEINS 
 Refolding and purification of bioactive protein is the major bio-processing parameter 
for efficient production of prophylactic, diagnostic or therapeutic proteins from E. coli. As 
level of expression for soluble proteins are in general low in E. coli, rarely such process is 
employed for large-scale production of therapeutic protein. High level expressions of protein 
in the form of inclusion body are generally used for large-scale production of therapeutic 
protein (Fahnert, 2004). The formation of inclusion bodies in E. coli facilitates the isolation 
of the protein of interest from the cytoplasm at the cost of its native structure. In general 
inclusion bodies are solubilized by the use of high concentration of denaturants such as urea 
or guanidine hydrochloride, along with a reducing agent such as DTT or -mercaptoethanol 
(Wang et al., 2007). The solubilized proteins are then refolded by slow removal of the 
denaturant in the presence of oxidizing agent. In most of the therapeutic recombinant protein 
cases, the yield of bioactive protein from the inclusion bodies is around 15-25 % of the total 
expressed protein. The overall process yield and economic viability of the recombinant E. 
coil fermentation process mostly depend on the efficient recovery of bioactive protein from 
the inclusion bodies (Esfandiar et al., 2010). It is thus necessary to have information about 
the solubilization and refolding of inclusion body protein from E.coli. 
2.5.1 Recombinant Protein as Inclusion Bodies   
 The formation of inclusion bodies is mainly attributed to the overexpression of 
recombinant proteins in the cell lacking required accessories for its folding to native form. 
There is no direct correlation between the propensity of the inclusion body formation of a 
certain protein and its intrinsic properties, such as molecular weight, hydrophobicity, folding 
pathways and so on (Panda, 2003; Garcia, 2010). In case of proteins having disulfide bonds, 
formation of protein aggregation as inclusion bodies is anticipated since the reducing 
environment of bacterial cytosol inhibits the formation of disulfide bonds (Berkmen, 2012). 
The consequences result in improper folding of the protein in aggregation in to inclusion 
bodies. Although protein expression in the form of inclusion body is often considered 
undesirable, their formation can be advantageous, as their isolation from cell homogenate is a 
convenient and effective way of purifying the protein of interest (Babu et al., 2000). 
Converting this inactive misfolded inclusion body protein in to soluble active form can result 
in high recovery of recombinant protein. 
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2.5.2  Inclusion Body Formation, Isolation and Solubilization  
 Inclusion bodies are dense particles of aggregated protein found in both cytoplasmic 
and periplasmic space of E. coli during high level expression of foreign protein (Jurgen et al., 
2010). The exact reason for protein aggregation in to inclusion body formation is not clear 
yet. There could be several possible reasons for the intracellular aggregation of the 
recombinant protein and the predominant ones could be due to (1) high local concentration of 
protein synthesis in cytoplasm  (2) lack of cellular compartmentation and oxidizing 
environment the E. coli cell thus preventing S-S bond necessary for proper folding (3) lack of 
mammalian post translational modifying enzymes and foldases ( PDI, PPI and chaperone 
system) during high level expression of protein (4) aggregation behavior of the intermediates 
of the protein folding path ways (Singh and Panda, 2005). The propensity to form insoluble 
aggregates does not correlate with other factor such as size of the expressed protein and use 
of fusion construct. Recombinant protein deposition in inclusion body is commonly observed 
with hydrophobic proteins as hydrophobic interaction among the partially folded protein 
molecules have been found to be responsible for aggregation in to inclusion bodies (Jurgen et 
al., 2010). Significant features of protein aggregates in inclusion bodies are the existence of 
native-like secondary structure of the expressed protein and their resistance to proteolytic 
degradation. Analysis of the secondary structure of -lactamase inclusion bodies from E. coli 
by Raman spectroscopy indicated the presence of amide bond, thus indicating the existence 
of native like protein structure in the inclusion body protein (Panda, 2003; Fahnert, 2004).  
The formation of inclusion bodies thus facilitates the easy isolation and recovery of the 
expressed proteins in denatured form (Rodriguez et al., 2010; Peternel and Komal, 2010). As 
the inclusion bodies have high density (~ 1.3 mg ml 
-1
), these are easily separated by high-
speed centrifugation after cell disruption. The most common process for cell lysis is sonication, 
bead milling and high-pressure disruption following a lysozyme treatment.  Further purification 
of inclusion bodies can be achieved by washing with detergents, low concentration of salt and 
or urea (Dasari et al., 2008). With proper isolation and washing process, more than 80% pure 
inclusion body can be prepared from E. coli. Recently ultrafiltration using membrane of 
different pore size has been used for isolation of inclusion bodies from E. coli cells (Ledung et 
al., 2009) however centrifugal isolation have been found to be the best method for isolating the 
inclusion bodies from that of the membrane or cellular components.  
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In general, proteins expressed as inclusion bodies are solubilized by the use of high 
concentration (6-8 M) of chaotropic solvents. Chaotropic agents such as urea, guanidine 
hydrochloride, and detergents such as SDS along with reducing agents like  -
mercaptoethanol, dithiothreitol or cysteine have been extensively used for solubilizing the 
inclusion body proteins (Wang et al., 2006). In many cases of inclusion body solubilization, 
use of reducing agent like DTT, 2-mercaptoethanol improves the solubilization yield in the 
presence of chaotropic agents. This helps in maintaining cysteine residue in reduced state and 
thus prevent non-native intra or inter disulfide bond formation in highly concentrated protein 
solution at alkaline pH. Chelating agents like EDTA are frequently used in the solubilization 
buffer to prevent metal catalyzed air oxidation of cysteines (Dasari et al., 2008). Use of 
extreme pH with combination of low concentration of denaturing agent or temperature has 
also been used for solubilization of inclusion body protein (Singh and Panda, 2005; Li et al., 
2012). The choice of the solubilizing agent greatly affects the refolding yield and cost of the 
overall process.  
2.5.3 Refolding of Solubilized Recombinant Protein 
 The soluble proteins in general are refolded in to their native state after removing the 
chaotropic agents or other salts by dialyzing the proteins in buffers containing reducing and 
oxidizing agents (Wang et al., 2006; Tan et al., 2010). Purification of the recombinant protein 
either can be carried out before renaturation in denaturing conditions or after refolding of the 
solubilized protein. Refolding followed by purification is generally preferable as some of the 
high molecular aggregates along with the contaminants can be co-purified in single step. 
Dilution of the solubilized protein directly in to the renaturation buffer is the most commonly 
used method for small scale refolding of recombinant proteins. However the major limitation 
of the dilution method is the problems of scale-up and low yield. Refolding large amount of 
recombinant protein using dilution method needs large refolding vessel, huge amount of 
buffer and additional concentration steps after protein renaturation and thus adds to high cost 
of protein production (Panda, 2003; Alibolandi and Mirzahoseini et al., 2011). Pulse 
renaturation involving addition of small amount of solubilized protein to the renturation 
buffer at successive time interval helps in reducing the volume of buffer thus improves the 
overall performances of the refolding process. Pulse renaturation processes have been 
successfully tried for the recovery of gamma interferon and lysozyme (Singh and Panda, 
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2005; Wang et al., 2007). Renaturation of bioactive protein with little aggregation has also 
been achieved by addition of low molecular weight additives (Kolaj et al., 2009). The most 
commonly used low molecular weight additives have been glycerol, L-arginine, low 
concentration of (1-2 M) urea or guanidine hydrochloride, and detergents. Among the 
additives, the positive effect of glycerol, L-Arginine/HCl  in reducing aggregation have been 
demonstrated on various proteins like human gamma interferon (Babu et al., 2000; Wang et 
al., 2009) and for fibroblast growth factor (Alibolandi and Mirzahoseini et al., 2011).  
High throughput refolding of inclusion body solubilized protein at high protein 
concentration have been reported by using on-column refolding using affinity (Wang et al., 
2009; Esfandiar et al., 2010), ion-exchange (Wang et al., 2007), hydrophobic interaction 
(Wang et al., 2006) or gel filtration chromatography (Wang et al., 2008; Chen and Leong, 
2010) and diafiltration (Dasari et al., 2008). Intermolecular interaction leading to aggregation is 
minimized when the folding molecules are isolated through binding to the support matrix. 
Simultaneous used of denaturant free buffer and optimization of elution condition leads to the 
purification of protein in bioactive form. Such chromatographic matrices have been 
successfully used for the refolding of interferons, interleukins expressed as inclusion bodies in 
E. coli. Simultaneous renaturation and purification of inclusion body protein using nickel-
chelating chromatography have also been reported for interferons (Wang et al., 2009). Using 
similar methodology, reduced lysozyme at very high concentration (9 mg/ml) have been 
successfully refolded in to bioactive form with almost 100% recovery using immobilized 
liposome chromatography (Panda et al., 2003). This methodology is highly efficient in 
reducing protein aggregation and thus provides maximum recovery of the refolded protein. 
Protein refolding can also be achieved by the use of diafiltration and dialysis using 
ultrafiltration membranes (Dasari et al., 2008). Huge volumes of soulubilized protein material 
can be processed using such refolding procedures. It was found that use of chromatography 
results in higher yield of the refolded protein in comparison to dilution method. As affinity 
chromatography offer multiple advantages of buffer exchange, protein refolding and separation 
of pure protein, it provides an  ideal method for large scale refolding of inclusion body protein 
(Wang et al., 2009; Esfandiar et al., 2010).  
2. 5. 4  Chromatographic Purification Strategies for Recombinant Proteins 
 Purification is an important step in the production of recombinant proteins. The 
characteristics of large scale purification schemes, such as conventional chromatography, 
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have a significant impact on the final cost of production. It is often more efficient to use one 
of the available tags to ‗fish out‘ the target protein. The purpose for which the protein will be 
used determines required degree for its purity and authenticity. To purify intracellularly 
produced proteins the cells are harvested and lysed, which naturally contributes to the 
complexity of the protein mixture. The advantage of intracellular versus  secreted  protein  is  
the  volume  to  be handled,  i.e.,  the  secreted  proteins  usually exist diluted in the culture 
medium. Chromatographic methods (affinity, ion exchange, size exclusion and hydrophobic 
interaction) can be utilized either in traditional, low pressure or high performance liquid 
chromatography instrumentation.  
2.5.5 Affinity Chromatography 
 Affinity chromatography together with recombinant DNA technology offers a simple 
and fast technique to purify proteins to high purity with a single purification step (Tan et al., 
2010). Fusion can be made on either side or both sides of the target gene depending on 
specific application, but the majority of fusion proteins place the tag at the N-terminus of the 
protein (Nilsson et al., 1997). Although affinity chromatography can be used for laboratory 
scale purification, its utilization on a preparative scale can represent a major cost for the final 
protein product. Successful separation by affinity chromatography requires that a biospecific 
ligand is available, and that it is covalently attached to a chromatographic bed material. Due 
to the specificity of this recognition, it is often possible to obtain high purity of a protein 
sample (Arnou et al., 2006; Young et al., 2012). The packing material used, called the 
affinity matrix, must be inert and easily modified. Agarose is the most common substance 
used as a matrix, in spite of its relative high costs. The ligands, or ―affinity tails‖, that are 
inserted into the matrix can be genetically engineered to possess a specific affinity. In a 
process, the desired molecules adsorb to the ligands on the matrix until desorption is carried 
out e.g., with a high salt  concentration, a competition reaction (e.g., imidazole), strong 
chelating agents and/or low pH. To date, a large number of different fusion partners that 
range in size from one amino acid to whole proteins capable of selective interaction with 
ligand immobilized onto a chromatography matrix, have been described (Nilsson et al., 1997: 
Young et al., 2012). Immobilized metal affinity chromatography (IMAC) systems have three 
basic components:  an electron donor group, a solid support and a metal ion. The metal ion 
(usually Ni
2+
, Co
2+
, Cu
2+
 or Zn
2+
) is restrained in a coordination complex where it still retains 
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significant affinity towards macromolecules (Wang et al., 2009).  The use of polyhistidine 
tags has been demonstrated in a wide range of host cells including E. coli, S. cerevisiae, 
insect cells as well as in mammalian cells.  
2.5.6 Ion Exchange Chromatography 
 Ion exchange chromatography (IEC) has been the most widely used technique for the 
isolation and purification of biological macro-molecules. IEC is able to separate almost any 
type of charged molecules, from large proteins to small nucleotides and amino acids 
(Ahamed et al., 2007). The ion exchanger is insoluble solid matrices containing fixed 
ionogenic groups which bind reversibly to sample molecules (proteins, etc.). Desorption is 
then brought about by increasing the salt concentration or by altering the pH of the mobile 
phase. The two major classes of ion exhangers are cation exchangers and anion exchangers, 
having negatively and positively charged functional groups, respectively. Ion exchange 
containing sulpho propyl (SP) or diethyl aminoethyl (DEAE) is most frequently used. The 
major property which govern the adsorption to an ion exchanger is the net surface charge of 
the protein. Since surface charge is the result of weak acidic and basic groups on proteins, 
separation is highly pH-dependent. The optimum pH range for IEC for many proteins is 
within 1 pH units of the isoelectric point. Elution with increasing salt concentration or 
increasing/decreasing pH of buffer is most commonly used in the IEC (Khalilzadeh et al., 
2008; Bell et al., 2009). The higher the net charge of the protein, the higher the ionic strength 
needed to bring about desorption. Thus, to optimize selectivity in ion exchange 
chromatography, the pH of the running buffer is chosen so that sufficiently large net charge 
differences among the sample components are created. 
2.5.7 Gel Filtration or Size Exclusion Chromatography  
 The principle of gel permeation chromatography (GPC; size exclusion or gel filtration 
chromatography) is based on molecular mass (Wang et al., 2008). Large molecules are 
excluded from the matrix, whereas intermediate size molecule can partly enter and only small 
molecules can freely enter the matrix.  The porous three dimensional matrix acts as a steric 
barrier to solute molecules as they attempt to equilibrate with liquid inside and outside the 
bead. While purifying the protein GPC can also be used to estimate approximate molecular 
weights. The choice of the appropriate column type depends on the molecular size and 
physical properties of the proteins to be separated.  
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2.5.8 Hydrophobic Interaction Chromatography  
 Hydrophobic Interaction Chromatography (HIC) is used to separate proteins on the 
basis of relative hydrophobicity. At intermediate ionic strengths (1-1.5 M), proteins may be 
adsorbed from solution onto hydrophobic surfaces. This adsorption is reversible, and elution 
is achieved by simply lowering the ionic strength. Consequently, HIC is particularly useful 
for the purification from high ionic strength biological extracts since binding is performed in 
the presence of salt, and elution in the absence of salt. The technique may be applied to the 
purification of most soluble proteins. HIC has now used in laboratory scale, as well as in 
large scale purification of biomolecules, like serum proteins, nuclear proteins, hormones, 
recombinant proteins and enzymes (Roettger and Ladisch, 1989; Wang et al., 2004; 
Bhuvanesh et al., 2010). 
2.6 FLAVIVIRIDAE 
 Recent past has seen a global resurgence of viral diseases such as dengue, Japanese 
encephalitis, and yellow fever.  The viruses composing the family Flaviviridae are single 
stranded RNA viruses with positive polarity divided into three genera: Hepacivirus, Pestivirus 
and Flavivirus. More than half of the known flaviviruses are associated with human disease, 
including the important human pathogens dengue virus (DENV), Japanese encephalitis virus 
(JEV), yellow fever virus (YFV), West Nile virus (WNV), and the Tick-borne encephalitis 
viruses (TBEV) (Vasilakis and Weaver, 2008).  The most common outcome of human 
flavivirus infection is subclinical; however, clinical infections present as a flu-like disease with 
fever, arthralgia, myalgia, retro-orbital headache, maculopapular rash, leucopenia, vascular 
leakage, hepatitis and/or encephalitis. Viruses are taxonomically grouped within the Flavivirus 
genus by their antigenic relationships, which correlate with their vector: tick-borne, mosquito-
borne, and no known vector.  Viruses vectored by Culex mosquitoes are generally encephalitic 
and include the JEV serogroup, where birds are the natural reservoir, while viruses vectored by 
Aedes mosquitoes are viscerotropic and include the DENV serogroup as well as YFV, where 
humans or primates serve as the natural reservoir (Gaunt et al., 2001). 
2.6.1 Flavivirus Genome and Proteins 
 The flavivirus RNA genome is single-stranded and approximately 11 kilobases in 
length.  The genomic RNA is infectious and therefore of positive polarity.  Genomic length 
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RNA are the only viral mRNAs present in flavivirus infected cells.  The genomic RNA has a 
type I cap at the 5‘ end (m7GpppAmp) and lacks a poly(A) tail on the 3‘ end.  A striking 
feature of the flavivirus genome is the presence of a single long open reading frame (ORF) 
that spans nearly the whole genome, encoding at least 10 proteins (Figure 2.4).  The long 
ORF is flanked on each end by 5‘ and 3‘ non- 4 coding regions (NCR), respectively 
(Chambers et al., 1990; Rice, 1990).  The structural proteins capsid (C), membrane (M; 
expressed in the precursor form prM), and envelope (E) are encoded on the 5‘ quarter of the 
genome while the non-structural (NS) proteins compose the remainder (Rice et al., 1986).  
The ORF generates a single polyprotein in the order 5‘-C-prM/M-E-NS1-NS2A-NS2B-NS3-
NS4A-NS4B-NS5-3‘. Processing of the flavivirus polyprotein results in the formation of 10 
direct or indirect membrane-associated viral proteins: three structural proteins, seven non-
structural proteins, and two polypeptide cleavage fragments. The functions of all ten viral 
proteins are mentioned in table 2.2.  
The capsid (C) protein is a small protein, approximately 120 amino acids long, which 
constitutes the protein component of the nucleocapsid. The C protein is quite basic, probably 
acting to neutralize the negatively charged viral RNA in such a compact structure (Rice et al., 
1986). The prM protein is the precursor glycoprotein to the structural protein M and 
undergoes a delayed cleavage to form the M protein, a process that is linked to viral 
budding/maturation to prevent immature virions with host cell membranes (Li et al., 2008).  
 
 
 
  
 
 
 
Figure 2.4 Flavivirus genome organization. 5’UTR is followed by the open reading frame 
coding for the structural and non-structural proteins. 
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Table 2.2 Flavivirus Proteins. 
Protein Size 
(kDa) 
Number of 
amino acids 
functions 
Core   13-16  113  Core protein 
Pre-Membrane   19-23    166        Chaperone protein for E; precursor to M  
Membrane 8-8.5   75   Component of viral envelope 
Envelope  51-60 495 Major envelope protein 
NS1 44-49 350-410 Putative RNA replication cofactor 
NS2a 16-21 150-210 Putative RNA replication cofactor.  
Coordinates the  shift between RNA   
packaging and RNA replication 
NS2b   12-15    130      Cofactor for serine protease in viral protease 
complex 
NS3    67-76    615 Viral protease; RNA cofactor; NTPase and 
putative helicase  
NS4a   24-32   150-280       Putative RNA replication cofactor  
NS4b    10-11   110-250 Innate immunity  
NS5 91-98   900       Viral RNA dependent RNA polymerase                             
 The envelope protein is the major surface glycoprotein and is glycosylated in some, 
but not all flaviviruses.  Through crystallographic analysis, each flavivirus E protein has been 
shown to be composed of three structural domains (Rey et al., 1995) labeled E domain I 
(EDI) to EDIII.  EDI is the central beta-barrel domain, composed of 120 residues in three 
segments (1-51, 137-189, and 285-302).  EDI acts as a flexible hinge region that is important 
in fusion.  This domain is stabilized by two disulfide bridges, and has a conserved 
glycosylation site at Asn153, with an additional site at Asn 67 in EDII of dengue virus.  
These glycosylation sites do not have an effect on the antigenic recognition of the E protein 
by monoclonal antibodies (Heinz and Stiasny, 2012).  EDII is the dimerization domain 
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composed of two segments (52-136, 190-284), and containing three disulfide bridges.  EDII 
also contains an internal type II fusion loop at the distal end, which is packed against EDIII 
of the adjacent E protein, and undergoes a dramatic acid-mediated conformational change 
(Guirakhoo et al., 1989).   
EDIII has an immunoglobulin (Ig)-like fold and is composed of the C terminal 
portion of the E protein (303-395).  EDIII is joined to EDI through 15 residues and anchored 
by one intra-monomer disulfide bridge.  This interface is partly hydrophobic and partly polar.  
The Ig beta-barrel lies perpendicular to the virion surface and projects the furthest (Rey et al., 
1995).  Flavivirus E is involved in several important biological functions. Flaviviruses 
mediate host cell entry through receptor mediated endocytosis, utilizing EDIII for interaction 
with cellular receptors (Huerta et al., 2008; Guzman et al., 2010; Pulmanausahakul; 2010).  
Murine derived monoclonal antibodies (MAb) targeting EDIII, efficiently neutralize virus by 
blocking viral attachment (Crill and Roehrig, 2001; Heinz and Stiasny, 2012). In addition, 
recombinant EDIII is able to bind vertebrate target cells through interactions with heparan 
sulfates and inhibit viral infection (Chu et al., 2005; Hung et al., 2004; Guzmzn et al., 2010; 
Heinz and Stiasny, 2012).    
The NS1 protein contains two or three N-linked glycosylation sites and 12 conserved 
cysteines, all of which form disulfide bonds.  Rapidly after synthesis, NS1 forms highly 
stable homodimers with a high affinity for membranes; however, due to the largely 
hydrophilic amino acid content and lack of a transmembrane domain, the nature of this 
membrane association is unclear. NS1 is largely retained within infected cells (Lindenbach 
and Rice, 2003) and plays an important, yet unclear role in RNA replication.  Anti-NS1 
antibodies confer partial protection from virus challenge (Gould et al., 1986; Das et al., 2009; 
Pulmanausahakul; 2010).  
NS2A is a relatively small, hydrophobic, multifunctional, membrane-associated 
protein involved in RNA replication (Mackenzie et al., 1998). NS2B is also a small 
membrane-associated protein and forms a stable complex with NS3 and acts as a cofactor for 
catalytic activity of the viral serine protease. NS3 is a large, multifunctional protein required 
for polyprotein processing and RNA replication. NS4A/2K is a small hydrophobic protein 
that localizes to sites of RNA replication and interacts with NS1, which is essential for RNA 
replication, suggesting a role in viral replication (Mackenzie et al., 1998).  NS4B is the 
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largest of the small hydrophobic NS proteins, consisting of 248 amino acids. Coexpression of 
NS4A and NS4B enhances the inhibition of interferon-stimulated response element promoter 
activation in response to IFNα/β stimulation (Munoz-Jordan et al., 2005).   NS5 is the largest 
and most conserved of the flavivirus proteins, composed of approximately 900 amino acids.  
NS5 is essential in replication containing domains for RNA-dependent RNA polymerase 
(RdRp) and 5‘ capping.   
2.7 THE DENGUE VIRUS 
 Dengue virus serocomplex is composed of four distinct species within the flavivirus 
genus, which includes four genetically different, yet antigenically related serotypes (Dengue-
1, -2, -3, and -4) (Calisher et al., 1989). All four serotypes circulate in urban environments of 
the tropics and subtropics between humans and the peridomestic Aedes aegypti mosquito. 
This distribution puts nearly a third of the global population at risk for dengue virus infection 
(Farrar et al., 2007; Whitehorns and Simmons, 2011). Dengue virus infection was reported in 
the 1780 Philadelphia outbreak, it was probably rare and did not pose a serious public health 
problem (Vasilakis and Weaver, 2008). The first well documented cases of DHF were 
associated with epidemics in Thailand and the Philippines in the 1950s and thought to be a 
new disease. Since this time DHF/DSS have become endemic in all countries in Southeast 
Asia, with dramatic increases in case numbers, so much so that dengue is considered an 
archetypal ―emerging‖ disease. The most common clinical disease caused by dengue 
infection is dengue fever (DF), a febrile illness of older children and adults. DF is commonly 
associated with 5-7 day duration of fever, headache, retroocular pain, myalgia, arthralgia, and 
frequently a generalized maculopapular rash on the trunk. Treatment for DF is supportive and 
patients normally fully recover. Severe manifestations of dengue virus infection include 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Children under 16 are 
at the greatest risk for developing DHF/DSS. Severe disease and shock is frequently 
observed the day following defervescence and rarely lasts more than 48 hours. DHF/DSS is 
characterized by fulminant hepatitis, massive hemorrhage including positive tourniquet test, 
petechia, intestinal hemorrhage, and hemetemesis, organ failure, vascular leak with 
hypovolemic shock induced by plasma leakage, thrombocytopenia of less than 100,000 cells 
per mm
3
, elevated liver enzymes, and coagulation disorders including decreased fibrin and 
increased fibrin degradation products. Currently dengue has caused more illness and death 
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than any other arboviral diseases of humans, with an estimated 100 million cases of dengue 
fever and 500,000 DHF cases occurring annually in the world. The case fatality varies from 
0.5 to 3.5%, depending on severity of epidemic and is the highest in Asian countries. DHF is 
the leading cause of hospitalisation and death among children in Southeast Asian countries, 
where more than 90% of the DHF patients are children below the age group of 15 years. In 
the last two decades, outbreaks of dengue infections have accelerated enormously in India, 
with largest and severe being the DHF epidemic in Delhi in 1996, indicating a serious 
resurgence of dengue virus infection
 
(Chaturvedi and Nagar, 2008; Dash et al., 2011). The 
geographic distribution of dengue is shown in figure 2.5. 
 
Figure 2.5 Geographic distribution of dengue virus endemic areas in 2011 (WHO, 2012). 
Developing a vaccine for dengue virus is a very challenging task because of few 
complications (Guy et al., 2011; Thomas and Endy, 2011). Dengue virus has four serotypes, 
infection with one-serotype results in lifelong immunity to it but there is no cross-protection 
against the others. Persons living in the areas of endemicity can be infected with any one of 
the other three serotypes causing clinical illness, ranging from a non-specific febrile 
syndrome to severe and fatal dengue hemorrhagic fever (DHF) /dengue shock syndrome 
(DSS). Protection against any one or two of the dengue virus serotypes can increase the risk 
of more serious disease through the antibody dependent enhancement (ADE) phenomenon. 
During the secondary infection with heterologous dengue serotype, antibodies could 
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recognize the viruses and bind to them forming dengue virus-antibody complexes. These 
complexes are taken up more readily than uncoated viruses by mononuclear cells bearing Fc 
receptors, especially macrophages. However, these cross-reactive antibodies fail to neutralize 
the viruses, so the viruses could replicate freely inside the cells. This phenomenon is called 
antibody-dependent enhancement (ADE) (Pulmanausahakul et al., 2010; Guzman et al., 
2010; Simmons et al., 2012). 
2.7.1 Dengue Diagnosis  
 The diagnosis of dengue from clinical symptoms is not reliable, as around 50% of 
dengue patients will have only mild, undifferentiated fever. Symptomatically, dengue 
resembles Chikungunya fever, Leptospirosis, Typhoid and Malaria. So confirmatory 
diagnosis can only be achieved with laboratory support. The current trends of routine 
laboratory diagnosis include virus isolation, detection of antibody or antigen by serodiagnosis 
and/or molecular detection by demonstration of viral RNA by RT-PCR, Real time PCR 
(Guzman and Kouri, 1996; Peeling et al., 2010; Tripathi et al., 2010). Virus isolation is the 
gold standard routinely followed in the clinical laboratory. But it is a difficult task since 
dengue virus is highly fastidious and slow growing. For virus isolation, the sample should 
preferably be collected within 5-6 days of fever (viremic acute phase patient sera) (Yamada 
et al., 2002). Post-viremic sera are most likely to be dengue positive by serological tests, 
which are often complicated and time consuming. These techniques are labour intensive, 
expensive and cumbersome. Thus, in a majority of cases the only feasible diagnostic test 
would have to be based on the identification of anti-dengue IgG and IgM antibodies. ELISA 
or immunochromatography test is the most widely used serological test to diagnose dengue 
infection. Diagnostic kits based on whole virus are expensive due to the high costs associated 
with antigen production (Hapugoda et al., 2007; Tan and Ng, 2010). Now a days recombinant 
protein based ELISA for detection of antibodies may replace the native antigen based assays. 
The test is simple, rapid, sensitive and is also capable of discriminating between primary and 
secondary infections by detecting IgM and IgG antibodies (Hapugoda et al., 2007; Tripathi et 
al., 2011). Thus the aim of the present work is to evaluate recombinant dengue virus 
envelope domain III protein for detection of anti dengue IgM and IgG antibodies to detect 
dengue infection. 
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2.7.2 Dengue Vaccines  
 The development of a vaccine against dengue has been a high priority of the World 
Health Organization (WHO) for decades. Inactivated viral vaccines for other closely related 
flaviviruses, such as yellow fever, Japanese encephalitis and tick borne encephalitis viruses, 
are available but no safe and effective vaccine or therapeutic measures has been developed 
for dengue virus till date. The current status of flaviviral vaccines development is shown in 
table 2.3 (Pulmanausahakul et al., 2010; Simmons et al., 2012). Currently many virus-based 
dengue vaccines are in various stages of development (Table 2.3). Two of these are 
traditional tissue culture-based live attenuated vaccines whereas the remaining four are 
chimeric recombinant vaccine viruses developed using infectious clone technology. In all 
these instances, the vaccine viruses are monovalent in that each one is specific to one dengue 
serotype. A tetravalent dengue vaccine is based on producing vaccine formulations by 
mixing all four monovalent vaccine viruses. Investigations using virus-based recombinant 
and non-recombinant dengue vaccine candidates in monkeys (Guirakhoo et al., 2002) and 
man (Sabchareon et al., 2002), respectively, have shown that the current strategy of creating 
tetravalent dengue vaccine formulations can lead to an unbalanced immune response, specific 
to only one particular serotype.  While efforts are underway to optimize the tetravalent 
formulations, the inherent risk of viral interference associated with the current strategy of 
producing tetravalent dengue vaccine warrants investigation of other vaccines that eliminate 
this risk of viral interference. The primary drawback is that the attenuated virus may revert 
back to its virulent state while living in the host's body. This formalin-inactivated type of 
vaccine is probably the most common on the market today; however, despite the widespread 
use of this technique of vaccine preparation the resulting products are really not very 
effective because the formalin treatment often chemically alters the antigen in some way so 
as to render it less potent in eliciting an immune response in the host. Where as DNA based 
vaccines tend to induce relatively low antibody titres, presumably due to the poor efficiency 
of target cell transduction and concomitant low-level antigen expression. Induction of low 
titres of antibodies is potentially risky in the context of ADE.  
Recent developments and success in recombinant subunit protein vaccines for several 
viral diseases like hepatitis, malaria  and anthrax  opened new opportunities in dengue 
vaccine research. Keeping in view of the present scenario of severity and spread of dengue 
fever, studies on evaluation of new candidate recombinant dengue antigens for  possible 
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Table 2.3. Current flaviviral vaccines (Pulmanausahakul et al., 2010; Simmons et al., 
2012). 
Pathogen Available vaccines                       Vaccines under development 
Yellow fever YF 17D live attenuated virus None 
Japanese 
encephalitis 
Inactivated mouse brain 
derived; Inactivated cell 
culture derived; SA 14-14-2 
live attenuated 
ChimeriVax-JE; IC 51; 
Inactivated cell culture derived; 
Adenovirus type 5 vectored 
prM-E virus like particles subunit and 
naked DNA 
Dengue types 
1-4  
 
 
 
None Live attenuated yellow fever 17D/DENV 
chimeric vaccine; PDK cell-passaged, live 
attenuated vaccine; Live attenuated DENV 
Delta-30 mutation and intertypic DENV 
chimeric vaccines; Dengue prM-E DNA 
vaccine; Recombinant 80% E subunit 
antigen vaccine; Purified inactivated 
vaccine (PIV); Live  attenuated chimeric 
DENV vaccine 
West Nile No human vaccines; 
Veterinary inactivated cell 
culture derived vaccines 
Inactivated cell culture derived; 
ChimeriVax-WN; 
DEN-4/WN chimera 
Tick-borne 
encephalitis  
Inactivated cell culture 
derived 
Recombinant live 
DEN-4/TBE or DEN-4/Langat chimeras 
Virus attenuated by C protein deletion prM-
E virus-like particles truncated E protein 
subunit infectious DNA/RNA encoding 
attenuated/nonreplicating vaccines 
Kyasanur 
forest disease 
Inactivated cell culture 
derived 
None 
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vaccine development is the need of the hour. Since protein subunit vaccines employ only a 
portion of a virus, they are easy, safer in production and use than live vaccines containing the 
whole genome. Moreover production of subunit vaccines involves low cost when compared 
to inactivated vaccines. Recombinant DNA techniques provided the possibility of cloning 
specific genes encoding for protective antigens and of expressing them in other host cells, 
including E.coli, Yeast and insect cell systems. This technology has been used by several 
researchers for the development of subunit vaccines. 
 Majority of efforts have been made to express the recombinant envelope protein 
(Kelly et al., 2000; Jaiswal et al., 2004; Pattnaik et al., 2006; Zhang et al., 2007; Batra et al., 
2010; Pulmanausahakul et al., 2010; Guzman et al., 2010; Valdes et al., 2011; Clements et 
al., 2010; Coller et al., 2011; Chiang et al., 2012; Yang et al., 2012) while few have tried to 
express non structural proteins (Das et al., 2009; Pulmanausahakul et al., 2010; Simmons et 
al., 2012; Amorim et al., 2012) subunit vaccine candidates.  
2.7.3 Dengue Virus Envelope Domain III Protein as Diagnostic and Vaccine 
Candidate  
 The envelope protein comprises 3 regions: Domain I, Domain II and Domain III 
(Figure 2.6). Experimental evidences have shown that the EDIII protein is a receptor binding 
domain (Chin et al., 2007; Zhang et al., 2007; Block et al., 2010; Coller et al., 2011; 
Simmons et al., 2012). In addition, it has also been demonstrated to be highly immunogenic 
and able to elicit the production of neutralizing antibodies against the wild-type virus 
(Guzman et al., 2010; Tan et al., 2010; Chiang et al., 2012). The binding of the DIII-specific 
neutralizing antibodies to the virus caused an alteration of the spatial arrangement between 
the glycans on the E proteins. These changes in the structure of the viral surface were 
presumably responsible for inhibiting attachment to the cells (Lok et al., 2008). One major 
challenge to dengue virus vaccine development is the potential development of antibody-
dependent enhancement (ADE) of virus replication, which is believed to cause DHF and DSS 
(Simmons et al., 2012). In addition, immunization against one dengue serotype induces life-
long immunity against the homologous serotype and short-lived immunity against the other 
serotypes. Put together, it is widely believed that for a dengue virus vaccine to be effective, it 
must comprise neutralizing epitopes from all four serotypes (tetravalent) (Tan and Ng, 2010). 
Presently, EDIII protein immunization in animal has demonstrated promising results. In these 
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Domain II (A) 
Domain I (C) 
Domain III (B) 
studies, a variety of parameters affecting recombinant dengue virus EDIII protein 
immunogenicity has been investigated. These parameters include: antigen combination - 
monovalent, bivalent, or tetravalent EDIII and type of animal model used (Table 2.4).  
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Structural organization of dengue  virus envelope protein-domain I, II and III. 
 On the whole, recombinant EDIII protein immunization generated satisfactory levels 
of antibodies that are neutralizing against the virus. This observation is consistent for dengue 
virus and West Nile virus EDIII proteins expressed from E. coli (Babu et al., 2008; Chin et 
al., 2007; Martina et al., 2008). Unlike live attenuated vaccines, protein subunit vaccines 
need to be adjuvanted in order to elicit a suitably good immune response (Whitehead et al., 
2007; Chiang et al., 2012). It has been observed that recombinant EDIII protein mixed with 
either complete/incomplete Freund‘s Adjuvant, PELC, CpG or Montanide ISA 720 adjuvants 
elicited polyclonal antibodies (in mice) with higher neutralizing efficacies (PRNT90 of 1:128) 
as compared to the neutralizing antibodies generated using an recombinant EDIII protein-
Alum mix (PRNT90 of 1:64). Cell-mediated immune responses were also varied according to 
the type of adjuvant used (Babu et al., 2008; Chiang et al., 2012). However, the true potential 
of envelope domain III as a potential vaccine candidate has not been thoroughly investigated. 
Nonetheless, generation of recombinant dengue virus EDIII protein from infected tissue 
culture insect cells is a laborious and costly, subjected to batch-to-batch variation making it 
difficult to routine large-scale production. Production of recombinant EDIII protein in  
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Table 2.4. Recent studies on recombinant dengue virus EDIII based vaccine. 
Protein(s) tested Animal model Results Authors and years 
rDen 2 EDIII Rat Generation of anti-dengue 
2 EDIII antibodies 
Saejung et al., 2006 
rDen 1 and rDen 2 
EDIII 
Balb/C mice Generation of neutralizing 
antibodies invitro and 
blocking of viral entry 
Chin et al., 2007 
Tetravalent rDen 
1-4 EDIII 
Balb/C mice Protection against dengue 
virus 1, 2 and 4 (80%) and 
dengue virus 3 (18%) 
Chen at al., 2007 
Tetravalent rDen 
1-4 EDIII 
(Expressed in 
Pichia pastoris) 
Balb/C mice Generation of neutralizing 
antibodies against all four 
dengue serotypes 
Etemad et al., 2008 
rDen 2 EDIII Macaca 
fascicularis 
monkeys 
Generation of neutralizing 
antibodies against dengue 
virus 2 
Bernardo et al., 2008 
Tetravalent rDen 
1-4 EDIII 
Balb/C mice Generation of un-balanced 
neutralizing antibodies 
against dengue virys 1-4 
Block et al., 2010 
rDen 1 EDIII Balb/C mice Generation of neutralizing 
antibodies against dengue 
virus 1 
Tan et al., 2010 
rDen 2 EDIII BALB/c and 
C57BL/6 mice 
Generation of neutralizing 
antibodies against dengue 
virus 2 
Yang et al., 2012 
rDen 1 EDIII Balb/C mice Generation of neutralizing 
antibodies against dengue 
virus 2 
Chiang et al., 2012 
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E.coli strains is a much cheaper and a simpler procedure (Jaiswal et al., 2004; Zhang et al., 
2007; Tripathi et al., 2008; Tan et al., 2010; Tripathi et al., 2011). Currently, there is a need 
for the production of cost effective and safe EDIII protein related biologics for the 
development of protein subunit vaccines or diagnostic reagents. For these purposes, the 
recombinant proteins produced must maintain their biological activity (i.e., generate 
neutralizing antibodies against wild-type virus or able to bind to anti-dengue virus antibodies 
found in patient serum).  
Currently, dengue diagnosis is based on serology, virus isolation and RNA detection 
(Tripathi et al., 2011). Because of its sensitivity and ease of use, the ELISA platform is 
widely used as surveillance tool to detect antigen or anti dengue IgM and IgG antibodies in 
patient serum samples. Although to date, there is no EDIII protein-based diagnostic assay 
available commercially, many in-house tests have demonstrated the possibility of using the 
EDIII protein as a reagent to serologically detect dengue infection (Jaiswal et al., 2004; 
Hapugoda et al., 2007; Tripathi et al., 2008, 2009; Batra et al., 2011). IgM and IgG ELISA 
performed using recombinant dengue virus EDIII protein coated immuno-plate was used for 
the detection of antibodies in patient serum samples (Hapugoda et al., 2007; Batra et al., 
2010, 2011). IgG-ELISA was similarly performed using EDIII antigens for detection of anti-
EDIII antibodies in mice serum (Khanam et al., 2007; Babu et al., 2008; Coller et al., 2011). 
In addition, tetravalent EDIII proteins could also be used for the detection of antibodies 
against dengue virus via an IgG-ELISA platform (Chen et al., 2007; Etemad et al., 2008). 
Based on these findings, the EDIII protein demonstrates great potential in being produced as 
diagnostic reagents for the development of serological tools such as ELISA. These tools, if 
validated and available commercially, can enhance mass screening of patient serum samples 
and allow rapid initial detection of dengue virus suspect cases in clinics. The dengue EDIII 
protein is highly immunogenic and has vast potential as a protein subunit vaccine as well as a 
diagnostic reagent for dengue diagnosis. The current work is based on the premise that the 
development of a diagnostic and vaccine based on the production and purification of 
envelope domain III of dengue virus serotypes and the detailed study on their diagnostic 
potential as well as immunogenicity in mice models. Further studies are required to increase 
the Immunogenicity of subunit vaccines by incorporating them into adjuvants or other 
systems for stimulating immune responses. 
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2.8 THE JAPANESE ENCEPHALITIS VIRUS 
 One of the most important viral encephalitis causative agents in Asia is Japanese 
encephalitis virus (JEV) which is transmitted to human by Culex mosquitoes, principally 
Culex tritaeniorhynchus and Culex quinquefasciatus, which have fed on viremic animals, 
mostly domestic pigs. The geographic distribution (Figure 2.7) of JEV is mainly in the Asian 
region including India, China, and all of South-East Asia, although outbreaks have also been 
reported in Pakistan, Nepal and Australia. With nearly 3 billion people living under the 
current JE-endemic region, recurring incidents of epidemic are being reported at regular 
intervals. From the 1870s, recurring epidemics of encephalitis have been reported from the 
islands of Japan, especially during the summer season, with major outbreaks occurring every 
10 years. In 1935 the Nakayama strain of Japanese encephalitis virus (JEV) was isolated 
from the brain of a fatal case. Since then, the virus has spread in South Asia, Southeast Asia  
 
Figure 2.7 Geographical distribution of Japanese encephalitis (Ghosh and Basu, 2009). 
and the Pacific regions. Rapid globalization, population explosion, changes in global climatic 
condition, industrialization and deforestation, all seem to correlate with the spread of the 
virus into newer territories (Ghosh and Basu, 2009). In India, JE as a disease was first 
reported in 1955 when clinical cases were detected in Vellore and Pondicherry in southern 
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India. From then onwards to till date there have been JE cases reported JE in India every year 
(Dutta et al., 2010; Pujhari et al., 2011). In endemic areas, at least 50,000 cases of Japanese 
encephalitis (JE) are reported annually, among which some 10,000 cases result in death. 
Because of the high mortality rate, the disease is considered as one of the most important 
health problems in the South-East Asia region. A typical illness starts with fever and other 
symptoms including vomiting and photophobia. Neurological symptoms develop 
subsequently, with a spectrum ranging from neck stiffness, stupor and impaired 
consciousness to seizures, parkinsonian movement disorders, convulsions, flaccid paralysis 
and coma. Gradually the fever rises and encephalitis starts at which point the fatality rate is 
about 35% (Dutta et al., 2010; Pulmanausahakul et al., 2010; Abraham et al., 2011). Due to 
lack of effective medical treatment or a specific antiviral, attempts to develop a cost effective 
diagnostic and vaccine candidate against the JE are considered a high priority. 
2.8.1 Japanese Encephalitis Diagnosis 
 Due to lack of definitive therapeutic for JE, early diagnosis plays major role in patient 
management. The clinical picture of JE resembles the picture of acute encephalitis 
syndromes of other aetiologies and cannot be differentiated accurately. The confirmatory 
diagnosis therefore requires antigen or antibody determination. The routine laboratory 
diagnosis of JEV infection is based on virus isolation and serology followed by identification 
of the viral genome by reverse transcription polymerase chain reaction (RT-PCR) or real 
time PCR. PCR is based on the identification of the virus or its RNA genome which persists 
in circulation during short period of viremia (Parida et al., 2006; Ravi et al., 2006; Santhosh 
et al., 2007; Li et al., 2012). Virus isolation and PCR is costly and requires sophisticated 
setup. Cultivation of JEV from blood and cerebrospinal fluid (CSF) is rarely positive as the 
viraemic period lasts only a few days, thus diagnostics rely mostly on serological assays. The 
flavivirus group shows intense cross-reactivity which is highest on the IgG level. However 
IgM is relatively specific for the infecting virus. IgM is detectable in CSF and blood from 
almost all patients within 7 days after onset of disease. Since most of the JE cases occurs in 
rural areas, IgM ELISAs are used most commonly (Jacobson et al., 2007; Ghosh and Basu, 
2009; Ravi et al., 2009; Litza et al., 2010; Robbinson et al., 2010). Diagnostic kits based on 
whole virus are expensive due to the high costs associated with antigen production 
(Shrivastva et al., 2008). Now a days recombinant protein based ELISA for detection of 
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antibodies may replace the native antigen based assays (Tan and Ng, 2010; Chavej et al., 
2010). Thus, in a majority of cases the only feasible diagnostic test would have to be based 
on the identification of ant-JEV IgM antibodies by ELISA. Thus the aim of the present work 
is to evaluate recombinant JEV envelope domain III protein and nonstructural 1 protein in 
ELISA for detection of anti JEV IgM antibodies to detect JEV infection 
2.8.2 Japanese Encephalitis Vaccine 
 Due to lack of definitive therapeutic countermeasures to combat JE, implementation 
of prophylactic strategies remains the best way to prevent JE.  Human vaccination remains, 
till date, the most effective measure to prevent JE. Multiple vaccines exist to control JE 
(Table 2.3.), but all have their limitations. The available vaccines for JE is based on the 
mouse brain or cell culture derived formalin inactivated vaccine. Immunization against the 
virus is the single most important control strategy that could reduce dramatically the numbers 
of JE cases (Nitatpattana et al, 2008; Halstead and Thomas, 2010). Purified formalin-
inactivated mouse brain-derived vaccine and an inactivated Vero cell culture-derived vaccine 
have been licensed in the  United  States  and  a  live  attenuated vaccine (SA 14-14-2) is 
used in many countries in Asia (Misra and Kalita, 2010). These 3 commercially available 
vaccines against JE are based on the Nakayama, Beijing-1, and SA14-14-2 strains, which 
belong to genotype III (Dutta et al., 2010; Abraham et al., 2011; Liu et al., 2011). Despite 
widespread availability of these vaccines, it is comparatively expensive for large scale use in 
many Asian countries and there have been reports of severe allergic reactions to this vaccine 
(Plesner and Ronne, 1997; Pulmanausahakul et al., 2010). Considering cost and safety, 
recombinant protein based JEV vaccine is necessary for human use.  
Several efforts have been and are still being made to develop recombinant vaccines 
for JEV. Amongst the JEV viral proteins, JEV E protein seems to be the most suitable one 
for plasmid DNA based vaccines, since antibodies against E protein are capable of 
neutralizing JEV activity. Plasmid constructs that contain JEV E protein together with the 
prM protein have been shown to provide a protective immune response to lethal JEV 
challenge in adult mice (Chang et al., 2000; Konishi et al., 1999). There are also DNA 
vaccines candidates utilizing non-structural proteins of JEV. Immunization of mice with 
plasmid DNA constructs containing JEV NS1 provided 90% protection against lethal 
challenge with JEV while plasmids being longer constructs failed to provide protection. 
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However, vaccines utilizing JEV NS5 or NS3 failed to raise an effective immune response 
(Liang et al., 2009). Recombinant virus based vaccines have also been reported in JEV 
vaccine development. JEV structural and non-structural proteins including prM, E, NS1 and 
NS 2B expressed in different systems can produce a protective immune response in mice 
(Lin et al., 2008; Wang et al., 2009; Witthajitsomboon et al., 2010; Pulmanausahakul et al., 
2010; Lin et al., 2012). Envelope domain III based recombinant vaccine against JE virus has 
been proposed which carry dominant epitopes that induce neutralizing antibodies, has been 
created. JEV envelope domain III protein has also been evaluated in murine models (Li et al., 
2012; Tafuku et al., 2012). Thus, present study targeted the process development for 
production of envelope domain III protein of JE virus and its characterization for diagnostic 
and vaccine utility. 
2.8.3 JEV EDIII Protein as a Potential Diagnostic and Vaccine Candidate 
 Inactivated JEV vaccines, prepared from infected mouse brains (BIKEN or JEVAX)  
or  primary  hamster  kidney cells,  have  been  successfully  developed  to  control  JEV 
infection (Dutta et al., 2010; Halstead and Thomas, 2010). However, a major problem 
associated with the inactivated mouse brain vaccine is its failure to stimulate long-term 
immunity.  As a result, multiple immunizations are recommended to provide adequate 
protection. In addition, inactivated mouse brain or cell culture derived whole virus vaccines 
are costly to prepare and carry the risk of allergic reactions. The World Health Organization 
has designated JEV vaccines as a high-priority target for further research and development. 
Several experimental recombinant, attenuated, subunit and DNA-based JEV vaccines have 
been reported (Pulmanausahakul et al., 2010) however, only limited protective immunity 
could be obtained. Hence, new strategies should be developed to produce safer and more 
efﬁcacious vaccines against JEV infection. The envelope protein is formed as a flat, 
elongated dimer on the virus surface, and each monomer consists of three domains: domain I; 
domain II and domain III (Figure 2.6). Among these three domains, only the domain III can  
be  independently  folded  as  an  individual  fragment  that requires  one  disulfide  bridge  to  
maintain  its  conformational structure.  Envelope domain III carries several epitopes capable 
of eliciting virus-neutralizing antibodies (Alka et al., 2003; Verma et al., 2009). Since the 
envelope domain III protein  can fold independently into a stable conformation, it is  
therefore an  attractive  target  to block infectivity  either  through  the  design  of  molecules  
that  would compete with whole virus  to  enter cells or by eliciting neutralizing  antibodies 
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(Wu et al., 2003; Lin et al., 2008; Ramanathan  et al., 2009).  Experimental evidences have 
shown that the EDIII protein is a receptor binding domain and demonstrated to be highly 
immunogenic and able to elicit the production of neutralizing antibodies against the JE virus 
(Alka et al., 2003; Tafaku et al., 2012). Recombinant JEV EDIII protein immunization in 
animal has demonstrated promising results and generated satisfactory levels of antibodies 
that are neutralizing against the virus. This observation is consistent for dengue or West Nile 
virus proteins expressed from E. coli (Tan and Ng, 2010). It has been observed that EDIII 
protein mixed with Adjuvant elicited polyclonal antibodies (in mice) with higher neutralizing 
efficacies as compared to the neutralizing antibodies generated using an EDIII protein. In 
addition it should also be useful to identify receptors and co-receptors located at the cell 
surface for the development of a receptor blocking vaccine (Alka et al., 2003; Verma et al., 
2009). Nonetheless, generation of recombinant JEV EDIII protein from infected tissue 
culture insect cells is a laborious and costly, making it difﬁcult for routine large-scale 
production. Production of recombinant EDIII protein in E.coli strains is a much cheaper and 
a simpler procedure (Lin et al., 2008; Tafuku et al., 2012). 
Currently, JE diagnosis is based on serology, virus isolation and RNA detection 
(Ghosh and Basu, 2009). Because of its sensitivity and ease of use, the ELISA platform is 
widely used as surveillance tool to detect antigen or anti JE IgM antibodies in patient serum 
and CSF samples (Jacobson et al., 2007; Ravi et al., 2009; Litza et al., 2010). Although to 
date, there is no EDIII protein-based diagnostic assay available commercially, in-house tests 
have demonstrated the possibility of using the EDIII protein as a reagent to serologically 
detect JE infection. IgM ELISA performed using recombinant JE virus EDIII protein was 
used for the detection of antibodies in patient serum and CSF samples (Tripathi et al., 2010). 
IgG-ELISA was similarly performed using EDIII antigens for detection of anti-EDIII 
antibodies in mice serum (Verma et al., 2009; Lin et al., 2008; Tafuku et al., 2012). Based on 
these findings, the EDIII protein demonstrates great potential in being produced as diagnostic 
reagents for the development of serological tools such as ELISA. These tools, if validated 
and available commercially, can enhance mass screening of patient serum and CSF samples 
and allow rapid initial detection of JE virus suspect cases in rural areas. For this reason, the 
EDIII protein is an important immunogen for the development of a prospective protein 
subunit vaccine and also a prospective diagnostic reagent for the improved clinical diagnosis 
of JEV infections. However, the true potential of domain III as a potential vaccine candidate 
has not been thoroughly investigated. Further studies are required to increase the 
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Immunogenicity of subunit vaccines by incorporating them into adjuvants or other systems 
for stimulating immune responses. The objective of the study is to obtain high yield, refolded 
and purified envelope domain III protein of JEV for potential use in diagnostic and vaccine 
development studies.   
2.8.4 JEV Nonstructural 1 Protein as a Potential Diagnostic and Vaccine Candidate 
 Although the function of the NS1 is not elucidated fully, available evidence suggests 
that this protein is involved in viral RNA replication (Abraham et al., 2011). In addition, the 
high immunogenicity of the NS1 proteins of JE and other ﬂaviviruses has raised considerable 
interest both as an antigen for diagnostic methods (Konishi et al., 2009; Allonso et al., 2011; 
Kassim et al., 2011; Li et al., 2012) and as component of subunit vaccine formulations (Lin et 
al., 2008; Amorim et al., 2010; Li et al., 2012; Tafuku et al., 2012). Attempts to express the 
dengue virus NS1 protein in Escherichia coli strains have obtained limited success due 
mainly to the insolubility of the recombinant protein. In addition, the lack of post 
translational modiﬁcations and altered secondary structure of the recombinant protein affects 
the formation of dimers and results in decreased immunogenicity and antigenicity (Das et al., 
2009). Nonetheless, generation of recombinant NS1 protein from infected tissue culture 
insect cells is a laborious and costly, subjected to batch-to-batch variation making it difﬁcult 
for routine large-scale production. Production of recombinant NS1 protein in E.coli strains is 
a much cheaper and a simpler procedure (Lin et al., 2008; Das et al., 2009; Amorim et al., 
2010; Tafuku et al., 2012). Antibodies to JEV nonstructural proteins constitute a marker of 
natural infection among vaccinated populations. NS1 antigen was used in ELISA to detect 
antibodies in horse sera (Konishi et al., 2004). An ELISA using JEV NS1 antigen has been 
reported to measure anti JEV NS1 antibodies induced in sera of vaccinated clinical cases 
(Konishi et al., 2009). However, the true potential of JEV NS1 antigen as a potential 
diagnostics or vaccine candidate has not been thoroughly investigated. The present study 
aims to establish production systems in E. coli for high yield of recombinant JEV NS1 
protein and an in-house ELISA using this recombinant protein for detection of IgM antibody 
to JEV NS1 in human sera and CSF samples.  
 *** 
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The materials and methods described in the following section apply to all 
experiments. These are general materials and methods which have been used throughout the 
whole work, although specific contents used in particular parts of it can be also found in the 
corresponding chapters. 
3.1 STRAINS AND VECTORS.  
 Three different E. coli based systems were used to overexpress recombinant JE virus 
envelope domain III and NS1 protein as well as dengue virus envelope domain III protein. 
All the three strains were stored at -80ºC in glycerol stocks made from exponential phase 
culture in Luria Bertani medium supplemented with antibiotics.  
The first expression system was used to overexpress recombinant JE virus envelope 
domain III protein with a hexahistidine tag. The E. coli strain BL21 (DE3) [Novagen, USA] 
harbouring recombinant plasmids pET30a+  (Novagen, USA) encoding envelope domain III 
gene of JE virus was used for its overexpression. This strain was previously cloned and 
transformed with a commercially available plasmid, pET30a+ inducible expression vector,  
in which the rJEV EDIII gene was inserted into the NdeI and XhoI sites and the resultant 
NdeI-XhoI fragment was cloned downstream of T7 promoter of E. coli expression vector 
pET30a+  to yield plasmid pET-JEV EDIII. The resultant transformants were selected on 
kanamycin plates.  
The second expression system was used to overexpress recombinant JE virus 
nonstructural 1 protein with a hexahistidine tag. The E. coli strain SG13009 (Qiagen, 
Germany) harbouring recombinant plasmids pQE-30UA  (Qiagen, Germany) encoding 
nonstructural 1 gene of JE virus was used for its overexpression. This NS1 gene was 
previously cloned downstream of T5 promoter of E. coli expression vector pQE-30UA to 
yield plasmid pQE-JEV NS1.  The resultant transformants were selected on ampicillin and 
kanamycin plates.  
The third expression system was used to overexpress recombinant dengue virus type 
1 to 4 envelope domain III proteins separately with a hexahistidine tag. The E. coli strain 
BLR (DE3) [Novagen, USA] harbouring recombinant plasmids pET30a+ encoding envelope 
domain III gene of dengue virus serotype 1 to 4 separately was used for overexpression. 
Transformation of this strain was performed using commercially available plasmid, pET30a+ 
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inducible expression vector, in which recombinant dengue virus type 1, 2, 3 and 4 envelope 
domain III gene was inserted into the NdeI and SalI sites and the resultant NdeI-SalI 
fragment was previously cloned downstream of T7 promoter of E. coli expression vector 
pET30a+ to yield plasmid pET-rDen 1, 2, 3 and 4 envelope domain III gene. The resultant 
transformants were selected on kanamycin and tetracycline plates.    
3.2 CHEMICALS, BIOLOGICALS AND OTHER CONSUMABLES  
 All chemicals used in this study were purchased from Sigma, USA. All the media and 
its components were obtained from Difco, USA. SDS-PAGE related reagents were obtained 
from Bio-Rad, USA. Protein molecular weight markers and silver staining kit were from 
MBI Fermentas, USA. HRP conjugated anti-mouse IgG antibodies, HRP-conjugated anti-
human IgG and IgM antibodies. Antibiotics and IPTG were purchased from Sigma, USA. 
HRP conjugated anti-his antibodies (6x His) were from Qiagen, Germany. Freund‘s complete 
adjuvant (FCA) and Freund‘s incomplete adjuvant (FIA) were procured from Sigma, USA. 
BCA protein assay kit was from Pierce, USA.  
3.3 ANTIBIOTICS AND INDUCER 
 The concentration of antibiotics and inducer used in this study are given in table 4.1. 
Table 4.1 Antibiotics and inducer for shake flask culture and fermentations. 
Reagent Stock solution Final concentration in use 
Tetracyclin 12.5 mg/ml 12.5 µg/ml 
Kanamycin 50 mg/ml 50 µg/ml 
Ampicillin 100 mg/ml 100 µg/ml 
IPTG 238  mg/ml             1  µg/ml 
3.4 MEDIA COMPOSITION  
 Detailed media composition used for shake flask culture, batch and fed-batch 
fermentations are given below. All the media were prepared in triple distilled water (TDW) 
and sterilized by autoclaving for 20 min at 15 psi pressure unless otherwise indicated.  
 (a)  Luria bertani (LB) broth (per liter) 
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 Tryptone     10 g 
 Yeast extract     5 g 
 Sodium chloride    5 g 
 (b) Super optimal broth (SOB) (per liter) 
 Tryptone     20 g 
 Yeast extract      5 g 
 Sodium chloride     0.5 g 
 Magnesium sulphate    2.4 g 
 Potassium chloride     0.186 g   
 (c) Super optimal broth with catabolic repressor (SOC) (per liter) 
 Tryptone      20 g 
 Yeast extract     5 g 
 Sodium chloride    0.5 g 
 Magnesium sulphate    2.4 g 
 Potassium chloride    0.186 g   
 Glucose     3.6 g 
 (d)  M9 minimal medium (per liter) 
  Di-sodium phosphate      6.78 g 
  Mono-potassium phosphate   3 g 
  Sodium chloride     0.5 g 
  Ammonium chloride      1 g 
  Glucose    20 g 
 (e)  Terrific broth (per liter) 
 Tryptone     12 g 
 Yeast extract     24 g 
 Di-potassium phosphate   9.4 g 
 Mono-potassium phosphate   2.2 g 
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 Glycerol     4 ml 
 (f)  Super broth (per liter) 
 Tryptone     12 g 
 Yeast extract    24 g 
 Di-potassium phosphate  11.4 g 
 Mono-potassium phosphate  1.7 g 
 Glycerol    5 ml 
 (g) Defined medium (per liter) 
  Di-sodium phosphate      6.78 g 
  Mono-potassium phosphate   3 g 
  Sodium chloride     0.5 g 
  Ammonium chloride      1 g 
 Magnesium sulphate    2 g 
 Glycerol    20 ml  
 (h)  Modified super broth (per liter) 
 Tryptone     12 g 
 Yeast extract    24 g 
 Di-potassium phosphate  11.4 g 
 Mono-potassium phosphate  2.2 g 
 Sodium chloride   0.5 g 
 Magnesium sulphate    2.4 g 
 Ammonium chloride    1 g 
 Glycerol    20 ml  
 (i) Feed medium for fed batch fermentation (per liter) 
  Glycerol   400 ml 
  Yeast extract  300 g 
  Magnesium sulphate  10 g 
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 (j) Trace metal solution (per liter)  
 FeSO4·7H2O    2.8 g 
 MnCl2·4H2O    2 g 
 COCl2·7H2O    2.8 g 
 CaCl2·2H2O    1.5 g 
 CuCl2·2H2O     0.2 g 
 ZnSO4·7H2O    0.3 g 
 H3BO3,    0.02 g  
 HCl     1 M 
 (k)  Eagles minimum essential medium (EMEM) (per liter)  
  EMEM   9.4 g 
  NaHCO3   2.0 g 
  Streptomycin    100 mg 
  Penicillin   100000 U 
  Gentamycin   40 mg 
  Milli Q water   900 ml 
 The medium was filtered through 0.22 µm filter and 10% Fetal bovine serum (FBS) 
[Sigma, USA] was added at the time of use to make complete EMEM. 
 (l)  Overlay Medium Prepared in EMEM 
  Carboxymethyl cellulose   1.25%  
  FBS     2% 
3.5 Instrumentation 
 Shaker-incubator (Kuhner AG, Switzerland), Fermentors of working capacity 5, 10 
and 100 liters (New Brunswick, USA), Floor model and table top centrifuge (Thermo, USA), 
Lab (Pellicon mini) and large Scale (Prostak system, Pellicon Spl.) TFF system (Millipore, 
USA) for Microfiltration, Ultrafiltration and Diafiltration, Agitator bead mill (Willy A 
Bachofen, Switzerland), Sonicator (Sonics, USA), Lab and pilot Scale Liquid 
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Chromatography systems (GE Healthcare, Sweden), Spectrophotometer (Thermo, USA ), 
ELISA Reader (Biotek, USA), Electrophoresis and  Gel Documentation system (Bio-Rad, 
France), Freezers, Biosafety cabinet, Incubator, Bioprocess Scale up Facility and Laboratory 
Animal Facility of this Establishment was used for this study. 
3.6 PROTEIN PURIFICATION COLUMNS, RESINS AND 
FILTRATION DEVICES 
 Ni-Sepharose and SP sepharose columns [1 ml, 5 ml and 20 ml (16/10) pre-packed] 
were used for laboratory scale affinity and ion-exchange chromatographic purification of 
recombinant proteins respectively. Ni-Sepharose and SP sepharose resin, for affinity and ion-
exchange purification of proteins using 5 ml and 10 ml gravity flow column, XK 16/20, XK 
26/20, XK 26/40, XK 50/30 were used. Superdex 75 10/300 GL and High load 16/60 gel 
filtration column were used for gel filtration chromatography. All these columns and resins 
were from GE Healthcare, Sweden. Quik Scale 70/55 Biochromatography pilot scale column 
was from Millipore, USA. All the micro (0.45 µ) and ultrafiltration (3, 5, 10 and 30 kDa) 
membranes (50 cm
2
, 0.1 m
2
, 0.5 m
2
 and 20 ft
2
), centrifugal cut-off devices (15 and 50 ml) 
were purchased from Millipore, USA. Dialysis membranes were from Sigma, USA. PVDF 
membrane for Western blotting was from Millipore USA. Amicon ultra centrifugal filter 
devices were from Millipore, USA.  
3.7 VIRUS, CELLS, SERUM SAMPLES & EXPERIMENTAL ANIMALS  
 Dengue virus type 1 to 4 and Japanese encephalitis virus were previously obtained 
from National Institute of Virology, Pune, India. Cell lines (LLC-MK2, Vero and C6/36) were 
previously obtained from National Centre for Cell Science, Pune, India. The well 
characterized serum samples previously collected in Gwalior and Delhi in India (for dengue), 
Gorakhpur in India (for Japanese Encephalitis) and healthy serum samples are included in 
this study for characterization of proteins. BALB/c mice (CDRI Strain) between 3-4 weeks of 
age were obtained from the animal facility of DRDE, Gwalior. Viruses, cells, serum samples 
and CSF samples used in this study were obtained whenever required from Division of 
Virology of this Establishment. 
3.8 REAGENTS AND BUFFERS       
 All reagents and buffers for protein work were prepared in Milli Q grade water. These 
are general reagents and buffers which have been used throughout the whole work, although 
specific things used in particular parts of it can be also found in the corresponding chapters. 
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 Reagents and Buffers for SDS-PAGE 
 (a)  Acrylamide (30%)   
  Acrylamide     29.2 g 
  N, N' methylene bisacrylamide  0.8 g 
  Milli Q water     60 ml 
 The solution was stirred to dissolve the acrylamide. The volume was made up to 100 
ml and the solution was filtered through Whattman filter paper no. 1 before use. 
 (b)  Ammonium per sulfate    10% (w/v) 
 (c)  TEMED        8.4% (v/v) 
 (d)  Resolving buffer 
  Tris base       9.08 g 
  SDS       0.2 g 
 Dissolve in 60 ml of distilled water and adjust pH to 8.8 with concentrated HCl and 
make up to 100 ml.  
 (e) Stacking buffer 
  Tris base       3.03 g 
  SDS       0.2 g 
 Dissolve in 60 ml of distilled water and adjust pH to 6.8 with concentrated HCl and 
make up to 100 ml. 
 (f)  10X Tris-Glycine buffer (per liter) 
  Tris base     30.3 g  
  Glycine     144.1g 
  SDS      10 g 
 (g) Coomassie brilliant blue staining solution (per liter)  
  Brilliant blue (R250)    1 g 
  Acetic acid     100 ml 
  Methanol     400 ml 
  Milli Q water    500 ml 
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 (h) Destaining solution (per liter) 
  Methanol    400 ml 
  Glacial acetic acid   100 ml 
  Milli Q water     500 ml  
 (i) Lysis Buffer (SDS-PAGE sample buffer) 
  Tris base      1.51 g 
  SDS       4 g 
  Glycine      20 g 
  Bromophenol blue     0.002 g 
 Dissolve in 60 ml of water and make up to 90 ml. Add 10 m1 -mercaptoethanol just 
before use. 
 Reagents and buffers for Western blot Analysis 
 (a) Transfer buffer  (per liter)  
  Tris Base    3 g 
  Glycine     14.4 g 
  Methanol     200 ml 
 (b)  Blocking buffer            5% BSA in PBS   
 (c)  Wash buffer    0.05% Tween 20 in PBS (PBS-T) 
 (d)  Developing buffer  
  DAB      4 mg 
  0.1 M Citric acid   2.57 ml 
  0.2 M Na2HPO4   2.43 ml 
  MQ water     5 ml 
  H2O2      15 µl 
 Reagents for ELISA 
 (a) Coating buffer (pH 9.6) 
  Na2CO3     0.159 g 
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  NaHCO3     0.290 g 
  Milli Q water    100 ml  
 (b)  Blocking buffer   2% BSA in PBS 
 (c)  Wash buffer    0.05% Tween 20 in PBS (PBS-T)  
 (d) Citrate Phosphate buffer (pH 5.0) 
  0.1 M Citric acid   2.57 ml 
  0.2 M Na2HPO4   2.43 ml 
  Milli Q water    5 ml  
 (e)  Developing buffer for micro plate
#
/dipstick* ELISA  
  Ortho Phenylene diamine
#
/DAB* 4 mg 
  0.1 M Citric acid   2.57 ml 
  0.2 M Na2HPO4   2.43 ml 
  MQ water     5 ml 
  H2O2       15 µl 
 Buffers for Processing of E. coli cell pellet for protein purification 
 (a) Cell wash buffer (pH 8.0) 
  Tris–HCl    10 mM 
  NaCl     100 mM 
  EDTA     10 mM 
 (b) Cell lysis buffer (pH 7.5) 
  Tris HCl   10 mM   
  NaCl       100 mM 
  EDTA    5 mM 
  β-Mercaptoethanol   5 mM 
  Benzamidine HCl      5 mM    
  PMSF        1 mM 
  Lysozyme      100 g/ml 
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 (c) IB Wash buffer 1 (pH 6.0) 
  NaH2PO4    50 mM 
  EDTA            5 mM 
  NaCl         200 mM 
  Urea          1 M 
  Triton X-100      1% 
 (d) IB Wash Buffer 2 (pH 6.0) 
  NaH2PO4    50 mM 
  EDTA        1 mM 
  NaCl         1 M 
 (e) Solubulization buffer (pH 8.0) 
  Tris HCl    10 mM  
  NaH2PO4    100 mM  
  β-Mercaptoethanol   20 mM 
  NaCl     100 mM  
  Urea     8 M 
 Buffers for Purification of Recombinant Protein by affinity Chromatography 
under denatured Conditions 
 (a) Equilibration buffer (pH 8.0) 
  Tris HCl    10 mM  
  NaH2PO4    100 mM 
  NaCl    100 mM 
  Urea     8 M 
 (b)  Column wash buffer (pH 6.3) 
  Tris HCl    10 mM   
  NaH2PO4    100 mM 
  NaCl     100 mM    
  Urea     8 M  
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 (c) Elution buffer (pH 4.3) 
  Tris HCl    10 mM  
  NaH2PO4    100 mM 
  NaCl     100 mM 
  Urea     8 M 
 Buffers for On-column refolding using affinity chromatography 
 (a) Refolding Buffer A (pH 8.5) 
  Phosphate buffer      50 mM 
  Urea     3 M 
  NaCl     300 mM 
  Glycerol    12% (v/v) 
 (b) Refolding Buffer B (pH 8.5) 
  Phosphate buffer      50 mM 
  Urea     3 M 
  NaCl     300 mM 
  Glycerol    12% (v/v) 
  Imidazole    50 mM 
 (c) Refolding Buffer C (pH 8.5) 
  Phosphate buffer      50 mM 
  Urea     3 M 
  NaCl     300 mM 
  Glycerol    12% (v/v) 
  Imidazole    300 mM 
 Buffers for Dialysis and Diafiltration  
 (a) Diafiltration buffer 1 (pH 6.0) 
  Urea      1 M 
  Phosphate Buffer    50 mM 
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 (b) Diafiltration buffer 2 (pH 6.0) 
  Phosphate Buffer    50 mM 
  NaCl     10 mM 
 Buffers for salt and pH based Ion-Exchange chromatography 
 (a)  Ion exchange buffer 1 (pH 5.8)-Salt based IEX 
  Phosphate buffer   50 mM 
  Sodium chloride   50 mM 
 (b)  Ion exchange buffer 2 (pH 6.0)-Salt based IEX  
  Phosphate buffer   50 mM 
  Sodium chloride    500 mM 
 (c) Ion exchange buffer 3 (pH 6.0)-pH based IEX 
  Phosphate buffer   50 mM 
  Sodium chloride   10 mM 
 (d) Ion exchange buffer 4 (pH 8.0)-pH based IEX 
  Phosphate buffer   50 mM 
3.9 EXPRESSION OF ENVELOPE DOMAIN III PROTEIN OF JE 
AND DENGUE VIRUSES AND NS1 PROTEIN OF JE VIRUS 
 E. coli BL21(DE3) cells harboring the pET-30a+ plasmids containing domain III 
gene for the expression of recombinant JE virus domain III protein; BLR (DE3) cells 
harboring the pET-30a+ plasmids containing domain III gene for the expression of domain 
III protein of dengue virus type 1 to 4 and SG13009 cells harboring the pQE30UA plasmid 
containing NS1 gene for the expression of NS1 protein of JE virus were grown in Luria 
bertani broth with 50 μg/ml kanamycin [additionally 12.5 μg/ml tetracycline for BLR(DE3) 
and 100 μg/ml of ampicillin for SG13009 ] at 200 rpm, 37°C.  Briefly, glycerol stock of 1.5 
ml was inoculated into 50 ml of LB medium with antibiotics and allowed to grow at 37°C in 
a incubator-shaker at 180 rpm overnight. About 1% (v/v) of overnight grown culture was 
inoculated into 100 ml of LB medium in 500 ml Erlenmeyer flasks. At mid-logarithmic 
phase, the cultures were induced with 1 mM isopropyl β-thiogalactopyranoside (IPTG) for 
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the expression of envelope domain III protein of dengue and JE viruses and NS1 protein of 
JE virus. Following induction, the cells were grown for 4 hours. The various culture 
conditions viz. induction time (mid logarithmic phase, stationary phase), inducer 
concentration (0.5, 1, 1.5, 2 mM), duration of induction (1-4 hours) and inoculums (1-5%)  
were optimized for maximum expression of proteins. Cultures were harvested by 
centrifugation at 6000 rpm for 30 min and pellet was recovered. All the samples were lysed 
in SDS-PAGE sample buffer and analyzed by SDS–PAGE. Un-induced control cultures were 
analyzed in parallel and the protein concentration was determined by densitometry. 
3.10 OPTIMIZATION OF MEDIA FOR PRODUCTION OF 
ENVELOPE DOMAIN III AND NS1 PROTEINS  
 Shake flask cultivation was performed in different media in order to find optimal 
growth conditions. Duplicate cultures were carried out in different media viz. Luria Bertani 
broth, SOB, SOC, M9 minimal salt, Terrific broth, Super broth (SB), modified super broth 
and defined medium.  A frozen culture (1.5 ml) of recombinant cells was inoculated into 50 
ml of primary culture medium (sterile LB medium) containing respective antibiotics in a 250 
ml Erlenmeyer flask and incubated for 8 h in an Incubator-shaker (Kuhner AG, Switzerland) 
at 180 rpm, 37
o
C. Primary seed culture (1 ml) was used to inoculate 100 ml of secondary 
culture medium (sterile corresponding medium) in 500 ml Erlenmeyer flasks and grown for 
15 h and 37ºC at 180 rpm. For media optimization, secondary seed cultures were used to 
inoculate at 2% (v/v) in a 1 liter flask containing 200 ml of each media and incubated at 200 
rpm and 37ºC in Shaker-Incubator. At mid-logarithmic phase, the cultures were induced with 
1 mM isopropyl β-thiogalactopyranoside (IPTG) for the expression of these proteins and 
further grown for 4 hours before harvesting. The cultures were centrifuged at 6000 rpm for 
30 min and the cell pellet was stored for further use. Cultures were analyzed for optical 
density at a wavelength of 600 nm (OD600), dry cell weight as well as protein yield.  The 
medium showing maximum protein yield among tested media was further used for the 
production of these proteins by batch and fed batch fermentations. Evaluation of effect of 
various culture media components viz. glycerol (5-30 ml/l), yeast extract (5-30 g/l) and 
magnesium sulphate (1.2-2.4 g/l) in combination with above media on cell growth was also 
carried out as procedure described above.  
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3.11 BATCH FERMENTATION FOR PRODUCTION OF ENVELOPE 
DOMAIN III AND NS1 PROTEINS 
 Laboratory scale batch fermentations were carried out in a bench top fermentor 
(Bioflo 3000, New Brunswick, USA) equipped with a 5.0 liter working volume glass vessel 
and stainless steel head plate. Biocommand Plus software was used for data acquisition and 
operation of the fermentors in batch mode. About 4.0 liters of culture medium was added to 
the vessel and sterilized by exposure to 121
o
C, 15 psi for 20 minutes. The dissolved oxygen 
(DO) probe and pH probe were also inserted and all addition and sampling ports were sealed 
or clamped and wrapped in aluminum foil before sterilization. A preinoculation sterility 
check was conducted for a minimum of 15 hours during which pH, agitation and temperature 
were continuously monitored. After 15 hours, the DO was also monitored along with 
turbidity. The vessel was adjudged to be sterile if the pH and DO remained constant and no 
increase in turbidity was observed. The calibration of pH was done before sterilization by 
using standard buffer pH 7 and 4. Dissolved oxygen probe (Mettler, Toledo, Germany) was 
calibrated before sterility checking procedure in fermentor as per manufacturer protocol. The 
initial culture was started in shake flasks by inoculating 1.5 ml of glycerol stock of E. coli in 
50 ml culture medium with respective antibiotics in 250 ml Erlenmeyer flask. The culture 
was shaken at 37
o
C for 8 hours at 180 rpm. About 1% (v/v) culture was added in 200 ml of 
medium with antibiotics in 1 liter Erlenmeyer flask. This secondary seed culture was 
incubated at 37
o
C for overnight at 180 rpm. Once the sterility of the vessel had been verified, 
the 5% (v/v) overnight grown culture was added to the vessel with respective antibiotics 
through the addition port of the headplate and the initial OD600 was recorded. The initial 
batch culture conditions in fermentor were as follows: initial culture volume 4.0 liter; 
temperature 37
o
C; air flow rate 4.0 liter per minute or 1 vvm (volume/volume/minute); stirrer 
speed, 200 rpm. Agitation was regulated between 200 and 600 rpm and aeration between 0.5 
and 2.0 vvm to keep the dissolved oxygen level in an appropriate level. DO was analyzed 
using a DO probe and was controlled at about 30% of air saturation by control of both 
airflow and stirrer speed. If necessary, the inlet air was enriched with pure oxygen using an 
automated thermal mass flow controller. The temperature was controlled by a heating sleeve 
and an integrated cooling system to 37°C throughout the process.  The pH was controlled 
between 6.8-7.0 by addition of 25% (v/v) aqueous ammonia or 1N HCl solution. Foaming 
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was controlled by the addition of antifoam A (Sigma) emulsion. The cell density and dry cell 
weight analysis were carried out by manual sampling of the fermentor culture through 
sampling port. The optical density (OD600) of the culture was measured using 
spectrophotometer at different time interval. Analysis of dry cell weight per 10 ml of culture 
with respect to OD600 revealed that the relationship between the both parameters was linear, 
confirming that OD600 accurately measured cell density. At mid-log phase the fermentor 
culture was induced with IPTG to a concentration of 1mM. Following induction the culture 
was further grown for 4 hours before harvesting. Finally the culture was centrifuged at 6000 
rpm for 30 min using floor model centrifuge and the cell pellet was stored for further use.  
3.12 FED BATCH FERMENTATION FOR PRODUCTION OF 
ENVELOPE DOMAIN III AND NS1 PROTEINS 
 The laboratory scale high cell density fed-batch fermentations were performed at 
37°C in a fermentor of 10.0 liter working volume (Bioflo 3000, New Brunswick, USA) 
equipped with Biocommand plus software system for control and data acquisition. The 
secondary seed culture as grown above (5% v/v) was inoculated to the media in the 
bioreactor vessel with respective antibiotics through the addition port and the optical density 
of the preculture was measured to obtain about  0.1-0.2 (OD600) at the onset of the batch 
phase. The initial batch culture conditions were as follows: initial culture volume, 8.0 liter; 
temperature, 37
o
C; air flow, 0.5 vvm; stirrer speed, 200 rpm. Optimized culture media were 
used as batch culture medium.  Mixing of air and oxygen was done using inbuilt thermal 
mass flow controller. A polarographic electrode was used to analyze the concentration of 
dissolved oxygen, which was maintained at about ~30% of air saturation. Agitation was 
varied between 200 and 900 rpm and aeration between 0.5 and 1.5 vvm. During high cell 
density, the inlet air was enriched with pure oxygen, subject to the oxygen demand of the 
bacterial culture. The pH was maintained at 6.8-7.0 similar to batch fermentations. All 
controls were carried out by the digital control unit of the bioreactor. After depletion of the 
initial nutrients in the batch medium, as indicated by an increase in the dissolved oxygen 
concentration or increase in pH, feeding of feed medium containing yeast extract and 
glycerol with magnesium sulphate was then started using inbuilt peristaltic pump in 
bioreactor console to achieve constant DO (DO stat feeding) and constant pH (pH stat 
feeding). Foam was detected using the bioreactor foam sensor and suppressed by the addition 
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of the antifoam reagent similar to batch fermentation. Culture growth was monitored by 
measuring OD600 during process.  The culture was induced with 1 mM IPTG at high cell 
densities and the induction phase lasted for 4 hours. Finally the culture was harvested by 
centrifugation and the cell pellet was stored for further purification process.  
3.13 PILOT SCALE FERMENTATION FOR PRODUCTION OF 
ENVELOPE DOMAIN III PROTEINS 
 Pilot scale fermentations were performed on a 100 liter fermentor (Bioflo 5000-New 
Brunswick, USA) containing 80-85 liter of modified SB medium. A recombinant strain of E. 
coli containing EDIII gene of JE virus or dengue virus type 3 was used as seed culture. About 
four liter of inoculum cultured in modified SB medium for 6 h either in lab scale fermentor 
as described above or four Erlenmeyer shake flasks of 5 liter capacity with 1 liter modified 
SB medium was used as inoculum for a 100 liter fermentor. For inoculum preparation, the 
primary and secondary culture was grown as above with respective antibiotics. About 2% 
(v/v) of overnight grown shake flask culture (secondary culture) in modified SB medium was 
added in each of flasks containing 1 liter of modified SB medium and  incubated at 37
o
C for 
6 h at 200 rpm. This seed culture (5% v/v) or 4 liter of 6 h grown batch fermentation culture 
was added aseptically to the media in the 100 liter fermentor vessel with respective 
antibiotics. It is important to monitor and control the following parameters throughout the 
fermentation process: temperature; DO; pH; agitation; aeration; foaming. The pilot scale 
fermentations were performed with following set-up: initial volume, 80-85 liter; air ﬂow rate, 
0.25-0.9 vvm; stirrer speed, 50-350 rpm; pH, 6.8-7.0; temperature, 37
o
C and dissolved 
oxygen, ~30%. The DO level was maintained at about 30% saturation using air, pure oxygen 
and stirring speed of up to 350 rpm. The pH of the medium was maintained by automatic 
addition of ammonia and phosphoric acid. Anti-foam was added as required. At mid log 
phase (after ~five and half hour of culture growth), IPTG was added as inducer into the 
fermentor vessel at a concentration of  1 mM and the total duration of  induction was 4 hours. 
Sampling  of  the  culture  medium  was  performed  during fermentation for measurement of 
OD600. The fermentation broth was harvested using Prostak TFF microfiltration system 
(Millipore) with 0.45 µm pore size of 20 square foot area membrane. After microfiltration, 
the concentrated broth was further centrifuged at 6000 rpm for 30 min using floor model 
centrifuge. After centrifugation, the cell pellet was stored for further use. 
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3.14 CELL DISRUPTION AND SOLUBILISATION OF INCLUSION 
BODIES 
 The cell pellet was washed twice with cell wash buffer (1:20, w/v) by centrifugation 
at 10,000 rpm for 20 min at 4
o
C. The washed pellet was re-suspended in chilled cell lysis 
buffer (1:20, w/v). The cell suspension was disrupted by passing it three times through 
agitator bead mill at the ﬂow rate of 50 ml/ min in 0.6 liter container at 1 bar pressure or by 
sonication using a sonicator (Sonics, USA) at a setting of 70% frequency using high gain 
probe. The sonicator was programmed to provide 9 s pulses with 9 s pause for a total period 
of 10 min. Lysate was centrifuged at 10,000 rpm for 40 min at 4°C and supernatant removed. 
The cell pellet containing the inclusion bodies (IBs) was washed with IB wash buffer 1 (1:20, 
w/v) followed by another wash with IB wash buffer 2 by centrifugation at 10,000 rpm for 40 
min at 4
o
C. The supernatant was carefully removed and the IB pellet was stored until further 
use. The IB washed pellet containing inclusion bodies was used for further purifications.  
Inclusion bodies were solubilized in solubilization buffer (1:20 v/w) using a 
mechanical homogenizer (Kinematica AG, Switzerland) at 5000 rpm for about 20 min or 
stirred on a magnetic stirrer for 6-8 hours at room temperature. This suspension was then 
centrifuged at 10,000 rpm for 40 min at 4°C as well as filtered with 0.45 µm membrane 
(Millipore, USA). The supernatant containing the solubilized IBs was collected and its 
protein concentration was determined by the BCA assay. We also estimated the total protein 
by taking absorbance at 280 nm in spectrophotometer and calculating the protein 
concentration using absorbance coefficient of EDIII proteins. This clear supernatant was used 
for affinity chromatography under denaturing conditions or on-column refolding of these 
proteins.  
3.15 PURIFICATION OF ENVELOPE DOMAIN III AND NS1 
PROTEIN USING AFFINITY CHROMATOGRAPHY 
 For small scale immobilized metal affinity chromatographic purifications, pre-packed 
Ni-sepharose columns were used. AKTA pilot and AKTA explorer chromatography systems 
were used for the large scale and lab scale puriﬁcation of proteins. For large scale 
purifications streamline chelating resin (GE Healthcare) was packed in an XK16/20 (20 ml 
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resin) or quik scale 70/55(500 ml resin) column. For packing the streamline chelating resin 
was poured into the column in one continuous motion. The inlet and outlet connections of 
column were connected to a chromatography system. The column was charged with three 
column volumes of 50 mM NiCl2 solution. The column was continuously washed with five 
column volumes of distilled water. The filtered solution containing denatured protein was 
loaded to the chromatography column  using AKTA chromatography system. The clear 
supernatant was loaded at a linear flow rate of 150 cm/h to the chromatography column. The 
packed column was pre-equilibrated with solubilization buffer before applying clear 
supernatant. After loading, the column was washed with column wash buffer at pH 6.3 and 
6.0, at a linear flow rate of 150 cm/h. The bound protein was eluted using elution buffer at 
pH 4.3. The elution buffer has similar composition as equilibration buffer, but the pH was 
different. The relevant elutes were pooled together and dialyzed/diafiltered successively 
against dialysis/diafiltration buffer (50 mM phosphate buffer) containing progressively 
decreasing urea concentration (6 M, 4 M, 2 M, 1 M and 0 M). This purified protein was used 
as an antigen in ELISA for detection of JE/Dengue infections. 
3.16 REFOLDING WITH SIMULTANEOUS PURIFICATION OF 
ENVELOPE DOMAIN III PROTEIN 
 For vaccine studies of envelope domain III protein, refolding is necessary to achieve 
native conformations. Immobilized metal affinity chromatography using AKTA pilot system 
(GE Healthcare, Sweden) was used for the large scale refolding with simultaneous 
puriﬁcation of rJEV EDIII and rDen 3 EDIII proteins. For small scale, Akta explorer system 
was used with 5ml or 16/10 prepacked IMAC column. Large scale column were packed and 
charged as described above. Three buffers were used in the simultaneous refolding and 
affinity chromatographic process: on-column refolding buffer A, buffer B and buffer C. The 
clarified supernatant containing EDIII protein was directly loaded onto a column  containing 
Ni charged resin equilibrated previously with the buffer A. The flow rate was 150 cm/ h.  
After loading, unbound proteins were removed by washing the column with five column 
volume of the buffer B. The EDIII protein was eluted with Buffer C.  
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3.17 DIAFILTRATION, SALT AND PH BASED ION-EXCHANGE 
CHROMATOGRAPHY 
 The eluted fractions were analyzed by SDS–PAGE and fractions having majority of 
EDIII protein band were pooled, concentrated using ultrafiltration device (Pellicon-
Millipore) with a 3-kDa cut-off ultrafiltration cassette (Millipore) and buffer exchanged 
against solution containing 50 mM phosphate buffer, 1 M urea, pH 6.0. The SP sepharose 
cation exchange resin packed in an XK 26/40 (150 ml) column or prepacked SP sepharose 
column (5 ml and 16/10) was used for cation exchange chromatographic purifications of 
proteins. After packing, the column was washed with five column volumes of distilled water 
and then equilibrated with ion exchange buffer 1. 
For salt based IEX, refolded and diafiltered sample was loaded onto the column 
containing pre-equilibrated SP- Sepharose cation exchange resin.   Column was washed with 
ion exchange buffer 1 and bound proteins were eluted with ion exchange buffer 2. The elutes 
were pooled, buffer exchanged with 50 mM phosphate buffer  pH 6.0, 10 mM NaCl by 
diafiltration using a 3-kDa cut-off, ultrafiltration device  and processed further for ion 
exchange chromatography using pH. This diafiltered protein sample was loaded onto the SP 
sepharose column matrix pre-equilibrated with ion exchange buffer 3 and EDIII protein was 
eluted from the column using ion exchange buffer 4. The fractions were analyzed on  SDS-
PAGE  gel  and  relevant fractions  containing EDIII protein were  pooled, ﬁlter sterilized, 
and stored at -80
o
C until further use. 
3.18 GEL FILTRATION CHROMATOGRAPHY 
 Gel filtration (GF) chromatography was used after IMAC or IEX chromatography for 
further purification for envelope domain III proteins if required. Superdex 75 (10/300 GL) or 
16/60 Hi-load gel filtration column was used for this purpose. The column was equilibrated 
with 50 mM phosphate buffer pH 5.8 or pH 8.0 at a constant linear flow rate of 50 cm/h. 
Purified protein was loaded to the pre-equilibrated Superdex 75 column at a linear flow rate 
of 50 cm/h.  Elution of purified protein from the column was done using same buffer and 
monitored at 280 nm. Elutes were analyzed by SDS-PAGE and stored at -80
o
C until further 
use. 
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3.19 OFFLINE MEASUREMENT AND PROTEIN ANALYSIS 
3.19.1 Optical Density and Dry Cell Weight  
 The Cell growth was monitored by measuring optical density, wet cell weight and dry 
cell weight. Optical density of the culture was measured at 600 nm (OD600) with UV-visible 
spectrophotometer. Samples with higher values of OD600 were diluted suitably to have OD in 
the range of 0.2–0.4. In order to obtain the dry cell weight, 10 ml of culture broth was 
centrifuged at 8,000 rpm for half an hour and washed with distilled water in pre weighed 
tubes. After draining the supernatant, the tube with the cell pellet was weighed on a balance 
to determine the wet cell weight. To determine the dry cell weight, the same tube was left 
overnight in an incubator at 105
o
C and was weighed next day till constant weight.  
3.19.2 Sodium Dodecyl Sulphate–polyacrylamide Gel Electrophoresis 
 Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) using a 
Mini-protean III apparatus (Bio-Rad) were used to monitor the purity of protein after 
chromatographic procedures. Electrophoresis was performed at 60 V using 12% 
polyacrylamide gels. Detection was performed with Coomassie brilliant blue and silver 
staining. 
3.19.3 Determination of Protein Concentration by Bicinchoninic Acid (BCA) Assay 
 The BCA protein assay is a detergent-compatible formulation based on BCA for the 
colorimetric detection and quantification of total protein. This method combines the well-
known reduction of Cu
+2 
to
 
Cu
+1
 by protein in an alkaline medium
 
(the biuret
 
reaction) with 
the highly sensitive and selective colorimetric detection of the cuprous cation ( Cu
+1
)
 
using a 
unique reagent containing BCA. The purple coloured reaction product of this assay is formed 
by chelation of two molecules of BCA with one cuprous ion. This water soluble complex 
exhibits a strong absorbance at 562 nm that is nearly linear with increasing protein 
concentrations over a broad working range (20-2000 µg/ ml). Working reagent was prepared 
by mixing 49 parts of BCA reagent A and 1 part of BCA reagent B. About 25 µl of each 
standard or unknown sample replicates were pipetted into a micro plate well. About 200 µl of 
working reagent added to each well and mixed thoroughly. The plate was covered and 
incubated at 37°C for 30 min and absorbance was measured at 560 nm on plate reader. A 
standard curve was plotted by taking known concentrations of Bovine serum albumin (BSA) 
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ranging from 20-2000 µg/ml
 
and the concentration of test protein sample was calculated from 
the standard curve. 
3.19.4 Analysis of Protein Purity by Silver Staining  
 For determination of protein purity 500 ng of purified protein was resolved on 12% 
SDS-PAGE and subjected to silver staining using Silver staining kit (Fermentas, USA) as per 
manufacturer‘s instructions. Briefly after gel electrophoresis, the gel was placed in a fixing 
solution with gentle agitation for 20 min. Fixing solutions were decanted and gel was rinsed 
in distilled water. Then gel was placed in sensitizing solution with gentle agitation.  After gel 
washing with distilled water, staining solution was added and gel was stained for 
approximately 20 min or until desired staining intensity was reached. After staining 
developing solution was added to develop the protein band and reaction was stopped by 
addition of stopping solution for a minimum of 15 min. After stopping the reaction, the gels 
were rinsed in distilled water for 5 min. 
3.19.5 Western Blotting 
 For Western blot analysis, the purified protein was run on 12% denaturing gel (SDS–
PAGE), along with pre-stained protein markers (Fermentas, USA) on adjacent lanes and 
transferred electrophoretically to polyvinylidene difluoride (PVDF) membrane. The unoccupied 
sites on PVDF membrane was blocked with 5% BSA (Bovine Albumin Serum) in PBS 
(Phosphate Buffer Saline) and incubated at 4
o
C overnight. Blocked membranes were washed 
three times each with duration of 5 min with PBS containing 0.05 % Tween-20 (v/v) and 
incubated at 37
o
C with IgG antibodies positive serum sample (1:100 dilution in PBS, v/v) or anti-
histidine antibodies or hyper immune serum (1:5000 dilution in PBS, v/v) raised in mice against 
EDIII proteins for 1 hour. The membrane was washed again as above and incubated with Goat 
anti mouse or anti human IgG horseradish peroxidase (HRP) conjugate for 1 h at 37
o
C in 1:1000 
in PBS (v/v). The membrane was washed again and developed by incubation in developing 
buffer containing DAB (Diaminobenzidine)/H2O2 substrate for 15 min at 37
o
C.  
3.20 EVALUATION OF DIAGNOSTIC POTENTIAL OF ENVELOPE 
DOMAIN III AND NS1 PROTEIN 
 The affinity purified and dialyzed/diafiltered domain III/NS1 protein was used in 
ELISA for evaluation of its diagnostic potential. The purified protein was evaluated for the 
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detection of IgM and IgG antibodies from dengue suspected patient‘s serum samples and 
IgM antibodies form JE suspected serum and CSF samples. A panel of clinical samples 
comprising serum and cerebrospinal fluid (CSF) samples for JE and serum samples for 
dengue was included in this study. In addition, a panel of serum samples obtained from 10 
healthy persons was also included in this study. In-house indirect microwell plate ELISA 
(quantitative) as well as indirect dipstick ELISA (qualitative) was carried out for detection of 
anti-JEV IgM antibodies in serum and CSF samples and anti-dengue IgG and IgM antibodies 
in serum samples using IMAC purified protein.  
3.20.1 Indirect Microwell Plate ELISA 
 For indirect microwell plate ELISA, purified protein was diluted to attain 0.4 µg 
(EDIII protein) or 0.5 µg (NS1 protein) per 100 µl in coating buffer (Na2CO3 0.1 M, 
NaHCO3  0.2 M; pH-9.6)  and used for coating 96-well (100 µl/well) micro titer plates (Nunc, 
Germany)  at 37°C for 1 h. The coated wells were washed once with PBS and blocked with 
2% BSA in PBS overnight at 4°C. The wells were washed once again with PBS-T washing 
buffer and then incubated for 1 h at 37°C with 100 µl serum (1:100) and CSF (1:10) samples 
in PBS +2% BSA with 0.01% Tween-20 separately. Wells were washed three times using 
wash buffer and incubated with anti-human IgM HRP conjugate (1:2,000 dilution in 
PBS+2% BSA). The wells were washed once again as above and incubated with 100 µl of 
citrate-phosphate buffer with OPD substrate for 10 min at 37°C. Peroxidase reaction was 
terminated with 100 µl of 1N H2SO4 and the absorbance was read at 490 nm using ELISA 
reader (Biotek Instruments, USA). The in-house microplate ELISA for anti-dengue IgG 
antibodies was performed as above with patient serum samples (1:1000 dilution) and Goat 
anti-human IgG horseradish peroxidase (HRP) conjugate (1:3000 dilution). Suitable positive 
and negative controls were always included while performing the test.  
3.20.2 Indirect Dipstick ELISA 
 The in-house indirect dipstick ELISA for detection of anti-JE IgM and anti-dengue 
IgM and IgG antibodies was also carried out. For this purpose, the purified protein was 
coated  onto nitrocellulose (NC) combs (MDI, India) with 12 projections, at the rate of 0.4 µg 
(EDIII protein) or 0.5 µg (NS1 protein)  per 2 µl coating buffer per projection and incubated 
at 37
o
C for 1 h. The unoccupied sites were blocked with 2% (BSA) in PBS and incubated at 
4
o
C overnight. These coated NC projections were washed with PBS-T wash buffer. Serum 
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(1:100) and CSF (1:10) samples were diluted with serum diluents (0.01% Tween-20 in 
PBS+2% BSA) and dispensed at 200 μl/well. The antigen coated combs were dipped in the 
wells of this microtiter plate and incubated for 1 h at 37
o
C. Combs were then washed with 
wash buffer three times, each with duration of five min. After washing, the combs were 
dipped in Goat anti-human IgM HRP conjugate, diluted (1:2000) in conjugate diluent (PBS 
with 2% BSA), and incubated for 1 h at 37
0
C. The combs were then washed as above and 
developed with phosphate-citrate buffer containing diaminobenzidine (DAB) and H2O2. 
Appearance of brown colour dot indicated presence of IgM antibodies. The in-house dipstick 
ELISA for anti-dengue IgG antibodies was performed as above with patient serum samples 
(1:1000 dilution) and Goat anti-human IgG horseradish peroxidase (HRP) conjugate (1:3000 
dilution). Suitable positive and negative controls were always included while performing the 
test.  
All the serum and CSF samples for JE were also tested by JEV Chex IgM capture 
ELISA (XCyton, India) and Pan-Bio IgM capture ELISA (Pan-Bio, Australia) as per 
manufacturer‘s protocol. All the serum samples for dengue were tested by using Pan-Bio 
IgM and IgG capture ELISA and Pan-Bio IC test as per manufacturer‘s protocol. The results 
of in-house ELISA were compared with findings of commercial test. The in-house ELISA 
tests were also carried out with healthy serum samples to check non-specific reactivity.  
3.21 BIOLOGICAL ACTIVITY OF ENVELOPE DOMAIN III 
PROTEIN FOR POSSIBLE VACCINE POTENTIAL 
3.21.1 Biological Activity of EDIII Protein by ELISA 
 The biological activity of the EDIII protein was determined by ELISA. The pH based 
IEX purified EDIII protein was used for raising hyper immune sera in a group of six BALB/c 
mice.  For this purpose, 25 µg of purified protein was injected per mice per dose. The 
techniques used for bleeding, and sacrifice of animals were strictly performed following 
mandates approved by the animal ethics committee (Committee for the Purpose of Control 
and Supervision of Experiments on Animals, Govt. of India).The endotoxin content of the 
purified and refolded EDIII protein was determined by Limulus Amebocyte Lysate (LAL) 
QCL-1000 kit (Cambrex, USA). The endotoxin content of purified protein was less than 5EU 
per 25 µg of EDIII antigen, the dose used per immunization, as determined using standard 
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LAL assay. The EDIII protein was emulsified with FCA (Freund‘s Complete Adjuvant) in 
1:1 ratio. For subsequent booster doses, EDIII was formulated with FIA (Freund‘s 
Incomplete Adjuvant) instead of FCA. The control group of mice was injected with adjuvant 
only in phosphate buffer saline (PBS). About 200 µl of emulsified EDIII protein (25 µg) was 
injected subcutaneously at interval of  0, 21 and 42 days. After 14
th
 day of last inoculation the 
mice were bled and serum was collected and stored at –20oC for use in ELISA and Western 
blotting. 
Sera collected from mice were tested for the recognition of EDIII protein by ELISA. 
Microtitre ELISA plate (Nunc, Germany) was coated with this protein (400 ng per 100 µl per 
well) in coating buffer and incubated at 37
o
C for 1h. The plate was washed with phosphate 
buffered saline containing 0.05% Tween 20 (PBST) and blocked with 200 µl of 5% bovine 
serum albumin in PBS for overnight at 4
o
C. Test sera serially diluted two fold in PBS starting 
with 1:1000 were incubated in triplicate wells (100 µl/well) at 37
o
C for 1h. The wells were 
washed three times with PBST wash buffer. Goat Anti-mouse (IgG) antibodies conjugated to 
horseradish peroxidase were diluted 1:2500 in 2%  BSA with PBS, added to wells (100 µl 
per well) and  incubated for 1h at 37
o
C.  The reaction was developed at room temperature 
with 100 µl of developing buffer containing orthophenylenediamine dihydrochloride (Sigma) 
as chromogen and hydrogen peroxide as the substrate. The reaction was stopped with 2 N 
sulfuric acid. The absorbance was measured at 490 nm using an ELISA plate reader. Mean 
A490 values for each group were calculated. Sera from individual mice in each group are 
used for the determination of ELISA end point titers. Dilutions of sera at which A490 is 2 
times the background (A490 using sera from day-1, blank wells, or sera from adjuvant 
controls) were considered to be the ELISA end point titers. 
3.21.2 Plaque Reduction Neutralization Test (PRNT) 
 Sera collected from mice immunized with envelope domain III protein in 
combination with FCA or pre-immune sera (control) were evaluated using plaque reduction 
neutralization test to determine the neutralizing ability of these antibodies to JE virus or 
dengue virus type 3 infectivity. Two hundred microlitres of serum in two fold serial dilutions 
(from 1:2 to 1:64) were prepared in eppendorf tubes. JE or dengue virus type 3 stock adjusted 
to 50 pfu in virus diluent [10% Hank‘s balanced salt solution (HBSS), 0.1% BSA; pH 7.2-
7.4] was added to the tube containing serially diluted antibodies. The antibody and virus 
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dilutions prepared were mixed, pulse centrifuged and then incubated at 37°C for 1 h. A 24 
well plate with confluent monolayer of Vero cells for JE virus and LLC-MK2 cells for 
dengue virus was used for virus infection. Before inoculation of the antibody-virus mixture, 
the cell monolayer was rinsed once with PBS, after which 200 µl of the antibody-virus 
mixture was added to the appropriate wells. The plates were left at 37°C for 1 h, and rocked 
at 15 min intervals. After incubation, the inoculm was removed and the cell monolayer was 
rinsed once with virus diluent. Overlay medium (1.25% carboxymethyl cellulose in EMEM 
containing 2% FBS) was added and incubated further at 37°C for 6 days, and virus plaques 
were stained with 0.2% crystal violet. 
           *** 
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CHAPTER 4 
PRODUCTION OF RECOMBINANT JEV EDIII PROTEIN BY 
BATCH AND FED-BATCH FERMENTATION AS WELL AS 
EVALUATION OF ITS DIAGNOSTIC POTENTIAL 
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ABSTRACT 
 Japanese encephalitis (JE) is one of the leading causes of acute
 
encephalopathy 
affecting children
 
and adolescents in the tropics. Optimization of media was carried out for 
enhanced production of recombinant JE virus envelope domain III (EDIII) protein in 
Escherichia coli. Further, batch and fed-batch cultivation process in Escherichia coli was 
also developed in optimized medium.  Expression of this protein in E. coli was induced with 
1 mM IPTG and yielded an insoluble protein aggregating to form inclusion bodies. The 
inclusion bodies were solubilized in 8 M Urea and the protein was purified under denaturing 
conditions using immobilized metal affinity chromatography. After fed-batch cultivation, the 
recombinant E. coli resulted in dry cell weight and purified protein about 36.45 gl
-1
 and 910 
mgl
-1
 of culture respectively. The purity of the recombinant JE virus EDIII protein was 
checked by SDS-PAGE analysis and reactivity of this protein was determined by Western 
blotting and ELISA with JE virus infected human serum samples. These results establish the 
application of this protein to be used for the diagnosis of JE virus infection or for further 
studies in vaccine development. This process may also be suitable for the high yield 
production of other recombinant viral proteins.  
4.1 INTRODUCTION 
 Japanese encephalitis (JE), a mosquito borne viral disease is a major public health 
problem in South-East Asia and Western Pacific countries. Around 30,000–50,000 cases of 
JE and up to 15,000 deaths are reported annually (Ghosh and Basu, 2009). Approximately 
2.8 billion people inhabit this vast geographical area, where JE is likely to remain an 
important public health problem in the 21
st
 century (Shukla et al., 2009).  Early diagnosis 
plays a crucial role to forecast an early warning of epidemic and to undertake effective 
vector control measures. Laboratory diagnosis of JE virus relies on virus isolation, detection 
of genomic RNA and virus-specific antibodies by RT-PCR and serodiagnosis, respectively 
(Solomon et al., 1998; Parida et al., 2006).
 
Both virus isolation and RT-PCR are time 
consuming and costly laboratory methods. Thus, in a majority of cases the only feasible 
diagnosis is based on the detection of anti-JE IgM antibodies using capture ELISA and 
indirect ELISA format (Solomon et al., 1998; Ravi et al., 2006; Jacobson et al., 2007; 
Shrivastva et al., 2008; Ravi et al., 2009; Litzba et al., 2010). However, all these kits are 
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expensive due to the high costs associated with antigen production, making them 
unaffordable for use in the economically weaker countries where JE occur most frequently. 
Envelope protein of Japanese encephalitis virus constitutes the major immunogen and 
the major target of the host antiviral immune response (Tiroumourougane, 2002). Most of the 
recombinant DNA-based strategies focus on the envelope (E) proteins of the JE virus. 
Envelope (E) protein of JE virus is a major antigen responsible for eliciting neutralizing 
antibody response and protective immunity in hosts (Kaur and Vrati, 2003; Wang et al., 
2009; Witthajitsomboon et al., 2010). The E protein is organized into distinct domains 
designated as I, II and III. Of these, domain III is particularly important from the viewpoint 
of diagnostic and vaccine development as it contains neutralizing epitopes and the host cell 
receptor recognition sites (Wu, 2003; Alka et al., 2007; Shukla et al., 2009; Verma et al., 
2009).  
Escherichia coli is the most commonly used host for heterologous protein production 
(Lee, 1996; Babu et al., 2000; Khalilzadeh et al., 2004) because its genetics are well 
understood. Using recombinant E. coli in batch and fed-batch cultivations, recombinant 
proteins have been successfully expressed in E. coli. Recombinant E. coli can be grown to 
high densities in common media such as Luria Bertani broth (LB), SOB medium, SOC 
medium, M9 minimal salt medium and Super broth (SB) medium (Lim et al., 2000; 
Madurawe et al., 2000; Manderson et al., 2006). To ensure that oxygen supply does not 
become limiting, the fed-batch operation is used extensively in cultures. This improves 
biomass and recombinant protein yield relative to batch culture. There is currently a need for 
developing cultivation process for enhanced production of recombinant Japanese encephalitis 
virus envelope domain III (rJEV EDIII) protein and development of cost-effective, safe and 
simple diagnostics with sensitivity, specificity and applicability in laboratory as well as field 
conditions. In this chapter, we describe the media optimization, high yield production of 
rJEV EDIII protein in E. coli using bioreactor of 10.0 liter working volume, its purification 
and characterization. Further,
 
we present data demonstrating its utility as a diagnostic reagent
 
by an in-house ELISA in detection of anti-JE IgM antibodies in patient cerebrospinal fluid 
(CSF) and serum samples.  
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4.2 MATERIALS AND METHODS  
 The details about materials used for production of rJEV EDIII protein are desribed in 
the material and methods section (Chapter 3). The methods for expression, media 
optimization, small scale batch fermentation, fed-batch fermentation, affinity 
chromatography, SDS-PAGE, Western blot and ELISA are described in the material and 
methods section  (Chapter 3). A typical flow diagram for production and purification of rJEV 
EDIII protein used as a diagnostic reagent are shown in figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Flow diagram of production and purification of rJEV EDIII protein for 
diagnostic use. 
4.3 RESULTS 
4.3.1 Expression of Recombinant JE Virus EDIII Protein 
 To express recombinant JE virus envelope domain III protein in E. coli, shake flask 
culture was carried out in LB medium. A typical induction experiment comparing the proﬁles 
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of un-induced and IPTG-induced E. coli cultures is shown in figure 4.2.a. It is evident that 
IPTG induction results in the expression of a unique 13 kDa JEV EDIII protein. IPTG (1 
mM) at 4 h post induction time has shown the maximum protein expression (Figure 4.2.b). 
Therefore, in all subsequent experiments induction was carried out with 1 mM IPTG for 4 h.   
 
 
 
 
 
 
 
 
 
        
       (a)                                             (b) 
Figure 4.2. SDS-PAGE analysis of expression of rJEV EDIII protein. Lane 1, 4 : Molecular 
weight marker (kDa) ; lane 2: Un-induced culture ; lane 3 : Induced culture ; lane 5-9: 
Induced culture of  0, 1, 2, 3 and 4 h respectively. 
4.3.2 Effect of Media on Production of rJEV EDIII Protein 
 In the shake flask culture, the final cell density and cell concentration was found to 
depend upon the media used. Super broth medium achieved final dry cell weight about 2.55 
gl
-1
. Five times LB (5x) medium produced the final cell density (OD600) of about 0.306. SOB 
and SOC medium resulted final dry cell weight about 1.43 gl
-1
 and 1.89 gl
-1
 respectively. 
However, LB medium produced 1.30 gl
-1
 dry cell weight. Growth of this culture in M9 
minimal defined medium also resulted OD600 of about 0.167. The higher concentration of LB 
(5x LB) and M9 minimal salt medium provide resistance to the cell growth and resulted in 
lower cell densities. Comparative yields of purified rJEV EDIII protein in different media are 
summarized in table 4.1. 
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Table 4.1. Comparative yield of purified rJEV EDIII protein in shake flask culture. 
Media       Dry cell weight (g/l)      Protein (mg/l) 
Luria Bertani Broth   1.30    25.17 
SOB     1.43    27.23  
SOC     1.89    28.86 
Terrific Broth    2.40    35.08 
Super Broth    2.55    35.55 
4.3.3 Production of rJEV EDIII protein in E. coli 
 For maximizing the volumetric production, the E. coli cells expressing rJEV EDIII 
protein were grown in a fed-batch cultivation process. The culture at cell OD of 44.10 was 
induced with 1 mM IPTG and grown for another 4 h. Production of the maximum amount of 
rJEV EDIII protein was attained after 4 h post induction.  The final dry cell weight of about 
Table 4.2. Comparative yield of purified rJEV EDIII protein in bioreactor. 
 Media   Culture Condition   Dry cell weight (g/l)      Protein (mg/l) 
Terrific Broth  Batch fermentation  4.05   112.37 
Super Broth  Batch Fermentation  4.16   114.06 
Super Broth  Fed-batch Fermentation 36.45   910.23 
36.45 gl
-1
 (Table 4.2.) was attained at ~14 h of cultivation in fed batch mode. In batch 
cultivation with super broth medium, the DCW at induction and harvest was 2.18 gl
-1
 and 
4.16 gl
-1
 respectively. The final DCW at harvest using terrific broth medium in batch 
cultivation was 4.05 gl
-1
. Real time profile of fed-batch cultivation for production of rJEV 
EDIII protein is shown in figure 4.3. Comparative yields of rJEV EDIII protein by batch and 
fed-batch cultivation process is shown in table 4.2. 
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Figure 4.3. Real time profile of fed-batch fermentation for production of recombinant 
Japanese encephalitis virus envelope domain III (rJEV EDIII) protein. Feeding was started 
when OD value reaches about 4.91 after ~4.0 h of inoculation. 
4.3.4 Purification and Characterization of rJEV EDIII Protein 
 We have demonstrated the single step purification of rJEV EDIII protein using 
immobilized metal affinity chromatography. The chromatogram of affinity purification is 
shown in figure 4.4. The gel analysis showed that more than 95% purity has been achieved 
(Figure 4.5.a). The purity of this protein was evaluated densitometrically from SDS-PAGE 
gels using Quantity One image quantiﬁcation software (Bio-Rad, USA). The final yield of 
rJEV EDIII protein was ~910 mgl
-1
  (Table 4.2.), which was increased after fed-batch 
cultivation to about more than thirty six times in comparison with commonly used shake 
flask culture with LB medium (Table 4.1.).  
 
Figure 4.4. Real time profile rJEV EDIII protein purification by affinity chromatography. 
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Purified rJEV EDIII protein migrates with an appropriate molecular weight of ~13 
kDa on denaturing SDS-PAGE gel (Figure 4.5.a). This protein was subjected to Western blot 
assay, to confirm its identity as rJEV EDIII protein. The affinity purified rJEV EDIII protein 
was probed with JEV positive hyper immune sera. These results revealed that the JEV 
positive serum sample reacted with rJEV EDIII protein (Figure 4.5.b). It is evident that the 
rJEV EDIII protein specifically reacted with anti-JE virus antibody and thus suggests that 
this protein could be used for the purpose of diagnosis of JE virus infection. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. (a) SDS–PAGE analysis of final purified rJEV EDIII protein after affinity 
purification.   Lane 1, Molecular Weight Marker (kDa); lane 2, AC purified rJEV EDIII 
protein. (b) Western blot analysis of the purified rJEV EDIII protein with hyper immune 
serum sample. Upon 12% SDS-PAGE, the protein was electroblotted and probed with hyper 
immune serum raised in mice at 1:500 dilution followed by incubation in secondary antibody 
HRP conjugate (1:1000) and finally developed in DAB/H2O2 substrate solution. (c) Results 
of Dipstick ELISA with rJEV EDIII protein. NC comb coated with 0.4 µg of  purified protein 
was tested with both CSF (1:10 dilution) and serum sample (1:100 dilution) followed by 
incubation in secondary antibody HRP conjugate (1:2000 dilution) and finally developed in 
substrate solution (DAB/H2O2).  Lane 1, IgM positive CSF; lane 2, IgM positive serum; lane 
3, negative CSF and lane 4, negative serum samples. 
4.3.5 Evaluation of rJEV EDIII Protein by in-house ELISA   
 In the present study, a total of 80 clinical specimens (50 serum and 30 CSF samples) 
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was included. All the samples were tested with Pan-bio IgM capture ELISA, JEV Chex IgM 
capture ELISA and in-house dipstick as well as microwell plate ELISA. Optical density 
(OD450) values of serum and CSF samples determined with Pan-bio IgM capture ELISA are 
shown in table 4.3. The cut-off value (OD490) for detection of antibodies using in-house 
microwell plate ELISA was 0.20 for detection of anti-JEV IgM antibodies in CSF and 0.60 
for serum samples. The cut-off value for Pan-Bio capture ELISA was determined by taking 
average of OD450 values of cut-off calibrator in triplicate as per manufacturer‘s protocol.  
Table 4.3. OD450 values in Pan-Bio IgM capture ELISA for CSF and serum samples. 
Range of OD values
a
             No. of samples 
                                CSF   Serum 
0.000–0.199       09                     20 
0.200–0.399      04                     08 
0.400–0.599      08                     10 
0.600–0.799      06                     07 
                    ≥ 0.80                    03             05     
  Total       30                     50 
a
ELISA OD450 values of ≥ 0.20 were considered positive as per manufacturer‘s instruction. 
Optical density (OD450) values of serum and CSF samples determined with JEV Chex 
IgM capture ELISA is shown in table 4.4.  
Table 4.4. OD450 values in JEV-CheX IgM capture ELISA for CSF and serum samples. 
Range of OD values
a  
        No. of samples 
                                          CSF  Serum 
0.000–0.699       09              19 
 0.700-0.799       02   03 
0.800–1.19        06             05 
1.20–1.59       06             10 
1.60–1.99        05             08 
      ≥ 2.00       02                   05 
             Total        30  50  
 
a
ELISA OD450 values of ≥ 0.70 and  ≥ 0.80 were considered positive for CSF and Serum 
sample respectively as per manufacturer‘s instruction. 
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Out of 50 serum samples, 29 samples were positive and 21 samples were negative 
and of 30 CSF samples 20 were positive and 10 samples were negative by in-house dipstick 
as well as microwell plate ELISA. Out of 50 serum samples, 30 samples were positive and 20 
samples were negative and of the 30 CSF samples 21 were positive and 9 samples were 
negative by Pan-Bio IgM capture ELISA. Out of 50 serum samples, 31 samples were positive 
and 19 samples were negative and of the 30 CSF samples 21 were positive and 9 samples 
were negative by JEV-CheX  IgM capture ELISA.  
Table 4.5. Comparative evaluation of in-house ELISA with reference to Pan-Bio IgM 
capture ELISA for detection of anti-JEV IgM antibodies in patient serum and CSF 
samples. 
Type of sample    % Agreement
a 
    % Sensitivity
b
     % Specificity
c 
        
Serum        98%(49/50)     96%(29/30)    100%(20/20)                                                           
CSF                              96%(29/30)     95%(20/21)     100%(09/09)                                         
a
(Number of samples positive by both method + number of samples negative by both 
methods) /(total number samples) x100. 
b
True positive/(true positive + false negative) x 100. 
c
True negative /(true negative + false positive) x 100. 
Comparison of the in-house dipstick ELISA using rJEV EDIII protein with Pan-Bio 
IgM capture ELISA and JEV Chex IgM capture ELISA for detection of IgM antibodies to JE 
revealed comparable sensitivities, specificities and overall agreements (Table 4.5 and 4.6). 
The reaction pattern of in-house developed dipstick ELISA using rJEV EDIII protein with 
positive and negative serum and CSF samples are shown in figure 4.5.c. Prior to evaluation 
with patient sera, rJEV EDIII protein was checked using hyper immune sera against JE virus. 
Moreover rJEV EDIII protein has further been evaluated with six JE virus infected PCR 
positive samples (Parida et al., 2006). The rJEV EDIII protein recognized antibodies in JE 
virus infected and PCR positive samples thereby revealing its usefulness. To check non-
specificity, this protein was tested with 20 serum samples collected from healthy person. 
None of these serum samples were, however, found to give positive reaction with this antigen 
and established its specificity for detection of JEV infection.   
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Table 4.6. Comparative evaluation of in-house ELISA with reference to JEV CheX IgM 
capture ELISA for detection of anti-JEV IgM antibodies in patient serum and CSF 
samples. 
Type of sample   % Agreement
      
% Sensitivity      % Specificity      
Serum         96%(48/50)         93%(29/31)              100%(19/19)                                        
CSF                          96%(29/30)        95%(20/21)             100% (09/09)                                  
4.4 DISCUSSION 
 Laboratory scale expression of recombinant protein is generally performed using 
complex medium such as LB at shake flask culture. However, for producing protein in 
bioreactor, trial with different media is necessary. Composition of media seem to be 
important to ensure proper cell growth and for rJEV EDIII protein production. The present 
study therefore had an objective to produce rJEV EDIII protein with a high yield and 
evaluate its use in diagnosis of the disease as well as for vaccine development in future. The 
use of complex media as well as chemically defined media in producing recombinant 
proteins is a common practice (Lim and Jung, 1998; Kweon et al. 2001; Manderson et al., 
2006; Tripathi et al., 2009). The complex media give more consistent yields, allow easier 
process control and simplify downstream recovery of the target protein. High-cell densities 
attained with SB medium can be explained, as this media is rich in yeast extract and 
phosphate salts as well as supplemented with glycerol compared to the other media used. 
Yeast extract is a known source of trace components and can relieve cellular stress responses 
such as the production of proteases during synthesis of recombinant protein. The phosphate 
salts in the media provided a buffering capacity to prevent pH fluctuations that could 
adversely affect normal metabolism (Lim et al., 2000). 
Several recombinant proteins have been successfully produced in E. coli by fed-batch 
cultivation using various regimes of nutrient feeding resulting in different biomass and 
product yields (Lee, 1996; Babu et al., 2000; Khalilzadeh et al., 2004). To enhance the yield, 
rJEV EDIII protein was produced by batch and fed-batch cultivation processes. As the 
biomass is accumulated during the cultivation, the oxygen demand is also increased. Once 
feeding is initiated and E. coli enters into log phase, the feed is consumed more or less in an 
exponential manner. But, the feeding rate has to be controlled so that it does not exceed the 
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nutrient demand or feed consumption rate. It is done by maintaining the pH and DO around 
their set values. A fall in pH and DO is an indication of substrate overdosing. Rise in pH and 
DO values indicate that the carbon source or one of the substrate is limiting hence feed is 
required. The composition of the growth media is crucial for enhancing product formation as 
well as acetate reduction. Acetate is not produced when glycerol is used as the source of 
carbon, and the high cell densities with less foaming may be achieved relatively easily using 
glycerol. The lower rate of glycerol transport in the cell, compared with that of glucose, 
apparently leads to a reduction in the flux of carbon through glycolysis; greatly reducing 
acetate formation. E. coli is able to utilize acetate as a carbon source when glucose is absent. 
The consumption of acetate is characterized by a deviation from the preset values to lower 
pH values and cyclic patterns start appearing in the consumption of oxygen, till the preset pH 
value is gradually regained by the culture (Bhatnagar et al., 2008). At this time feeding is 
restarted. Phosphate is also known to be important for attaining high-cell densities of E. coli, 
as phosphate can easily become a limiting nutrient when provided in low doses (Korz et al. 
1995). The feeding strategy used in the present experiments was a combination of both the 
pH-stat as well as DO-stat methods. Monitoring of both the parameters simultaneously gives 
better control over the growth conditions of the growing culture. The final dry cell weight 
after fed-batch cultivation (36.45 gl
-1
) is about twenty eight times greater than that of shake 
flask culture (1.30 gl
-1
) using LB medium and more than eight times when compared with 
batch cultivation (4.16 gl
-1
) using SB medium. 
Expression of heterologous protein in E. coli allows its rapid and economical 
production in large amounts. Efforts to obtain soluble target protein in host E. coli strain, 
inclusion body formation is still considered as a convenient and effective way in recombinant 
protein production. Expression of target protein (5-30%) of the total cellular protein, easy 
isolation of the inclusion bodies from cells, lower degradation of the expressed protein, high 
level of target protein homogeneity in inclusion bodies, and possibility to reduce the number 
of purification steps are usually indicated as the main advantages of IBs formation (Singh 
and Panda, 2005). In contrast to many reported protocols for the purification of recombinant 
viral envelope EDIII protein (Pattnaik et al., 2007; Verma et al., 2009), the present data 
demonstrate the feasibility of obtaining pure protein utilizing a single chromatographic step. 
More than 95% purity of protein as determined densitometrically from SDS-PAGE gels has 
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been achieved following a single step purification strategy which yielded ~910 mgl
-1
 of rJEV 
EDIII protein. Thus, fed-batch cultivation has led to about more than eight times purified 
protein yield in comparison with batch cultivation using SB medium.   
The rJEV EDIII protein shows reactivity with the antibodies in JE virus infected 
patient serum and CSF samples. Thus this protein could be used in the diagnosis of JE 
infection. The diagnosis of JE has advanced considerably in recent years and routine 
laboratory diagnosis of JE virus infection is primarily carried out by detection of anti-JE 
virus antibody by serological methods. MAC-ELISA and indirect IgM ELISA is considered 
as a valuable diagnostic tool in JE virus infection (Bundo and Igarashi, 1985; Solomon et al., 
1998; Ravi et al., 2006; Jacobson et al., 2007; Shrivastva et al., 2008; Ravi et al., 2009; 
Litzba et al., 2010).The Pan-Bio IgM capture ELISA (Pan-Bio, Australia) and JEV CheX 
IgM capture ELISA are commonly used test for JE virus infection. Both tests are based on 
the capture principle and JEV Chex kit (Ravi et al., 2006) uses native viral antigens (high 
production cost and produces biohazards). Pan-Bio JE-Dengue IgM combo ELISA is based 
on recombinant envelope protein that can be exploited for the detection of both Dengue and 
JE virus but showed cross-reactivity. Therefore, there is a genuine need for a promising test 
system for detection of JE infection.  
In the present study, we have tested 80 specimens (50 serum and 30 CSF) for the 
presence of IgM antibodies by Pan-Bio IgM capture ELISA, JEV-CheX IgM capture ELISA 
and in-house ELISA test. The in-house indirect ELISA test has shown comparable 
sensitivity, specificity and more than 94% accordance for detection of anti-JEV IgM 
antibodies as compared to both commercial assays. The in-house dipstick ELISA is a 
qualitative test meant for field use. The common problem with JE serological assays lies in 
detection of circulating cross reactive antibodies against other members of Flavivirus. This 
cross reactivity could be found to be significantly reduced while identifying JE virus 
infection with ELISA employing pre-coated cell culture purified antigen as compared to 
mouse brain or crude cell culture antigen (Yang et al., 2006). The rJEV EDIII protein 
obviates expensive and time consuming cultivation of virus (for antigen preparation) and the 
associated biohazard risk. The present study demonstrates that the in-house developed 
ELISA test using rJEV EDIII protein can be used as a promising test in developing countries, 
which will help authorities to undertake effective control measures and adopt management 
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strategies against impeding JE menace. The domain III of the envelope protein of Japanese 
encephalitis virus is particularly an important antigen for vaccine development as well as its 
use as a reagent for diagnostic purposes, as it contains neutralizing epitopes and host cell 
receptor recognition (Kaur and Vrati, 2003; Wu et al., 2003; Alka et al., 2007; Shukla et al., 
2009; Verma et al., 2009) site. Increase in the production of rJEV EDIII protein for 
application in diagnostic use as well as for further vaccine studies was necessary. 
Optimization of cultivation medium and cultivation conditions as described in this study, 
made its application more feasible. Further, the use of rJEV EDIII protein as an antigen in 
dipstick ELISA resulted in good agreement with the findings of commercial capture ELISA 
systems. These results show that the product has a promising potential for its use in diagnosis 
of JE both in laboratory and field condition with comparable sensitivity and specificity.  
4.5 CONCLUSION 
 A simple fed-batch cultivation process has been demonstrated to produce rJEV EDIII 
protein in E. coli with a high yield in its biologically active form. E. coli is the most widely 
used organism for recombinant protein production because of its rapid growth to high-cell 
densities on inexpensive substrates and its well-characterized genetics and proteomics. 
Production of recombinant JE virus envelope domain III protein was influenced by media. 
Recombinant JEV EDIII protein, produced in super broth and terrific both media gave better 
growth and produces more protein in comparison with other media. For cost-effective reasons, 
it is important to maximize protein production by development of efficient cultivation process 
and appropriate purification methods. The fed-batch cultivation strategy employed in this study 
is probably one of the cost-effective means to enhance cell mass and proteins production. 
Taking advantage of high-volumetric yields obtained by fed-batch cultivation, ~910 mg of 
rJEV EDIII protein per liter of culture broth was produced. These result exhibit the ability to 
produce high yield of JE virus EDIII protein. Large quantity of antigenically active 
recombinant protein, produced by these methods may possibly be used for diagnosis as well as 
for further studies of immunoprophylaxis in JE virus infection. This production strategy can 
also be used for high yield production of other recombinant viral proteins. 
           *** 
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CHAPTER 5 
DEVELOPMENT OF A PILOT SCALE PRODUCTION 
PROCESS FOR RECOMBINANT JEV EDIII PROTEIN AND 
CHARACTERIZATION FOR ITS VACCINE POTENTIAL 
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ABSTRACT 
 Japanese encephalitis (JE) virus is the most important cause of encephalitis in most of 
Asian regions. JE virus envelope domain III (JEV EDIII) protein is involved in binding to 
host receptors and it contains speciﬁc epitopes that elicit virus neutralizing antibodies. A 
highly immunogenic, recombinant JEV EDIII protein was expressed in Escherichia coli. In 
order to take this vaccine candidate for further studies, recombinant JEV EDIII protein was 
produced employing a pilot scale fermentation process.  Recombinant JEV EDIII protein 
expressed as inclusion bodies was solubilized in 8 M urea and renatured by on-column 
refolding protocol in the presence of glycerol. Three step purification process comprising of 
affinity chromatography, ion-exchange chromatography (IEX) based on salt and IEX based 
on pH was developed. About ~124 mg of highly purified and biologically active EDIII 
protein was obtained from 100 g of biomass.  Biological function of the puriﬁed EDIII 
protein was conﬁrmed by their ability to generate EDIII speciﬁc antibodies in mice that could 
neutralize the virus. These findings suggest that recombinant JEV EDIII protein in 
combination with compatible adjuvant is highly immunogenic and elicit high titer 
neutralizing antibodies. Thus, recombinant JEV EDIII protein produced at large scale can be 
a potential vaccine candidate.  
5.1 INTRODUCTION 
 Japanese encephalitis is the most important form of viral encephalitis in Eastern and 
Southern Asia and parts of Western Pacific (Liang  et al, 2009; Fischer et al, 2010). There is 
no specific treatment for JE and hence vaccination of susceptible populations is the sole 
logical alternative.  The vaccines that are available, namely the mouse brain or cell culture 
derived formalin inactivated JEV vaccines are inherent with certain drawbacks. Besides 
being expensive and in short supply, it causes allergic reactions in some recipients (Plesner, 
2003). Moreover, the immunity conferred by the vaccine is of short-term duration (Poland et 
al., 1990). Hence, there is an urgent need to develop alternate vaccine candidates that are 
effective, safe as well as affordable (Bharati and Vrati, 2006).  The envelope protein (53–55 
kDa) is  a  typical  membrane  glycoprotein,  forming  the  outer structural protein component 
of the virus, and is responsible  for  a  number  of  important  processes  such  as  viral 
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attachment, fusion, penetration, virulence and attenuation (Sumiyoshi et al., 1987; 
Lindenbach and Rice, 2001; Witthajitsomboon et al., 2010). The envelope domain III protein 
is also the major antigen responsible for eliciting neutralizing antibodies that confer 
protection to the host (Wu et al., 2003; Alka et al, 2007). Thus, EDIII protein could be 
employed as an immunogen for developing a JEV subunit vaccine.  
 Currently, there is a need for the production of cost effective and safe recombinant 
EDIII protein for the development of protein subunit vaccines or diagnostic reagents. For 
vaccine purpose, the recombinant proteins produced must maintain their biological activity 
(i.e., generate neutralizing antibodies against wild-type virus or able to bind to anti-JEV 
antibodies found in patient serum). The recombinant E, NS1 or EDIII proteins may be 
expressed using various hosts, such as bacteria, yeast and tobacco plants (Lin et al., 2008; 
Shukla et al., 2009; Appaiahgari et al., 2009). Escherichia coli is by far the most commonly 
used host for the expression of recombinant viral proteins. Small scale expression is widely 
used for optimizing conditions for a large-scale production of recombinant proteins (Tripathi 
et al., 2009).   
The scale up process of  recombinant  JEV EDIII protein production may be 
performed by replacing commonly used shake flasks (Alka et al., 2007; Lin et al., 2008; 
Shukla al., 2009)  to fed-batch or batch fermentations (Tripathi et al., 2010). To facilitate the 
purification of recombinant proteins, the proteins are commonly produced as fusion proteins 
that comprise of the EDIII protein fused with an affinity tag, such as the hexahistidine tag 
(Wang et al., 2009; Shukla et al., 2009). High-level expression of recombinant proteins in E. 
coli often accumulates as insoluble aggregates in the form of inclusion bodies (Fahnert et al., 
2004). To recover active protein, inclusion bodies must be solubilized and refolded. 
Chemical chaotropes have been traditionally used to solubilize proteins from inclusion 
bodies. High concentrations of chaotropes (such as up to 6 M guanidine hydrochloride or 8 
M
 
urea) are required to provide the chemical energy to thermodynamically dissociate the 
aggregates with concomitant denaturing of the protein. Reducing agents such as dithiothreitol 
(DTT) or β-mercaptoethanol are added to  reduce  all  disulﬁde  bonds (Wang et al., 2009).  
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Refolding is usually achieved by removing the chaotrope via buffer exchange after 
solubilizing the inclusion bodies, using dilution, dialysis, diaﬁltration in the presence of 
reduced glutathione and oxidized glutathione. However, refolding yields are typically low 
(Singh and Panda, 2005; Wang et al., 2009). Protein refolding by liquid chromatography is 
an alternative to the dilution refolding and has been put much highlight in recent years, and it 
was recently nominated protein folding liquid chromatography (Wang et al., 2009). 
Immobilized metal ion afﬁnity chromatography (IMAC) has become a well-established and 
versatile technique for both analytical and large scale of protein separations. It has recently 
been reported that IMAC has the potential to perform protein refolding with high recovery of 
purified recombinant proteins (Wang et al., 2009). After the preliminary purification using 
affinity chromatography, the purity level of these proteins can be further enhanced by ion 
exchange or size exclusion chromatography (Mazumdar et al., 2010; Tan and Ng, 2010).  
In previous chapter, we described the small scale production of rJEV EDIII protein 
from E. coli
 
as well as affinity purification under denaturing conditions for use as diagnostic 
reagent (Tripathi et al., 2010). In the present study, we  described  here  a scalable  process  
for  the  production, refolding  and  purification  of  recombinant EDIII protein from  E. coli 
for use as vaccine candidate. This process utilized a scale up of fermentation  process and  
rJEV EDIII protein purification using affinity chromatography with simultaneous refolding, 
followed by  ion exchange chromatography (IEX) based on salt and pH based ion exchange 
chromatography. Further,
 
we present data demonstrating that the antibodies raised in mice 
against refolded and purified rJEV EDIII protein neutralize the JE virus. The rJEV EDIII 
protein was highly pure and found to be biologically active.  
5.2 MATERIALS AND METHODS  
 The details about materials and methods used for pilot scale fermentation, on-column 
refolding, ion exchange chromatography, immunogenicity studies and plaque reduction 
neutralization test are  described in the chapter 3. Figure 5.1 provides an overall ﬂow diagram 
for the production of rJEV EDIII antigen for vaccine studies. 
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Figure 5.1. Process flow-sheet outline for production of  rJEV EDIII protein. 
5.3 RESULTS 
 Japanese encephalitis is a major cause of encephalitis in Asia. Cases occur largely in 
rural areas of the South and East Asian region resulting in significant morbidity and 
mortality. Multiple vaccines exist to control Japanese encephalitis, but all of them suffer 
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from problems. Envelope protein domain III of Japanese encephalitis virus is involved in 
binding to host receptors and it contains specific epitopes that elicit virus-neutralizing 
antibodies. To conduct vaccine studies with rJEV EDIII antigen, pure and biologically active 
protein was required. A recombinant clone of  E. coli BL21 (DE3) cells was previously 
developed using the plasmid (pET 30a+rJEV EDIII) construct  to produce this protein at 
small scale and using this clone we further developed a pilot scale fermentation process to 
produce rJEV EDIII protein  in  large  quantities for  use  in  vaccine studies.  
5.3.1 Pilot Scale Production of recombinant JE virus EDIII protein 
 Pilot scale fermentations were carried out to produce large amount of biomass for 
purification of rJEV EDIII protein used in vaccine studies. Before the pilot scale 
fermentation, the fermentation conditions and culture medium were optimized at the small 
scale using shake flask culture and 5 liter fermentor. Under the fermentation conditions 
optimized at the small scale, production of rJEV EDIII protein was carried out using 100 liter 
working volume fermentor with 85 liter modified SB medium. During the cell growth period, 
pH was maintained around 7.0 by an automatic pH control system, and the cultivation 
temperature was 37°C; the air was supplied at the rate of  25-50 liter min
-1 
(LPM) and  the  
dissolved oxygen  level  was  not lower  than 20%.  The agitation speed, the ﬂow rate of 
aeration, and supply of pure oxygen were adjusted to maintain the DO level above 20% air 
saturation.  This fermentation process continued for nine and half hour which comprised of 
the pre-induction (five and half hour) and post induction (four hour) phase. At the beginning 
of the fermentation DO was above 30% and decreased during course of process. The DCW 
and OD600 increased continuously and reached a final value of 6.31 g l
-1
 (Table 5.1) and 
19.80 (figure 5.2) respectively. The DCW at induction was 2.70 g l
-1
. The DCW at induction 
and harvest after batch fermentation using 5 liter fermentor was 2.60 g l
-1
 and 6.22 g l
-1
 
(Table 5.1) respectively. The successful production of this protein in fermentor with a high 
yield was initiated to foster further applications and research with JE vaccines. 
Reproducibility of all batch fermentations were confirmed with additional experiments 
conducted under the above specified optimal conditions and the final yield was within less 
than 10% of the result shown in table 5.1. The pilot scale fermentation yielded approximately 
2 kg cell paste that was aliquoted and frozen at −80oC. The real time profile of a pilot scale 
batch fermentation process is shown in figure 5.2.  
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Figure 5.2. Real-time  proﬁle  of  pilot scale batch fermentation  of  E.  coli  BL21(DE3) 
[pET30a+rJEV EDIII gene]  for the expression of rJEV EDIII protein. Culture was grown in 
batch mode in modified SB media and induced with 1 mM IPTG at OD600 of 10.8 (DCW = 
2.7 g l
-1
) for expression of rJEV EDIII protein. Figure shows time proﬁle for agitation (rpm), 
dissolved oxygen concentration (%), air ﬂow rate (liter min-1), temperature (oC), pH and 
OD600. 
Table 5.1. Production characteristics of E. coli expressing rJEV EDIII protein. 
Media type Cultivation mode  Dry cell weight  Specific product   Final product     
                                                  (DCW) (g l
-1
)   yield (mg g
-1
 DCW) concentration
c
 (mg l
-1
)  
SB   Shake flask  2.15  11.31   24.32  
Modified SB  Shake flask  2.64  16.15   42.66  
Modified SB Batch fermentation
a
 6.22  20.93   130.24 
Modified SB Batch fermentation
b
 6.31  21.36   134.83 
a
At 5.0 liter scale; 
b
At 100 liter scale; 
c
After on-column refolding with affinity purification. 
5.3.2 Refolding and purification of rJEV EDIII protein 
 We  developed  puriﬁcation  process  for  recombinant Japanese encephalitis envelope 
domain III protein to obtain  a high quality  protein  suitable  for  human  Japanese 
encephalitis  vaccine studies.  Puriﬁcation of rJEV EDIII protein was performed from the cell 
109 
 
pellet obtained from fermentation.  After cell disruption and centrifugation, analysis of the 
lysate confirmed the presence of the major proportion of ~13 kDa protein band. Inclusion 
bodies were harvested and purified from the induced and lysed cell mass. On-column 
refolding was carried out using immobilized metal affinity chromatography. The ﬁnal 
product concentration of rJEV EDIII protein following IMAC was signiﬁcantly higher for 
pilot scale batch fermentation as compared to shake flask culture. Improvement in DCW 
(2.5-fold higher) and product yield (5-fold higher) was obtained for both lab and pilot scale 
batch fermentation using modified SB medium as compared to shake flask culture using SB 
medium (Table 5.1). Chromatogram of simultaneous refolding and purification of rJEV 
EDIII protein using IMAC is shown in figure 5.3. 
 
 
 
 
 
  
 
 
 
Figure 5.3. Chromatogram showing simultaneous refolding and affinity chromatography for 
rJEV EDIII protein.The solubilized IBs containing rJEV EDIII protein was loaded onto a 
70/55 Quick scale chromatography column containing 500 ml Ni charged streamline 
chelating. Unbound proteins were removed by washing the column with five column volume 
of the buffer containing 50 mM imidazole and the refolded rJEV EDIII protein was eluted 
with buffer containing 300 mM imidazole.  
 Further, rJEV EDIII protein was purified to improve purity using ion exchange 
chromatography. Processing  of  biomass  from   pilot scale batch  fermentation  yielded  
~124 mg  of  highly  pure, refolded rJEV EDIII protein from 100 g wet biomass. The rJEV 
EDIII protein yield after different purification steps is given in table 5.1 and 5.2. 
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Table 5.2. Purification profile of rJEV EDIII protein purification process from 100 g 
biomass (cell pellet). 
Purification process                 Amount of protein
a
 (mg)     Purity (%)  Overall yield (%) 
Solubilizing of inclusion bodies 1869.3    60  100 
Refolding and IMAC   606.8    91  32.4 
IEX on SP-sepharose salt based  191.1    97  10.2 
IEX on SP-sepharose pH based 124.2    99  6.6 
 a
Amount of protein is given after chromatographic step 
5.3.3 Characterization of rJEV EDIII Protein 
 Pilot scale produced and purified rJEV EDIII protein was characterized for its purity 
and reactivity using SDS-PAGE and Western blot analysis respectively. SDS-PAGE analysis 
of rJEV EDIII protein showed single band corresponding to ~13 kDa (Figure 5.4, 5.5.a). 
 
Figure 5.4. Coomassie blue stained SDS-PAGE. The protein band at approximate molecular 
weight of ~13.0 kDa confirmed the predicted size of the recombinant JEV EDIII protein. The 
protein profiles of the eluted protein and solubilized IBs in gel were analyzed 
densitometrically using Quantity One image quantiﬁcation software which showed that more 
than 95% purity had been achieved. Lane 1, Molecular Weight Marker (kDa); lane 2, 
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Uninduced culture; lane 3, Induced culture, lane 4, Solubilized IBs; lane 5, on-column 
refolded and IMAC purified rJEV EDIII protein (10 µg). 
  A densitometry analysis of the protein bands of eluted protein and solubilized IBs in 
SDS-PAGE gel (Figure 5.4, 5.5.a) using Quantity One image quantiﬁcation software (Bio-
Rad, USA) clearly indicates greater than 98% purity. The western blot with hyper immune 
sera raised in mice revealed that the sera reacted with rJEV EDIII protein (Figure 5.5.b) and 
confirmed the usefulness of this protein. The endotoxin content of puriﬁed protein was less 
than 5 endotoxin unit (EU) per 25 µg of rJEV-DIII antigen used for  immunization. 
 
Figure 5.5. Characterization of pH based IEX puriﬁed rJEV EDIII protein produced at 100 
liter scale. (a) Purity of rJEV EDIII was assessed on SDS-PAGE gel after silver staining. 
Lane 1, Molecular Weight Marker (kDa); lane 2, Purified rJEV EDIII protein (10 µg). (b) 
Western blot analysis of rJEV EDIII protein with polyclonal sera raised against rJEV EDIII 
protein in mice. Lane 1, Molecular weight marker; lane 2, Purified rJEV EDIII protein. 
5.3.4 Humoral Response in Mice Immunized with rJEV EDIII Protein 
 Refolded, purified and characterized recombinant JEV EDIII protein was formulated 
with FCA adjuvant and used to immunize six BALB/c mice (25 µg rJEV EDIII protein per 
dose). The control group, which received adjuvant alone, was also comprised of six mice. A 
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ﬁnal bleed was collected two weeks after second boost. Sera collected from mice were 
serially diluted and tested for recognition of rJEV EDIII protein by ELISA. Adjuvant control 
sera tested at 1:1000 dilution yielded absorbance value at 490 nm (A490) which was used as 
negative control. The A490 values with sera from mice immunized with FCA are clearly 
higher (Figure 5.6). The rJEV EDIII antigen specific antibody titer was found to be more 
than 2, 56,000 (Figure 5.6). The result shows that rJEV EDIII expressed in E. coli is able to 
elicit EDIII-specific antibody responses. Absorbance of control mice sera in 1:1000 dilution 
was 0.720. The end point titers of the FCA group and control sera are shown in figure 5.6. 
The rJEV EDIII antigen with FCA was highly immunogenic and yielded good ELISA titers. 
 
Figure 5.6. Endpoint ELISA titers for recognition of rJEV EDIII protein.  Sera from mice 
collected at days 56 were tested for recognition of recombinant JEV EDIII at various 
dilutions by ELISA. 
5.3.5 Plaque Reduction Neutralization Test  
 The neutralization effect of polyclonal antibodies raised against recombinant JEV 
EDIII protein on the Japanese encephalitis virus was evaluated by plaque reduction 
neutralization test in Vero cells. Two-fold serum dilutions were tested starting at 1:2 against 
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100 p.f.u. of JE virus. PRNT90 values of JE virus by anti-rJEV EDIII antibodies was 
observed up to a dilution of 1:64 (Figure 5.7). PRNT90 titers of the rJEV EDIII anti-serum 
were approximately 1:32 for FCA group sera. Complete neutralization of  JE virus by anti-
EDIII antibodies was observed up to a dilution of around 1:16 and high neutralization effect 
remained up to a dilution of 1:64 (Figure 5.7).  
 
Figure 5.7. Neutralizing ability of sera generated against the recombinant JEV EDIII protein 
in mice formulated with Freund’s adjuvant. Plaque reduction neutralization test was carried 
out with JE virus. Complete neutralization was achieved till 1:16 dilution and high 
neutralizing antibody titers remained till 1:64 dilution. 
5.4 DISCUSSION 
 Selection of an antigen is an important aspect for the development of a vaccine. The 
envelope protein of Japanese encephalitis virus is the major antigen used to elicit neutralizing 
antibody response and protective immunity in hosts. In the previous studies, investigators 
have expressed the EDIII protein of JEV at shake flask culture in E. coli and evaluated the 
protection using these proteins (Wu et al., 2003; Alka et al., 2007; Lin et al., 2008; Verma et 
al., 2009). Production of important foreign proteins in E. coli expression system has been 
highly successful in recent past as this system offers several advantages over the other 
expression systems, including its fast growth rate, utilization of cheap growth media, high 
level of expression of foreign proteins (Yee and Blanch, 1993; Khalilzadeh et al., 2008; 
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Mazumdar et al., 2010) as well as simple and easy purification (Singh and Panda, 2005; 
Bhuvanesh et al., 2010). Therefore it is imperative to develop an efﬁcient and scalable 
production and puriﬁcation process. To enhance the expression of rJEV EDIII protein in E.   
coli, super broth and modified super broth media  were  tested.  Modified SB medium 
resulted in more biomass and protein yield. Thus, modified SB medium was used for further 
studies. High-cell densities attained with modified SB medium (Table 5.1) can be explained, 
as this media is rich in glycerol as compared with SB media. 
Scaling up production of an interesting recombinant protein requires both increasing 
the productivity and the expression level of the target protein, which are strongly influenced 
by fermentation conditions (Bell et al., 2009). The other critical factor for the development of 
any vaccine is the ability to produce the vaccine with a process that is amenable to scale-up, 
is reproducible and produces a reasonable number of doses of the vaccine. According to BC 
Buckland ―Process development is the technological foundation that underlies the 
manufacture of new vaccines and is central to successful commercialization‖ (Buckland, 
2005). Based on the earlier studies on rJEV EDIII protein, we envisaged to produce this 
vaccine candidate on large scale using pilot scale fermentor. In this study, we describe the 
process development by fermentation, purification and immunogenicity of a candidate 
vaccine recombinant rJEV EDIII antigen. Before scale-up, it is essential to ensure the 
reproducibility of the process to ensure its robustness. We have performed several 
fermentations and purifications to ensure that the process was easily scalable from the 
laboratory setup to the pilot scale production. Pilot scale fermentation was carried out using 
modified SB medium. Modified SB medium mainly comprised of yeast extract, phosphate 
salts and glycerol. Yeast extract present in growth media has been reported to enhance the 
specific cellular yield of the expressed protein particularly during high cell density 
cultivation where the demand of nitrogenous source becomes very high following induction 
(Manderson et al., 2006; Tripathi et al., 2009; Mazumdar et al., 2010). Glycerol is one of the 
commonly used carbon source. By using glycerol, high dry cell weight and cell densities may 
be achieved with less frothing (Khamduang et al., 2009). The phosphate salts in the media 
provided a buffering capacity to prevent pH fluctuations that could adversely affect normal 
metabolism (Lim et al., 2000; Babaeipour et al., 2010).      
 We  developed  puriﬁcation  process  for  rJEV EDIII protein to obtain a high quality  
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protein  suitable  for  human JE  vaccine studies. The initial step of purification with 
simultaneous refolding using immobilized metal affinity chromatography (IMAC) removed a 
majority of contaminants as well as denaturants. To refold the bound rJEV EDIII protein, the 
column with bound proteins was washed with the refolding buffer B which eliminated most 
of the contaminants in the ﬂowthrough, and the urea concentration in the IMAC column was 
decreased to initiate the refolding of the denatured rJEV EDIII protein to its native state. The 
refolded rJEV EDIII protein was eluted with increased concentration of imidazole in the 
elution buffer. Therefore, rJEV EDIII protein can be refolded and puriﬁed simultaneously in 
one IMAC run. It was reported that a suitable concentration of urea (3 M) and glycerol (12%) 
in mobile phase is beneﬁcial to protein refolding due to increased renaturation yield, protein 
stability and reduction in the formation of aggregates in liquid chromatography (Wang et al., 
2009). To further purify rJEV EDIII protein, two-step process comprising of ion-exchange 
chromatography based on salt and pH was developed. Because the refolding of proteins is in 
competition with its aggregation, it is of great importance to find effective step for target 
protein monomer separation from dimer and other oligomers (Sereikaite et al., 2008). 
However, there was a drop in the yield of rJEV EDIII protein following ion exchange 
chromatography using salt and pH.  We predict that this loss in the yield of rJEV EDIII 
following  ion  exchange chromatography was  due to formation  of  multiple  conformers  of  
rJEV EDIII protein  in  E. coli having different surface charge properties, which may not be 
distinguishable on SDS-PAGE gel. Further attempt to purify single conformer of rJEV EDIII 
protein based on their surface charge property by ion exchange chromatography resulted in 
lower yield than OCR-AC. This observation also indicates that  the  higher  yield  of  rJEV 
EDIII protein at affinity purification with simultaneous refolding stage  may  not necessarily  
lead  to  higher  yield  of  puriﬁed rJEV EDIII protein following   subsequent   puriﬁcation 
step as affinity chromatography will purify  all  conformers  of  rJEV EDIII protein produced  
in  E.  coli through  histidine  tag. About 124 mg of highly pure, refolded and biologically 
active rJEV EDIII protein was obtained form 100 g of pilot scale produced biomass. Though 
this yield is reasonable to proceed for production of this cGMP grade protein for use in 
human vaccine trials, efforts are being made to further improve the ﬁnal yield. The 
subsequent characterization of recombinant JEV EDIII protein by SDS-PAGE, Western blot 
and ELISA confirms that rJEV EDIII protein is highly pure and reactive. It is evident from 
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the results that the rJEV EDIII protein specifically reacted with anti-JE virus antibody and 
thus suggests that this protein could also be used for the purpose of diagnosis of JE virus 
infection. 
We have also studied the immunogenicity of recombinant JEV EDIII formulated with 
FCA adjuvant in BALB/c mice. When the antigen is small molecule or poorly immunogenic, 
the immune system requires a stimulus to induce an effective immune response. Adjuvants 
can be used for this purpose, and can direct an immune response towards a more cellular or 
humoral response (Cox and Coulter, 1997). FCA is an important adjuvant for investigators 
and is regarded scientifically as an effective means of potentiating immune responses in 
laboratory animals. Though, Freunds adjuvant is not approved for human use, the study 
further needs to be performed with human compatible adjuvants i.e., aluminium hydroxide 
gel, liposome based adjuvants or novel nanoparticle (Huang et al., 2010) based adjuvants. 
There is no universal adjuvant and it must be adapted according to several criteria in order to 
have the best balance between safety and efficacy. Our initial evaluations indicated that the 
rJEV EDIII protein in combination with adjuvant elicited humoral immune response in mice. 
The humoral response was characterized by high titers of antibodies as well as high 
neutralizing titers by plaque reduction neutralization assay. Neutralizing antibodies can bind 
to virus and prevent virus from binding to host cell receptors. The polyclonal antibodies 
raised in BALB/c mice using rJEV EDIII protein were found to be neutralizing JE virus entry 
in to Vero cells. This implies that the refolding of protein could correctly present the 
conformational epitopes on the surface of the recombinant JEV EDIII protein.  FCA group 
showed virus neutralization at dilution of 1:32 and this corresponds to the high antibody end 
point titers with FCA adjuvant. The PRNT50 titers ≥1:10 are considered indicative of 
protective immunity (Lin et al., 2008). The present study clearly reveals the potential of 
recombinant JEV EDIII protein to elicit neutralizing, and therefore, presumably protective 
antibodies against JE virus. The PRNT50 titers reported recently using domain III based 
proteins were approximately 1:24 (Wu et al., 2003), 1:54 (Alka et al., 2007) and 1:28 (Lin et 
al., 2008).  Hence, an ideal subunit vaccine using envelope protein needs to be correctly 
folded and should be well characterized. This is the first report on the use of a pilot scale 
produced, refolded and purified as well as fully characterized domain III protein which has 
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been used for the immunomodulatory studies in combination with adjuvant and detailed 
evaluation of humoral immune response. 
5.5 CONCLUSIONS 
 In conclusion, we have developed a 100 liter pilot scale fermentation process for high 
yield production of recombinant Japanese encephalitis virus envelope domain III protein 
from E. coli. A simple,  three-step  puriﬁcation  strategy  involving  immobilized metal 
afﬁnity chromatography with simultaneous refolding, followed by salt  based ion  exchange  
and  pH  based ion exchange chromatography, was used to purify rJEV EDIII protein that 
was highly pure, homogeneous and recognized by anti-JEV antibodies. Further, 
characterization for its immunogenicity and ability to induce neutralizing antibodies 
established its application more attractive. These ﬁndings suggest that rJEV EDIII protein in 
combination with compatible adjuvant is highly immunogenic and can elicit high titer 
neutralizing antibodies, which proves that refolded and purified rJEV EDIII protein can be a 
potential vaccine candidate. The method described here to produce rJEV EDIII protein may 
also be useful in producing other viral and bacterial proteins in E. coli.  
*** 
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ABSTRACT 
 Japanese encephalitis (JE) is a major public health problem in South-East Asia and 
Western Pacific countries. The recombinant nonstructural 1 (rNS1) protein of JE virus is a 
potential diagnostic as well as vaccine candidate. Developments of cost effective and simple 
culture media as well as appropriate culture conditions are generally favorable for large scale 
production of recombinant proteins. The effects of medium composition and cultivation 
conditions on the production of  rNS1 protein were investigated in shake flask culture as well 
as batch cultivation of Escherichia coli. Further, the fed-batch process was also carried out 
for high cell density cultivation (HCDC) of E. coli expressing rNS1 protein. Isopropyl-β-D-
thiogalactopyranoside (IPTG) was used to induce the expression of  rNS1 protein at ~13 g 
dry cell weight (DCW) per liter of culture. The final DCW after fed-batch cultivation was 
~17 g/l. The Inclusion bodies were isolated and puriﬁed through affinity chromatography to 
give a ﬁnal product yield of ~142 mg/l. The reactivity of purified protein was confirmed by 
Western blotting and Enzyme linked immunosorbent assay. These results show that  rNS1 
protein may be used as a diagnostic reagent or for further prophylactic studies. This approach 
of producing rNS1 protein in E. coli with high yield may also offers promising method for 
production of other viral recombinant proteins. 
6.1 INTRODUCTION 
 Japanese encephalitis virus (JEV) is the most important cause of epidemic 
encephalitis in most Asian regions with about 35,000-50,000 cases and 10,000 deaths 
annually (Solomon and Vaughn, 2002; Abraham et al., 2011). The Envelope (E) protein and 
nonstructural 1 (NS1) protein (Hua et al., 2010) elicits neutralizing antibodies and plays an 
important role in inducing immunologic responses in the infected host (Xu et al., 2004; Lin et 
al., 2008; Appaiahgari et al., 2009; Wang et al., 2009; Witthajitsomboon et al., 2010). NS1 
specific antibodies have been demonstrated to provide protective immunity against dengue 
viruses (Amorim et al., 2010) and JE virus (Lin et al., 1998; Xu et al., 2004; Lin et al., 2008). 
In addition, the high immunogenicity of the NS1 proteins of JE, Dengue and other 
flaviviruses has raised considerable interest both as an antigen for diagnostic methods 
(Konishi et al., 2004; Lin et al., 1998; Huang et al., 2001; Xu et al., 2004; Konishi et al., 
2009) and as component of subunit vaccine formulations (Lin et al., 1998; Xu et al., 2004; 
120 
 
Lin et al., 2008;). For this reason, the NS1 protein is an important immunogen for a subunit 
vaccine and also a prospective diagnostic reagent for the improved clinical diagnosis of JE 
virus infections. 
There is no specific therapy for JE and vaccination is the only available preventive 
measure in addition to mosquito vector control. The internationally licensed vaccine has 
several limitations in terms of cost, availability and safety, apart from ethical issues (Plesner 
and Ronne, 1997; Appaiahgari et al., 2009). Early diagnosis of disease plays an important 
role to forecast an early warning of epidemic and to undertake effective vector control 
measures. The early diagnosis of JEV infection is achieved by serodiagnosis using ELISA 
based on the identification
 
of NS1 antigen (Konishi et al., 2004; 2009) or anti-JEV IgM 
antibodies (Ravi et al., 2006; Jacobson et al., 2007; Shrivastva et al., 2008; Ravi et al., 2009; 
Litzba et al., 2010; Tripathi et al., 2010). 
 
Some of ELISA tests for detection of anti-JEV IgM 
antibodies utilizes whole-virus antigen prepared from cell culture so it is costly and also 
associated with biohazard risk. Replacement of the whole-virus
 
antigens with recombinant 
envelope (E) protein eliminated the bio-safety risk but
 
not the cross-reactivity problem (Ravi 
et al., 2006). However, all these kits are expensive due to the high costs associated with 
antigen production, making them unaffordable for use in the developing countries where JE 
is mostly prevalent. Thus, there is a need to develop detection system as well as an improved 
JE vaccine that may be safer, cheaper and readily available. Hence, production and 
purification of this protein is necessary for further studies. E. coli is the most commonly used 
host for heterologous protein production because it is a well-characterized organism in the 
genetics, physiology and cultivation condition (Lim et al., 2000; Khalilzadeh et al., 2008).  
Protein expression level depends on cultivation conditions, such as medium 
composition, induction time, inducer concentration and inducer type, which can be optimized 
for over-expression of a recombinant protein (Manderson et al., 2006; Tripathi et al., 2009). 
Recombinant E. coli can be grown to high densities in complex media, semi-defined and 
defined media (Manderson et al., 2006; Khalilzadeh et al., 2008; Tripathi et al., 2011). The 
composition of the growth media is crucial for enhancing product formation as well as 
reduction of inhibitory compound formation (Manderson et al., 2006; Tripathi et al., 2009). 
Furthermore, one of the most popular methods to achieve high cell density is fed-batch 
culture by controlling the nutrient feeding via pH, dissolved oxygen (DO) or specific growth 
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rate (Lim et al., 2000; Manderson et al., 2006; Khalilzadeh et al., 2008; Bhuvanesh et al., 
2010). Recombinant protein purification using the minimum possible steps is crucial to meet 
the required level of purity. Affinity chromatography is versatile and can be used for 
improved purification of recombinant proteins (Tripathi et al., 2010; Bhuvanesh et al., 2010).  
There is currently a need for developing cultivation process for high yield production 
of recombinant NS1 protein of JE virus and development of cost-effective, safe and simple 
diagnostics. Thus, we have focused on the production of rJEV NS1 protein from E. 
coli which over-expressed this protein in the form of insoluble inclusion bodies. The culture 
media and culture conditions optimization; batch and fed-batch cultivation were performed to 
maximize overall productivity of this protein. Further, characterization of this protein was 
carried out for its potential as a diagnostic tool using ELISA makes its application more 
feasible. 
6.2 MATERIALS AND METHODS 
 The materials used for this study are described in chapter 3. The methodologies used 
for this study are described in materials and methods section (chapter 3). 
6.3 RESULTS AND DISCUSSION 
6.3.1 Expression of Recombinant JE Virus NS1 Protein 
 The JE virus as well as dengue virus NS1 protein is a potential candidate for the 
design of subunit vaccines as well as diagnostic methods. Nonetheless, generation of 
recombinant (r) NS1 protein of dengue virus from infected tissue culture insect cells is a 
laborious and costly, subjected to batch-to-batch variation making it difficult for routine 
large-scale production (Huang et al., 2001). Expression of rNS1 protein of dengue virus in 
E. coli is a much cheaper and a simpler procedure (Huang et al., 2001; Das et al., 2009).  In 
the present study, rJEV NS1 protein is produced in E. coli and used as a diagnostic reagent 
for detection of antibodies. The JEV NS1 coding sequence was previously cloned and, 
transformation of the E. coli SG13009 strain was carried out. The expressed proteins, 
following 4 h incubation in the presence of 1m M IPTG, were monitored by SDS-PAGE 
(Figure 6.1). These protein bands with molecular mass of ~44 kDa in the insoluble protein 
extracts of the recombinant strain corresponded to the predicted mass of JEV NS1 protein.   
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Figure 6.1. SDS–PAGE analysis of rJEV NS1 protein expression. The culture was induced 
with 1 mM IPTG and further grown for 4 h. Lane M, Molecular weight marker (kDa); lane 1, 
Un-induced coomassie stained E. coli lysates; lane 2, Induced culture lysates. 
The appropriate medium for rJEV NS1 protein production was analysed by using 
shake flask experiments.  For this purpose, four different media were tested. Maximum 
protein yield was obtained in modified SB medium followed by super broth medium. 
However, defined medium produced the lowest final cell density. Chemically defined media 
are generally known to produce slower growth and protein titers than semi-defined or 
complex media (Bhuvanesh et al., 2010). Thus modified SB medium was considered for 
further studies. The rJEV NS1 protein yield in different media are shown in table 6.1. 
Table 6.1. Production characteristics of rJEV NS1 protein expressed in E. coli using 
different media in shake flask culture. 
 Media                     DCW (g/l)       rJEV NS1 Protein (mg/l)     
LB Broth        1.18   8.84   
Super broth (SB)      1.77   13.02    
Modified SB medium
    
 2.14   16.10  
Defined medium     1.05   6.69 
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6.3.2 Batch and Fed-batch Fermentation to Produce rJEV NS1 Protein 
 For E. coli or any other cultivation systems, the level of intracellular accumulation of 
a recombinant protein is dependent on the final cell density. Several recombinant proteins 
have been successfully produced in recombinant E. coli by fed-batch cultivation using 
various regimes of nutrient feeding resulting in different biomass and production yields. The 
development of a fed-batch process for high yield production of  rJEV NS1 protein is 
required for further studies as a diagnostic reagent or prophylactic purpose. Batch 
cultivations with SB medium and modified SB medium were carried out. The DCW at the 
time of induction (after 5 h of cultivation) was 2.80 and 3.10 g/l respectively. The final DCW 
(~9 h of growth) at harvest in all media is given in table 6.2. The modified SB medium again 
resulted in more DCW and rJEV NS1 protein in comparison with SB medium (Table 6.2). 
This may be due to the presence of more glycerol in comparison with other media.  
Table 6.2. Production characteristics of rJEV NS1 protein expressed in E. coli using 
different media in bioreactor. 
 Media               Culture condition       DCW (g/l)      rJEV NS1 Protein  (mg/l)    
Super broth (SB)         Batch cultivation  4.30   32.75   
Modified SB medium
      
     Batch cultivation  6.25   48.42  
Modified SB medium        Fed-batch cultivation 17.78   142.16 
 This has already been established in earlier ﬁndings where yeast extract or glycerol 
was used as media components (Manderson  et al., 2006; Khamduang et al., 2009).  For 
further increasing the production of rJEV NS1 protein per unit volume, fed-batch cultivation 
using modified SB  medium was carried out. The inducer (1 mM IPTG) was added to the 
culture at DCW of about 13.41 g/l and allowed to grow for another 4 h before harvesting. 
The growth profile (OD vs. Time) during course of fed-batch cultivation is shown in figure 
6.2. The control of feeding rate is maintained by keeping  the DO and pH values at their set 
point. Yeast extract present in growth media have also been reported to enhance the specific 
cellular yield of the expressed protein particularly during high cell density cultivation where 
the demand of nitrogenous source becomes very high following induction (Tripathi et al., 
2009). Glycerol is one of the commonly used carbon source. By using glycerol, high DCW 
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and cell densities may be achieved with less frothing. The final DCW of about 17.78 g/l was 
obtained at ~13 h of growth in fed-batch mode (Table 6.2). The variation of cultivation 
parameters with time during fed-batch process is shown in figure 6.2. The DCW and rJEV 
NS1 protein yield in batch and fed-batch process with different media are given in table 6.2. 
The final DCW after fed-batch process was found to be increased more than fifteen times 
when compared with that of shake flask culture with LB medium and about ten times more 
with SB medium. 
 
Figure 6.2. Real time profile of fed-batch cultivation for production of rJEV NS1 protein. The 
culture was induced with 1 mM IPTG (after ~9 h of cultivation) at DCW of 13.41 g/l and 
cells were grown further for 4 hours to attain DCW of 17.78 g/l. 
6.3.3 Purification and Characterization of rJEV NS1 Protein 
 Expression of heterologous protein in E. coli allows its rapid and economical 
production in large amounts. In an effort to obtain target protein in host E. coli strain, IBs 
formation is still considered as a convenient and effective way in recombinant protein 
production (Singh and Panda, 2005). After cell disruption and centrifugation analysis of the 
lysate confirmed the presence of the major proportion of ~44 kDa protein band. IBs were 
harvested and purified from the induced and lysed cell mass. The IBs were solubilized in 
buffer containing 8M urea and purified by affinity chromatography under denaturing 
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conditions. The purified protein was further dialyzed before used for ELISA. The SDS-
PAGE profile of eluted protein is shown in figure 6.3a and 6.3b.  
 
Figure 6.3. (a) Coomassie stained SDS–PAGE. The protein band of ~44.0 kDa confirmed the 
predicted size of the rJE NS1 protein. The protein profiles of the eluted protein in coomassie 
stained gel were analyzed densitometrically using Quantity One image quantiﬁcation 
software which showed that more than 90% purity has been achieved. Lane 1, Molecular 
Weight Marker (kDa); lane 2, purified rJEV NS1 protein. (b) Silver stained SDS-PAGE.  
Lane 1, Molecular Weight Marker (kDa);  lane 2, Purified rJEV NS1 protein.(c) Western blot 
analysis of the purified rJEV protein. The sample showing reaction with protein at desired 
size (~44 kDa) was considered positive. Lane 1, rJEV NS1 protein with hyper immune serum. 
From the protein profiles of the eluted protein in SDS-PAGE (figure 6.3a and 6.3b) 
and densitometry analysis using Quantity One image quantiﬁcation software (Bio-Rad, 
USA), more than 90% purity was found to be achieved. The cell pellet harvested from 50 ml 
of induced fed-batch culture yielded ~7.0 mg purified rJEV NS1 protein with ~92% purity. 
This corresponds to a recovery of ~50% as the crude cell lysate was estimated to 
contain ~13.9 mg  of the rJEV NS1 protein and 104 mg total protein, based on densitometric 
analysis using Quantity One software (Bio-Rad, USA). The solubilized IBs was estimated to 
contain ~9.0 mg of the rJEV NS1 protein with ~64% recovery and ~75% purity (Table 6.3). 
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The ﬁnal product concentration of rJEV NS1 protein following affinity chromatography was 
signiﬁcantly higher for fed-batch cultivation as compared to batch cultivation (Table 6.2). 
Improvement in product yield about more than eight times for fed-batch  cultivation  as 
compared to shake flask culture resulted using modified SB medium (Table 6.2). The final 
rJEV NS1 protein yield after fed-batch cultivation was ~142.16 mg/l (Table 6.2).  
Table 6.3. Summary of purification of rJEV NS1 protein from 50 ml bioreactor culture. 
Step    Total protein (mg)
a 
     Purity (%)
b
         Yield (%)
c
 
Total cell lysate  104     0   100 
Solubilised IBs  9.0    75              64   
Affinity chromatography 7.0   92   49 
Total cell lysate represents 50 ml of bioreactor sample of 4 hours  post induction. 
a
The protein estimation was carried out using BCA method. 
b
The purity of protein was analysed by coomassie stained SDS-PAGE analysis. 
c
The amount of rJEV NS1 protein in the total cell lysate was ~13.9 mg as determined by 
densitometric analysis and specified as 100%. 
 The purified protein was subjected to Western blot assay, to confirm its identity as 
rJEV NS1 protein. The purified rJEV NS1 protein was tested with mice sera raised against 
rJEV NS1 protein. This revealed that the rJEV NS1 protein could react with anti-JEV NS1 
antibody (Figure 6.3c). It is evident that this protein specifically reacted with anti-JEV 
antibody and thus suggests that it could be used for the purpose of diagnosis of JEV 
infection. 
4.3.4 Recombinant JEV NS1 Protein as a Diagnostic Reagent 
 The usefulness of purified rJEV NS1 protein for the detection of anti-JEV IgM 
antibodies in human sera and CSF samples was carried out by in-house developed indirect 
dipstick and microwell plate ELISA. A total of 50 clinical samples (30 serum and 20 CSF 
samples) was included. Optical density (OD490) values of serum and CSF samples 
determined with in-house microwell plate ELISA are shown in table 6.4. Among 30 serum 
samples, 16 samples were positive and 14 samples were negative and of 20 CSF samples 12 
were positive and 8 samples were negative by in-house dipstick ELISA as well as in-house 
127 
 
microwell plate ELISA. Out of 30 serum samples, 18 samples were positive and 12 samples 
were negative and of the 20 CSF samples 13 were positive and 7 samples were negative by 
JEV-CheX IgM capture ELISA.  
Table 6.4. Range of OD490 values in the in-house indirect microwell plate IgM ELISA 
for human CSF and serum samples. 
In-house ELISA OD range
a
   No. of CSF samples   No. of serum samples 
0.000–0.199    08    02 
  0.200–0.399    05    07 
0.400–0.599   04    05  
0.600–1.00   03    06 
1.00–1.50   -    05 
1.50–2.00   -    03 
≥2.0    -    02 
Total    20    30 
a 
ELISA OD450 values of  ≥ 0.20 and ≥ 0.60 were considered positive at a CSF dilution of 
1:10 and serum dilution of 1:100. 
Comparison of the both in-house ELISA with JEV Chex IgM capture ELISA revealed 
comparable sensitivities, specificities and overall agreements (Table 6.5). In addition, 10 
healthy serum samples as well as 5 dengue positive serum samples were also included in this 
study. None of them gave positive result thereby confirming its specificity. The use of rJEV 
NS1 protein as an antigen in ELISA avoids costly and tedious production of viral antigen as 
well as the inherent biosafety issues. The diagnosis of JE has advanced considerably in 
recent years and routine laboratory diagnosis of JE virus infection is primarily carried out by 
detection of anti-JE virus antibody by serological methods namely MAC-ELISA and indirect 
IgM ELISA (Plesner and Ronne, 1997; Ravi et al., 2006; Jacobson et al., 2007; Shrivastva et 
al., 2008; Ravi et al., 2009; Litza et al., 2010; Kumar et al., 2011). Most of these tests are 
based on the capture principle and or uses native viral antigens (high production cost and 
produces biohazards). Therefore, there is a genuine need for a promising test system for 
detection of JEV infection. In the present study, the in-house indirect ELISA test has shown 
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more than 90% agreement for detection of anti-JEV IgM antibodies in CSF as well as serum 
samples as compared to commercial assay. The discrepancies in correlation between 
commercial kit and in-house ELISA (Table 6.5) may be attributed to the use of crude JE 
virus infected culture fluid as antigen in the commercial kit (Ravi et al., 2006) whereas in-
house ELISA uses affinity chromatography purified recombinant JE virus specific 
nonstructural 1 protein as antigen. The advantages of this in-house ELISA test are that it is 
cost effective because it uses E. coli expressed protein as well as faster than MAC ELISA. 
Further,
 
the in-house dipstick ELISA is a qualitative test meant for field use. The negative 
results of rJEV NS1 protein based indirect ELISA with dengue positive human sera as well 
as negative serum samples established its specificity for JE diagnosis. These ﬁndings suggest 
that the rJEV NS1 protein based indirect ELISA is a sensitive and speciﬁc test for early 
detection of JEV infection.   
Table 6.5. Comparative evaluation of in-house ELISA with reference to JEV CheX IgM 
capture ELISA for detection of anti-JEV IgM antibodies in patient serum and CSF 
samples. 
Type of sample        % Agreement
a       
% Sensitivity
b
      % Specificity
c
       
Serum      93%(28/30)          89%(16/18)                 100%(12/12)                                        
CSF                       95%(19/20)         92%(12/13)                100% (07/07)                                  
a
(Number of samples positive by both method + number of samples negative by both 
methods) /(total number samples) x100. 
b
True positive/(true positive + false negative) x 100. 
c
True negative /(true negative + false positive) x 100. 
Since the recombinant JE virus NS1 protein shown high immunogenicity (Lin et al., 
2008), it is useful antigen for immunodiagnosis of JEV infection and also for 
immunoprophylaxis. For use in serological diagnosis of JEV infection as well as further 
studies in immunoprophylactic development, large quantity of biologically active protein was 
required which could be produced using bioreactor. The media optimization, batch and fed-
batch cultivation strategies as mentioned in the present study demonstrated its use more 
appropriately. The results of in-house ELISA using purified rJEV NS1 protein with reference 
to commercial assay was in good concordance. The findings of present study exhibits that the 
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rJEV NS1 protein can be an antigen of choice for cost effective serological diagnosis of JEV 
infection with acceptable specificity, sensitivity and agreement.  
6.4 CONCLUSIONS 
 We  have  described  here  a  robust  and scalable   cultivation   method   to   produce   
recombinant JEV NS1 protein as  insoluble  form  at  10 liter  cultivation  scale. Usually 
recombinant E. coli is the host of choice for heterologous protein production as it is easier to 
grow it to higher biomass on inexpensive carbon and nitrogen sources. The composition of 
media affected the yield of rJEV NS1 protein production. From the economic point of view, 
it is necessary to increase the biomass as well as amount of protein of interest employing 
suitable cultivation strategies and efficient purification processes. In this study, the high cell 
density fed-batch cultivation was adopted to increase the protein yield.  A simple, one step 
puriﬁcation strategy involving metal afﬁnity chromatography was devised to produce rJEV 
NS1 protein with high purity. This process resulted in ~142 mg of purified rJEV NS1 protein 
per liter of culture. The purified  rJEV NS1 protein thus produced has a potential application 
for detection of anti-JEV IgM antibody as well as further studies in vaccine development for 
JEV infection. This approach of creating recombinant antigens coupled to over-expression in 
E. coli and simple purification offers a promising alternative option to JE diagnosis with the 
potential to circumvent the drawbacks of the whole virus antigen based assays. The method 
described here to produce rJEV NS1 protein may also be useful in producing other viral and 
bacterial proteins in E. coli as insoluble form for production at large scale. 
 
*** 
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CHAPTER 7 
PRODUCTION OF RECOMBINANT DENGUE VIRUS TYPE 3 
EDIII PROTEIN BY BATCH AND FED-BATCH 
FERMENTATION AS WELL AS EVALUATION OF ITS 
DIAGNOSTIC POTENTIAL 
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ABSTRACT 
 Dengue is a public health problem of global significance for which there is neither an 
effective antiviral therapy nor a preventive vaccine. The envelope protein of dengue virus is 
the major antigen to elicit neutralizing antibody response and protective immunity in hosts 
thus making it as a diagnostic and vaccine candidate. Optimization of culture media was 
carried out for enhanced production of recombinant dengue virus type 3 envelope domain III 
(rDen 3 EDIII) protein in E. coli. Further, batch and fed-batch cultivation process were also 
developed in optimized medium. After fed-batch cultivation, the recombinant E. coli resulted 
in dry cell weight of about 22.80 g/l of culture. The rDen 3 EDIII protein was purified from 
inclusion bodies using affinity chromatography. This process produced ~649 mg of purified 
rDen 3 EDIII protein per liter of culture. The purity of this protein was checked by SDS-
PAGE analysis and the reactivity was analyzed by Western blotting. The purified protein was 
also used to develop an in-house enzyme linked immunosorbent assays and tested with 
human serum samples. These results show that the purified protein has the potential to be 
used for the diagnosis of dengue virus infection or for further studies in vaccine 
development.  
7.1 INTRODUCTION 
 Dengue viruses comprise four antigenically distinct serotypes (1 to 4). Its genome 
encodes for three structural proteins: the capsid protein, the premembrane protein and the 
envelope glycoprotein and seven non-structural proteins (Mackenzie et al., 2004). The 
envelope (E) protein comprises 3 regions: Domain I, II and III. Out of these, domain III 
(DIII) is an immunoglobulin-like receptor binding domain (Rey et al., 2003; Chin et al., 
2007). In addition, it has also been demonstrated to be highly immunogenic and able to elicit 
the production of neutralizing antibodies against the wild-type virus (Crill and Roehrig, 
2001). Envelope DIII (EDIII), which spans amino acids (aa) 300 to 400 of the E protein, is a 
highly stable, independently folding domain that lies exposed and accessible on the virion 
surface. Multiple type and subtype specific neutralizing epitopes of the envelope protein have 
been mapped to EDIII (Kuhn et al., 2002; Gromowski et al., 2007; Guzman et al., 2010).  
 Since no effective vaccine is available for dengue, early diagnosis plays an important 
role to control the disease. In a majority of cases the only feasible diagnostic test is based on 
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the identification of anti-dengue virus IgM and IgG antibodies, which appear after the 
viremic phase and persist much longer. Recently, several dengue diagnostic tests, in different 
formats, have become available commercially (Groen et al., 2000; Abhyankar et al., 2006; 
Blacksell et al., 2006, 2008). Most of them uses infected mouse brain or insect cell extracts. 
It is associated with inherent biohazard risk, cross-reactivity with related Flaviviruses. 
Replacement of the whole-virus antigens with a mixture of recombinant envelope (E) 
proteins of the four dengue virus serotypes eliminated the safety risk but not the cross-
reactivity problem (Cuzzubbo et al., 2001). However, all these kits are expensive due to the 
high costs associated with antigen production (AnandaRao et al., 2006), making them 
unaffordable for use in the economically weaker countries where dengue occur most 
frequently. In an attempt to eliminate this cross-reactivity, we have focused on a discrete 
domain of the E protein, known as domain III (EDIII). Earlier studies suggested that the 
envelope domain III protein of dengue virus can be used for detection of anti-dengue virus 
antibodies (Simmons et al., 1998; Jaiswal et al., 2004; Hapugoda et al., 2007; Pattnaik et al., 
2007) and also for vaccine studies (Jaiswal et al., 2004; Chen et al., 2007; Pattnaik et al., 
2007; Babu et al., 2008; Sim et al., 2008). For this reason, the EDIII protein is an important 
immunogen for the development of a prospective protein subunit vaccine and also a 
prospective diagnostic reagent for the improved clinical diagnosis of dengue infections. 
A high cell density cultivation technique is important to maximize volumetric 
productivity. Escherichia coli is the most commonly used host for heterologous protein 
production because it is a well-characterized organism in the genetics, physiology and 
cultivation condition (Lee, 1996; Panda, 2003; Bhatnagar et al., 2008). Recombinant E. coli 
can be grown to high densities in common media such as Luria bertani broth, SOB medium 
and Super broth medium (Madurawe et al., 2000; Manderson et al., 2006). Growing E. coli to 
high density using fed-batch cultivation process is currently the method of choice for the 
production of recombinant proteins, mainly because of the high volumetric productivity 
associated with this method (Babu et al., 2000; Khalilzadeh et al., 2004, 2008). However, 
high cell density cultures also have a few drawbacks such as substrate inhibition, the 
formation of growth inhibitory by-products. The composition of the growth media is crucial 
for enhancing product formation as well as reduction of inhibitory compound formation 
(Manderson et al., 2006; Tripathi et al., 2009).  
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There is currently a need for developing cultivation process for enhanced production 
of recombinant dengue virus type 3 envelope domain III (rDen 3 EDIII) protein and 
development of cost-effective, safe and simple diagnostics with sensitivity, specificity and 
applicability in laboratory as well as field conditions. In order to produce recombinant 
proteins in E. coli with high yield, over-expression of the recombinant protein in a cultivation 
process and a purification procedure allowing efficient recovery of the protein from the 
resultant biomass are necessary. Thus, we have focused on the production of rDen 3 EDIII 
protein from recombinant E. coli which over-expressed this protein in the form of insoluble 
inclusion bodies. The media optimization, batch and fed-batch cultivation were performed to 
maximize overall productivity of rDen 3 EDIII protein.  Further, evaluation of this protein 
was carried out for its potential as a diagnostic tool using dipstick ELISA for the detection of 
anti-dengue virus IgM and IgG antibodies using patient serum samples. 
7.2 MATERIALS AND METHODS  
 The details about materials used for production of rDen 3 EDIII protein are desribed 
in the material and methods section (Chapter 3). The methods for expression, media 
optimization, small scale batch fermentation, fed-batch fermentation, affinity 
chromatography, SDS-PAGE, Western blot and ELISA are described in the materials and 
methods section  (Chapter 3). A typical flow diagram for production and purification of rDen 
3 EDIII protein used as a diagnostic reagent is similar to that shown in figure 4.1. 
7.3 RESULTS AND DISCUSSION 
7.3.1 Expression of Recombinant Dengue Virus type 3 EDIII Protein  
 The present study was envisaged to produce large amount of rDen 3 EDIII protein 
and its evaluation as a diagnostic reagent for Dengue. To produce this protein in E. coli, a 
synthetic gene encoding Den 3 EDIII protein was previously cloned in pET30a+ bacterial 
expression vector. This construct is predicted to encode a recombinant protein with an 
approximate molecular weight of ~12 kDa. To express recombinant dengue virus type 3 
envelope domain III protein in E. coli, shake flask culture was carried out in LB medium. A 
typical induction experiment comparing the proﬁles of un-induced and IPTG-induced E. coli 
cultures for dengue virus serotype 1-4 is shown in Figure 7.1.a. It is evident that IPTG 
induction results in the expression of a ~12 kDa Den 3 EDIII protein. Growth culture induced 
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with different concentration of inducer (0.5, 1.0 and 1.5 mM IPTG) at 4 h post induction time 
has shown the maximum protein expression with 1 mM IPTG (Figure 7.1.b). Therefore, in all 
subsequent experiments induction was carried out with 1 mM IPTG for 4 h. 
 
Figure 7.1. SDS-PAGE analysis of expression of rDen 1-4 EDIII protein. (a). Lane M : MW 
marker (kDa) ; lane 1: Un-induced culture lysate ; lane 2-5: Induced culture lysate 
expressing rDen 1-4 EDIII protein respectively (~12.0 kDa). (b) lane 1: Un-induced culture 
lysate ; lane 2-4: 0.5, 1.0 and 1.5 mM IPTG induced culture lysate expressing rDen 3 EDIII 
protein (~12.0 kDa). 
7.3.2 Effect of Media on Production of rDen 3 EDIII Protein  
 Composition of media seem to be important to ensure proper cell growth and for rDen 
3 EDIII protein production. The present study therefore had an objective to produce rDen 3 
EDIII protein with a high yield and evaluate its use in diagnosis of the disease. In the shake 
flask culture, final cell density and cell concentration was found to depend upon the media 
used. The growth profile of E. coli cells expressing this protein is shown in figure 7.2. Super 
broth achieved final dry cell weight of about 2.42 g/l. SOB medium resulted in final dry cell 
dry weight about 1.41 g/l. However, LB medium produced 1.34 g/l dry cell weight. High-cell 
densities attained with SB can be explained, as these media are rich in yeast extract and 
phosphate salts compared to the other media used. Production characteristics of rDen 3 EDIII 
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protein expressed in E. coli in terms of OD, dry cell weight and rDen 3 EDIII protein yield at 
shake flask culture using different media are summarized in table 7.1. 
 
Figure 7.2.  Growth profile of recombinant E. coli  in shake flask culture with  four different 
culture media. 
Table 7.1.Production characteristics of rDen 3 EDIII protein expressed in E. coli using 
different media in shake flask culture. 
 Media   OD600             DCW (g/l)        rDen 3 EDIII Protein  (mg/l)     
LB Broth  3.18   1.34   39.25    
SOB   3.66   1.41   42.16  
Super Broth  6.24   2.42   54.64   
7.3.3 Production of rDen 3 EDIII Protein in E. coli  
 The optimization of media for rDen 3 EDIII protein production was also performed in 
the bioreactor using batch mode under controlled cultivation parameters. In batch cultivations 
with LB, SOB and SB medium, the dry cell weight at induction was 0.96, 1.32 and 2.30 g/l 
respectively. The final dry cell weight at harvest in all three media is shown in table 7.2. We 
found that the SB medium again resulted in more OD, dry cell weight and level of rDen 3 
EDIII protein expression in comparison with LB and SOB media (Table 7.2). This may be 
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due to the presence of yeast extract and or glycerol in comparison with other media. For 
further maximizing the volumetric production, E. coli cells expressing rDen 3 EDIII protein 
were grown in a fed-batch cultivation process using optimized medium. The cultures at cell 
OD of 42.79 (15.10 g/l dry cell weight) were induced with 1 mM IPTG and grown for 
another 4 hours. The growth profile (OD vs. Time) during course of fed-batch cultivation is 
shown in figure 7.3. Once feeding is initiated and E. coli enters into log phase (Figure 7.3), 
the feed is consumed more or less in an exponential manner. Therefore, the feeding rate has 
to be controlled so that it doesn't exceed the nutrient demand or feed consumption rate. It is 
done by maintaining the pH and DO around their set values. Rise in pH and DO values  
 
Figure 7.3. Real time profile of fed-batch cultivation for production of rDen 3 EDIII protein. 
The culture was induced with 1 mM IPTG (after ~9 h of cultivation) at OD of 42.79 and cells 
were grown further for 4 hours. The culture OD at harvest (after ~13 h of cultivation) was 
62.13. 
indicate that the carbon source or one of the substrates is limiting and hence feed is required. 
Yeast extract present in growth media help in reducing secretion of acetic acid as well as 
utilisation of acetic acid during carbon limitation at the time of growth of E. coli. Yeast 
extract have also been reported to enhance the specific cellular yield of the expressed protein 
particularly during high cell density cultivation where the demand of nitrogenous source 
becomes very high following induction (Panda, 2003; Zhang et al., 2010). Glycerol is used as 
a carbon source and high cell densities with less frothing (anti foaming effect) may be 
137 
 
achieved relatively easily using glycerol. The final dry cell weight of about 22.80 g/l was 
attained at ~13 h of cultivation (Table 7.2). Real time profile of fed-batch cultivation for 
production of rDen 3 EDIII protein is shown in figure 7.3. Comparative evaluation of OD, 
dry cell weight and rDen 3 EDIII protein in batch and fed-batch cultivation using different 
media is shown in table 7.2. Reproducibility of all batch and fed-batch cultivations was 
confirmed with additional experiments conducted under the above specified optimal 
conditions and the final yield was within less than 10% of the result shown in table 7.2. The 
final dry cell weight after fed-batch cultivation was about seventeen times more in 
comparison with shake flask culture using commonly used LB medium and about nine times 
more with SB medium. 
Table 7.2. Production characteristics of rDen 3 EDIII protein expressed in E. coli using 
different media in bioreactor. 
 Media   OD600             DCW (g/l)        rDen 3 EDIII Protein (mg/l)     
LB Broth
b 
 5.35   2.10   66.13      
SOB
b
   8.28    2.96   97.60     
Super Broth
b
  13.14   4.50   176.76    
Super Broth
c
  61.78   22.80   649.24    
b
Batch cultivation; 
c
Fed-batch cultivation 
7.3.4 Purification and characterization of rDen 3 EDIII protein  
 The present study demonstrated the feasibility of obtaining pure rDen 3 EDIII protein 
utilizing a single chromatographic step using affinity chromatography. The inclusion bodies 
were solubilized in buffer containing 8 M urea and purified by affinity chromatography 
under denaturing conditions. The SDS-PAGE profile of rDen 3 EDIII protein is shown in 
figure 7.4a. From a comparison of the protein profiles of the eluted protein, solubilized IBs 
and the crude cell lysate in silver stained SDS-PAGE (Figure 7.4a) densitometrically, it is 
clearly evident that more than 95% purity has been achieved. The cell pellet harvested from 
50 ml of induced fed-batch culture yielded ~32 mg purified recombinant dengue virus type 3 
envelope domain III protein. This corresponds to a recovery of ~52% as the crude cell lysate 
was estimated to contain ~61.5 mg of the recombinant protein (Table 7.3), based on 
densitometric analysis.  
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Table 7.3. Summary of purification of rDen 3 EDIII protein from bioreactor culture. 
Step    Total protein (mg)
a 
   Purity (%)
b
    Yield (%)
c
 
Total cell lysate  510     0   100 
Solubilised IBs  40     80              65   
Affinity chromatography 32    95   52 
Total cell lysate represents 50 ml of bioreactor sample of 4 hours post induction. 
a
The protein estimation was carried out using BCA method. 
b
The purity of protein was analysed by silver stained SDS-PAGE analysis. 
c
The amount of rDen 3 EDIII protein in the total cell lysate was ~61.5 mg as determined by 
densitometric analysis and specified as 100%. 
 
 
Figure 7.4. (a) Silver stained SDS-PAGE.  The protein band at approximate molecular 
weight of ~12.0 kDa confirmed the predicted size of the  rDen 3 EDIII protein. The protein 
profiles of the eluted protein, solubilized IBs and the crude cell lysate in silver stained gel 
were analyzed densitometrically which showed that more than 95% purity has been 
achieved. Lane 1, Molecular Weight Marker (kDa); lane 2, Total cell lysate; lane 3, 
Solubilized IBs; lane 4, Purified rDen 3 EDIII protein. (b) Western blot analysis showing the 
reactivity of serum sample with purified rDen 3 EDIII protein. Lane 1, Molecular weight 
marker; lane 2, rDen 3 EDIII protein with anti-dengue IgG positive serum samples. (c) 
Results of Dipstick ELISA with rDen 3 EDIII protein. Lane 1, Positive control; lane 2, IgM 
positive; lane 3, IgG positive; lane 4, Negative control; lane 5, Both (IgM and IgG) negative 
serum sample.          
 The ﬁnal product concentration of rDen 3 EDIII protein following affinity 
chromatography was signiﬁcantly higher for fed-batch cultivation as compared to batch 
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cultivation (Table 7.2). Improvement in product yield about more than eleven times for fed-
batch  cultivation  as compared to shake flask culture resulted using SB medium (Table 7.1 
and 7.2). The final rDen 3 EDIII protein yield after fed-batch cultivation was ~649.24 mg/l 
(Table 7.2).  
 The purified protein was subjected to Western blot assay, to confirm its identity as 
rDen 3 EDIII protein. The affinity purified rDen 3 EDIII protein was tested with dengue 
positive serum sample. The results revealed that the dengue positive human serum sample 
reacted with rDen 3 EDIII protein (Figure 7.4b). It is evident that the rDen 3 EDIII protein 
reacted with anti-dengue virus antibody and thus suggests that this protein could be used for 
the purpose of diagnosis of dengue virus infection. 
7.3.5 Evaluation of rDen 3 EDIII protein by in-house ELISA  
 Evaluation of the utility of this protein as a diagnostic tool for the detection of both 
anti-dengue virus IgM and IgG antibodies using patient serum samples was carried out by in-
house developed dipstick as well as microwell plate ELISA. In the present study, a panel of 
90 human serum samples from patients with suspected dengue infections was included. 
OD450 values for all serum samples determined by Pan-Bio IgM and IgG capture ELISA are 
shown in table 7.4.  
Table 7.4. Range of OD450 values in the IgM and IgG capture ELISA for human serum, 
used to evaluate in-house ELISA. 
Capture ELISA OD range
a
    No. of serum samples
b
  No. of serum samples
c
 
0.000–0.099    26    14 
0.100–0.199    12    21 
0.200–0.399   10    12 
0.400–0.599   22    17 
0.600–0.999   14    16 
  ≥1.00    6    10 
   Total   90    90 
a 
ELISA OD450 values of ≥ 0.20 were considered positive at a serum dilution of 1:100 for 
IgM antibodies and of 1:1000 for IgG antibodies. 
b 
No of serum samples in IgM capture ELISA. 
c 
No of serum samples in IgG capture ELISA.  
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OD490 values for all serum samples determined by in-house microwell plate ELISA 
are shown in table 7.5. Table 7.6 shows the comparative results of detection of anti-dengue 
virus IgM antibodies. Among 90 samples, 49 samples were positive and 41 samples were 
negative by in-house ELISA using rDen 3 EDIII protein. Out of 90 samples 52 samples were 
positive and 38 samples were negative by Pan-Bio IgM capture assay and 50 samples were 
positive and 40 samples were negative by Pan-Bio rapid IC test.  
Table 7.5. Range of OD490 values in the in-house indirect IgM and IgG microwell plate 
ELISA for human serum samples. 
        ELISA OD range
a
  No. of serum samples
b
  No. of serum samples
c
 
0.000–0.149    29    25 
0.150–0.249    12    11 
0.250–0.499   7    3 
0.500–0.799   23    13 
0.800–0.999   10    24 
  ≥1.00    9    14 
   Total   90    90 
a 
ELISA OD490 values of ≥ 0.25 were considered positive at a serum dilution of 1:100 for 
IgM antibodies and of 1:1000 for IgG antibodies. 
b 
No of serum samples in IgM ELISA; 
c 
No of serum samples in IgG ELISA.  
Table 7.7 also shows the comparative results of detection of anti-dengue IgG 
antibodies. Among 90 samples, 54 samples were positive and 36 samples were negative by 
in-house ELISA using rDen 3 EDIII protein. Out of 90 samples 55 samples were positive and 
35 samples were negative by Pan-Bio IgG capture assay and 52 samples were positive and 38 
samples were negative by Pan-Bio rapid IC test.  
Table 7.6. Comparative evaluation of in-house ELISA with reference to rapid IC test 
and IgM capture ELISA for detection of dengue IgM antibodies. 
Test             n     % Agreement
a    
% Sensitivity
b
      % Specificity
c
 
Dipstick ELISA/ IC Test          90      98% (89/90)     98% (49/50)         100% (40/40)         
Dipstick ELISA/ Capture ELISA    90     96% (87/90)      94% (49/52)         100% (38/38)  
n, total number of sera tested. 
a 
(Number of samples positive by both method + number of samples negative by both 
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methods) /(total number samples) x100. 
b 
True positive/(true positive + false negative) x 100. 
c 
True negative /(true negative + false positive) x 100. 
Comparison of the in-house dipstick and microwell plate ELISA using rDen 3 EDIII 
protein with Pan-Bio rapid IC test, Pan-Bio IgM and IgG capture ELISA for detection of IgM 
and IgG antibodies to dengue revealed comparable sensitivities, specificities and overall 
agreements (Table 7.6 and 7.7). The cut-off value (OD490) for in-house microwell plate 
ELISA was 0.25 for anti-dengue IgM and IgG antibodies detection. The cut-off value for 
Pan-Bio capture ELISA was determined by taking average of OD450 values of cut-off 
calibrator in triplicate as per manufacturer‘s protocol.  
Table 7.7. Comparative evaluation of in-house ELISA with reference to rapid IC test 
and IgG capture ELISA for detection of dengue IgG antibodies. 
Test              n       % Agreement
a     
% Sensitivity
b
    % Specificity
c
 
Dipstick ELISA/ IC Test          90        97% (88/90)  100% (52/52)      94% (36/38) 
Dipstick ELISA/ Capture ELISA    90        98% (89/90)  98% (54/55)      100% (35/35) 
The routine laboratory diagnosis of dengue virus infection is primarily carried out by 
detection of anti-dengue antibody by serological methods. A number of serological tests 
namely -capture ELISA, dot ELISA and imunochromatography based assays were 
evaluated and used successfully by various investigators (Porter et al., 1999; Wu et al., 2000; 
Abhyankar et al., 2006; Blacksell et al., 2008, 2008). IgM antibody detection is a crucial and 
reliable assay for samples collected from 5
th
 day of onset of symptoms (Lindegren et al., 
2005). The extensive evaluation revealed disparities among various commercial kits with 
respect to their sensitivity and specificity (Lindegren et al., 2005). However, the Pan-Bio 
IgM capture ELISA is the most reliable and widely used owing to its high sensitivity and 
specificity. Though a large number of rapid diagnostic tests (RDTs) are available in the 
market, however, their diagnostic accuracy falls well below the manufacturer‘s claim 
(Blacksell et al., 2006). Therefore, there was a genuine need for a promising test system for 
detection of dengue infection. In the present study an in-house ELISA was designed for use 
in the laboratory as well as in the field. The rDen 3 EDIII protein obviates expensive and 
time consuming cultivation of virus (for antigen preparation) and the associated biohazard 
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risk. The reaction pattern of in-house developed dipstick ELISA using rDen 3 EDIII protein 
with positive and negative serum samples is shown in figure 7.5c. In comparison with other 
assays used in this study, the in-house ELISA showed more than 95% accordance. The IC 
test using a mixture of recombinant envelope protein of dengue virus 1 to 4 has been 
developed and reported to be sensitive but less specific (AnandaRao et al., 2006). The rDen 3 
EDIII protein could react with sera against all the four serotypes because there lies a common 
antigenic epitope for the four serotypes (Innis et al., 1989; Gubler, 1998; AnandaRao et al., 
2006; Tan and Ng, 2010). Dengue 2 NS1-P1 peptide, corresponding to amino acid (aa) 
residues 1 to 15 of dengue-2 NS1, a linear, immunodominant IgM-specific epitope which 
was reactive towards patient sera from all four dengue serotypes has been reported (Huang et 
al., 1999). The amino acid sequences of domain III protein of all four dengue virus serotypes 
were aligned and analyzed which revealed that the amino acid similarity for DIII protein of 
dengue virus type 3 with that of dengue virus type 1, type 2 and 4 is 87.9%, 79.8% and 
69.7% respectively (Tan and Ng, 2010). Evaluation of rDen 3 EDIII protein with hyper 
immune sera against all the serotypes of dengue viruses showed positive reaction and thereby 
confirming its sensitivity for the diagnosis of dengue infection. Further this protein did not 
react with a panel of defined sera samples from 20 apparently healthy individuals. The amino 
acid sequence alignment of the domain III protein across the Flaviviridae family was 
performed which revealed that there are significant differences in the homology of the 
domain III amino acid sequences across flaviviruses (Chu et al., 2004). Earlier studies 
suggested the utility of domain III protein from dengue virus type 1-4 or JE virus as antigens 
for specific serological diagnosis of infections with those flaviviruses (Fonseca et al., 1991; 
Simmons et al., 1998). Further, West Nile virus recombinant domain III was found to be 
sensitive and very specific for West Nile virus infection and could also differentiate between 
closely related mosquito-borne flaviviruses. The recombinant domain III protein of West 
Nile virus was also found to be superior to whole virus antigens in discriminating specific 
antibody responses to West Nile virus (Beasly et al., 2004).  
The domain III of the envelope protein is particularly an important antigen for 
vaccine development as well as its use as a reagent for diagnostic purposes, as it contains 
multiple serotype specific conformation dependent neutralizing epitopes and host cell 
receptor recognition site. The antibodies raised against domain III may block the entry of 
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virus in to the cell. Choosing only domain III as a vaccine candidate instead of whole 
envelope protein has the advantage of reducing the menace of ADE because of the absence 
of other epitopes which elicit non-neutralizing, cross-reactive antibodies (Guzman et al., 
2010; Tan and Ng, 2010). Increase in the production of rDen 3 EDIII protein for application 
in diagnostic use as well as for further vaccine studies was necessary. Optimization of 
cultivation medium and cultivation conditions as described in this report, made its 
application more feasible. Further, the use of rDen 3 EDIII protein as an antigen in ELISA 
resulted in excellent agreement with the findings of commercial rapid IC test and capture 
ELISA. These results show that the product has a promising potential for its use in diagnosis 
of dengue with comparable sensitivity and specificity.  
7.4 CONCLUSIONS  
 An efficient cultivation process has been demonstrated to produce large amount of 
biologically active rDen 3 EDIII protein.  From the economic point of view, it is necessary to 
increase the yield of protein of interest. Recombinant E. coli is the most widely used 
organism for recombinant protein production because of its rapid growth to high-cell 
densities on inexpensive substrates and its well-characterized genetics and proteomics. 
Production of recombinant dengue virus type 3 envelope domain III protein was influenced 
by the media composition. For cost-effective reasons, it is important to maximize protein 
production by development of efficient cultivation process and appropriate purification 
methods. In this study, the fed-batch process yielded ~649 mg of purified rDen 3EDIII 
protein per liter of culture. These result exhibit the ability to produce high yield of dengue 
virus protein. The biologically functional rDen 3 EDIII protein thus produced has a potential 
application for detection of anti-dengue IgM and IgG antibodies as well as further studies in 
vaccine development for dengue virus infection. By using this strategy, other recombinant 
proteins can be produced at large scale with high yield and purity. 
 
*** 
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CHAPTER 8 
DEVELOPMENT OF A PILOT SCALE PRODUCTION 
PROCESS FOR RECOMBINANT DENGUE VIRUS TYPE 3 
EDIII PROTEIN AND CHARACTERIZATION FOR ITS 
VACCINE POTENTIAL 
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ABSTRACT 
 Dengue virus infection poses a serious global public health threat for which there is 
currently no therapy or a licensed vaccine. Envelope domain III protein of dengue virus is 
immunogenic and induced protective antibodies. In order to take this vaccine candidate for 
further studies, we developed a scalable process to produce and purify biologically active 
recombinant dengue virus type 3 envelope domain III (rDen 3 EDIII) protein. This protein 
was produced in E. coli by batch process using a 100 liter fermentor. The cells were 
harvested using tangential flow microfiltration followed by centrifugation. The cells were 
disrupted by bead milling and inclusion bodies were solubilized in urea. The rDen 3 EDIII 
protein was refolded and subsequently purified using immobilized metal affinity 
chromatography. The purity of protein was further improved by salt and pH based ion 
exchange chromatography. The purified protein was characterized for its purity by SDS-
PAGE and for reactivity by western blot analysis. The final yield of pilot scale produced 
protein after on-column refolding and affinity purification resulted in approximately 29 mg 
per g dry cell weight. Biological function of the refolded and puriﬁed protein was conﬁrmed 
by their ability to generate rDen 3 EDIII speciﬁc antibodies in mice that could neutralize the 
virus. The results presented here exhibit the ability to generate multi-gram quantities of rDen 
3 EDIII protein from E. coli that may be used for the development of dengue vaccines. 
8.1 INTRODUCTION  
 Dengue is the most important mosquito-borne flavivirus disease. People living in the 
tropical and subtropical areas are at risk of dengue virus infection, and more than 50 million 
dengue infected cases occur worldwide each year (Halstead et al., 2007; Guzman et al., 
2010). Vaccine inoculation is a cost-effective way of combating the threat of infectious 
diseases. In the past six decades, tremendous effort has been made to develop a dengue 
vaccine (Whitehead et al., 2007; Coller and Clements, 2011; Schmitz et al., 2011). However, 
despite these efforts, no licensed dengue vaccines are currently available. Many advanced 
biological technologies have been applied to dengue vaccine development, and numbers of 
vaccine approaches are currently in pre-clinical or clinical development. These approaches 
include chimerization with other flaviviruses or the deletion of portions of the genomes to 
obtain live attenuated dengue vaccines, viral vector vaccines, DNA vaccines, and 
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recombinant subunit vaccines (Whitehead et al., 2007; Coller and Clements, 2011; Schmitz 
et al., 2011; Chiang et al., 2012). All of the approaches are associated with different 
advantages and disadvantages. Among these approaches, the recombinant subunit vaccine 
provides the greatest degree of safety. The envelope protein comprises 3 regions: Domain I, 
Domain II and Domain III. Experimental evidences have shown that the EDIII protein is a 
receptor binding domain (Guzman et al., 2010; Block et al., 2010; Coller et al., 2011; 
Simmons et al., 2012). In addition, it has also been demonstrated to be highly immunogenic 
and able to elicit the production of neutralizing antibodies against the wild-type virus (Tan et 
al., 2010; Chiang et al., 2012). One major challenge to dengue virus vaccine development is 
the potential development of antibody-dependent enhancement (ADE) of virus replication, 
which is believed to cause DHF and DSS (Simmons et al., 2012). In addition, immunization 
against one dengue serotype induces life-long immunity against the homologous serotype 
and short-lived immunity against the other serotypes. Put together, it is widely believed that 
for a dengue virus vaccine to be effective, it must comprise neutralizing epitopes from all 
four serotypes (tetravalent) (Tan and Ng, 2010). For this reason, the DIII protein is believed 
to be a potential candidate as a protein subunit vaccine. Currently, there is a need for the 
production of cost effective and safe recombinant EDIII protein for the development of 
protein subunit vaccines. For these purposes, the recombinant proteins produced must 
maintain their biological activity (i.e., generate neutralizing antibodies against wild-type 
virus or able to bind to anti-dengue antibodies found in patient serum).   
The EDIII proteins may be expressed using various hosts, such as bacteria, yeast and 
even in the leaves of tobacco plants (Etemad et al., 2008; Guzman et al., 2010). E. coli is by 
far the most commonly used host for the production of EDIII proteins. Small scale 
expression is widely used for optimizing conditions for a large-scale production of 
recombinant proteins. The up-scaling process of rEDIII protein production may be performed 
by replacing commonly used shake flasks (Batra et al., 2010; Tan et al., 2011; Chiang et al., 
2012) to fed-batch or batch fermentation  in a fermentor. To facilitate the purification of 
EDIII proteins, the proteins are commonly produced as fusion proteins that comprise of the 
DIII protein fused with an affinity tag, such as the hexahistidine tag. After the preliminary 
purification using affinity chromatography, the purity level of these EDIII proteins can be 
further enhanced by ion exchange or size exclusion chromatography (Tan and Ng, 2010). We 
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described small scale production of envelope domain III protein of dengue virus type 3 from 
E. coli for diagnostic use. Using  this  work  as  a  starting  point,  we  detail  here  a scalable  
process  for  the  production, refolding  and  purification  of rDen 3 EDIII protein for vaccine 
studies. Further,
 
we present data demonstrating that the antibodies raised in mice against 
refolded and purified protein neutralize the dengue virus type 3. The rDen 3 EDIII protein 
was highly pure and found to be biologically active. This material would be an excellent 
starting material for the development of new dengue vaccines.  
8.2 MATERIALS AND METHODS 
 The details about materials and methods used for pilot scale fermentation, on-column 
refolding, ion exchange chromatography, immunogenicity studies and plaque reduction 
neutralization test are described in the material and methods section  (Chapter 3). Figure 5.1 
provides an overall ﬂow diagram for the production of rDen 3 EDIII antigen similar to 
process of rJEV EDIII protein. 
8.3 RESULTS AND DISCUSSION 
 Developing a dengue vaccine has been a challenging task because of the need to 
provide solid and long-lasting immunity to four serotypes without causing the potentially 
fatal ADE leading to DHF/DSS. Since conventional approaches based on live attenuated 
dengue viruses have not resulted in a licensed vaccine, increasing attention is being focused 
on recombinant strategies (Coller and Clements, 2011; Chiang et al., 2012). These 
approaches, which are geared towards developing monovalent vaccines targeting single 
dengue serotype, envisage the creation of a tetravalent vaccine by physically mixing the four 
monovalent components into a single formulation. To conduct vaccine studies with rDen 3 
EDIII antigen, sufficient quantities of purified protein material was required. We previously 
transformed E. coli BLR (DE3) cells using the plasmid (pET 30a+rDen 3 EDIII) construct 
used to produce small quantities of the protein at lab-scale and using this clone developed a 
pilot scale process to produce biologically active rDen 3 EDIII protein  in  good  quantities  
with  sufficient  purity  for  use  in  vaccine studies. 
8.3.1 Pilot Scale Production of Recombinant Dengue Virus type 3 EDIII Protein 
 Although lab scale production of  rDen 3 EDIII protein yielded significant protein 
levels, the potential requirement for this protein in larger quantity led to its production in 
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pilot scale fermentor. Since the primary goal of large scale fermentation research is cost-
effective production of recombinant products, it is important to develop a pilot scale 
fermentation method that allows the maximization of the yields of the desired product (Ravi 
et al., 2008; Bell et al., 2009). Production of important foreign proteins in E.  coli  expression  
system  has  been  highly  successful  in recent past as this system offers several advantages 
over the other expression systems, including its fast growth rate, utilization of cheap growth 
media, high level of expression of  foreign  proteins (Sahdev et al., 2008; Huang et al., 2012).  
The pilot scale batch fermentation process for production of rDen 3 EDIII protein was 
carried out using 100 liter working volume fermentor with 80 liter modified SB medium. 
This fermentation process continued for nine and half hour which comprised the pre-
induction (five and half hour) and post induction (four hour) phase. At the beginning of the 
fermentation DO was above 30% and decreased during course of process. The DCW and 
OD600 increased continuously and reached a final value of 6.82 g/l (Table 8.1) and 21.15 
respectively. The DCW at induction was 3.12 g/l.  
Table 8.1. Production characteristics of rDen 3 EDIII protein for vaccine studies. 
   Media           Culture Condition       Dry cell weight (g/l)        Protein
c
 (mg/l) 
Modified SB medium  Shake flask   2.48    63.64  
Modified SB medium  Batch fermentation
a
  6.74   185.24 
Modified SB medium  Batch fermentation
b
  6.82   201.36 
a
At 5.0 liter scale; 
b
At 100 liter scale; 
c
After on-column refolding with IMAC 
The real time profile of pilot scale batch fermentation is shown in figure 8.1. Before 
pilot scale fermentation, laboratory scale (5.0 liter working volume) batch process was also 
carried out using same medium to ensure success of scale up process. 
The DCW at induction and harvest after batch fermentation using 5 liter fermentor 
was 3.08 g/l and 6.74 g/l (Table 8.1) respectively. The real time profile of laboratory scale 
batch fermentation is shown in figure 8.2. 
The critical factor for the development of any vaccine is the ability to produce the 
vaccine with a process that is amenable to scale-up, is reproducible and produces a 
reasonable number of doses of the vaccine. Process development is the technological 
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foundation that underlies the manufacture of new vaccines and is central to successful 
commercialization (Buckland, 2005). Based on the earlier studies on rDen 3 EDIII protein, 
 
Figure 8.1. Real-time  proﬁle  of  pilot scale batch fermentation for the expression of rDen 3 
EDIII protein. Culture was grown in batch mode in modified SB media and induced with 1 
mM IPTG at DCW of 3.12 g/l. Figure shows time proﬁle for agitation (rpm), DO 
concentration (%), air ﬂow rate (liter per min), temperature (oC), pH and OD600. 
 
Figure 8.2. Real-time  proﬁle  of  laboratory scale batch fermentation for the expression of 
rDen 3 EDIII protein. Figure shows time proﬁle for agitation (rpm), DO concentration (%), 
air ﬂow rate (liter per min), temperature (oC), pH and OD600. 
we envisaged to produce this vaccine candidate on large scale using pilot scale fermentor. 
Pilot scale fermentation was carried out using modified SB medium. Modified SB medium 
comprised higher concentration of glycerol compared to other media. Glycerol is one of the 
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commonly used carbon source. By using glycerol, high dry cell weight and cell densities may 
be achieved with less frothing (Khamduang et al., 2009). To the best of our knowledge, this 
is the first report of producing rDen 3 EDIII protein in a 100 liter fermentor. The successful 
scalable production of this protein in fermentor with a high yield was initiated to foster 
further applications and research with dengue vaccines.  
8.3.2 Refolding and Purification of rDen 3 EDIII Protein 
We  developed  puriﬁcation  process  for  this protein to obtain  a high quality  protein  
suitable  for dengue vaccine studies.  Puriﬁcation of rDen 3 EDIII protein was performed  
from  the cell  pellets  obtained  from  pilot scale fermentations. The immobilized  metal 
afﬁnity  chromatography with simultaneous refolding  and  cation exchange chromatography 
based on salt followed  by  pH   was  used  to  obtain highly  pure  rDen 3 EDIII protein. The 
real time profile (Time vs OD280) of on-column refolding with affinity purification is shown 
in figure 8.3. The ﬁnal product concentration of rDen 3 EDIII protein following IMAC was 
signiﬁcantly higher for pilot scale batch fermentation as compared  to shake flask culture. 
Improvement  in DCW (2.5-fold higher) and product yield (3-fold higher) resulted  for batch  
fermentation  as  compared to shake flask culture (Table 8.1).  
 
 
 
 
 
 
 
 
Figure 8.3. Chromatogram showing simultaneous refolding and affinity chromatography for 
rDen 3 EDIII protein. 
However, there was a drop in the yield of rDen 3 EDIII protein following cation 
exchange chromatography using salt and pH with diafiltration.  This observation also 
indicates that the  higher  yield  of  rDen 3 EDIII protein at affinity purification with 
      Load       Wash and urea removal    Elution       
Time (min.) 
151 
 
simultaneous refolding stage  may  not necessarily  lead  to  higher  yield  of  puriﬁed  rDen 3 
EDIII protein following   subsequent   puriﬁcation   step   as  affinity chromatography   will 
purify  all  conformers  of  rDen 3 EDIII protein produced  in  E.  coli  through  histidine  tag.  
Processing  of  biomass  from   pilot scale batch  fermentation  yielded  35 mg (Table 8.2) of  
highly  pure, refolded rDen 3 EDIII protein per liter culture. Though this yield is reasonable 
to proceed for production of cGMP grade rDen 3 EDIII protein for use  in  human  dengue 
vaccine studies,  efforts  are  being  made  to further improve the ﬁnal yield.  
Table 8.2. Puriﬁcation of rDen 3 EDIII protein from batch fermentation at 100 liter 
scale. 
Purification steps                     rDen 3 EDIII protein (mg/l)
     
% Purity    % Yield       
Refolding and affinity chromatography   201.36      90%           100%     
Cation exchange chromatography salt based   65.44     95%           32.5%                                     
Cation exchange chromatography pH based  35.69     98%           17.7%                 
8.3.3 Characterization of rDen 3 EDIII Protein 
 Puriﬁed rDen 3 EDIII protein produced by batch fermentation at 100 liter scale was 
characterized for its purity and reactivity using SDS-PAGE and Western blot analysis. SDS-
PAGE analysis of rDen 3 EDIII protein showed single band corresponding to ~12 kDa 
(Figure 8.4a, 8.4b).  
 
Figure 8.4. (a) Coomassie blue stained SDS-PAGE. The protein band at approximate 
molecular weight of ~12.0 kDa confirmed the predicted size of the recombinant dengue virus 
type 3 EDIII protein. Lane M, Molecular Weight Marker (kDa); lane 1, on-column refolded 
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and IMAC purified rDen 3 EDIII protein; lane 2, Solubilized IBs.(b) Salt and pH based IEX 
puriﬁed rDen 3 EDIII protein. Lane 3, pH based IEX purified protein; lane 4, Salt based IEX 
purified rDen 3 EDIII protein.(c) Western blot analysis of rDen 3 EDIII protein with 
polyclonal sera raised against rDen 3 EDIII protein in mice. Lane M, Molecular weight 
marker; lane 5, Purified rDen 3 EDIII protein with hyper immune sera. 
 The puriﬁed rDen 3 EDIII protein was recognized by anti-dengue antibodies on  
Western  blot showing  its reactivity (Figure 8.4c). The characterization of rDen 3 EDIII 
protein by SDS-PAGE and Western blot confirms that rJEV EDIII protein is highly pure and 
reactive. It is evident from the results that the rJEV EDIII protein specifically reacted with 
anti-dengue virus antibody and thus suggests that this protein could also be used for the 
purpose of diagnosis of dengue virus infection. 
8.3.4 Humoral Response in Mice Immunized with rDen 3 EDIII Protein 
 No dengue vaccine is currently licensed for human use. To investigate whether the 
produced recombinant dengue protein could induce an antibody response specific for the 
rDen 3 EDIII protein, a group of mice was immunized with refolded and purified protein 
formulated with adjuvant.  ELISA determined domain III antigen-specific antibody responses 
after two week of last inoculation. Sera collected from mice were serially diluted and tested 
for recognition of  rDen 3 EDIII  by ELISA.  
  
Figure 8.5. Endpoint titers for recognition of rDen 3 EDIII protein. Sera from mice collected 
at days 56 were tested for recognition of recombinant Den 3 EDIII at various dilutions by 
ELISA. 
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 The EDIII antigen specific antibody titer was found to be more than 5,12,000 (Figure 
8.5). The results showed that rDen 3 EDIII expressed  in E. coli  is able to elicit EDIII-
specific antibody responses. Absorbance of healthy mice sera in 1:2000 dilution was 0.840. 
Figure 8.5 shows absorbance values and the titer of envelope domain III specific protein at 
490 nm in immunized mice sera. Formulation of rDen 3 EDIII protein with FCA was highly 
immunogenic and yielded good ELISA titers. For small molecule or poorly immunogenic, 
adjuvants can be used for induce an effective immune response or humoral response (Cox 
and Coulter, 1997). FCA is an important adjuvant for investigators and is regarded 
scientifically as an effective means of potentiating immune responses in laboratory animals. 
Our initial evaluations indicated that the rDen 3 EDIII protein in combination with adjuvant 
elicited humoral immune response in mice. 
8.3.5 Plaque Reduction Neutralization Test 
 The neutralization effect of polyclonal antibodies raised against recombinant Den 3 
EDIII protein on the dengue virus type 3 was evaluated by plaque reduction neutralization 
test in LLC-MK2 cells. Two-fold serum dilutions were tested starting at 1:2 against 100 p.f.u. 
of dengue virus type 3. A PRNT value of dengue virus type 3 by anti-rDen 3 EDIII 
antibodies was observed up to a dilution of 1:64 (Figure 8.6). PRNT90 titers of the rDen 3 
EDIII anti-serum were approximately 1:16 for FCA group sera. High neutralization effect 
remained up to a dilution of 1:32 (Figure 8.6).  
 
Figure 8.6. Neutralizing ability of sera generated against rDen 3 EDIII protein in mice. High 
neutralizing antibody titers remained till 1:32 dilution. 
Inhibition of dengue  
virus type 3 (%) 
Sera dilution 
154 
 
The humoral response was characterized by high neutralizing titers by plaque 
reduction neutralization assay. Neutralizing antibodies can bind to virus and prevent virus 
from binding to host cell receptors. The polyclonal antibodies raised in BALB/c mice using 
rDen 3 EDIII protein were found to be neutralizing dengue virus type 3 entry in to LLC-MK2 
cells. This implies that the refolding of protein could correctly present the conformational 
epitopes on the surface of the rDen 3 EDIII protein.  The PRNT50 titers  1:10 are considered 
indicative of protective immunity (Delenda et al., 1994). Our data clearly demonstrate the 
potential of the rDen 3 EDIII protein to elicit neutralizing, and therefore, presumably 
protective antibodies against dengue virus type 3.  
The results from the present study showed that the purified recombinant dengue virus 
type 3 EDIII protein could protect host cells from dengue virus type 3 infection. It is likely 
that the recombinant protein was correctly refolded without loss of its biological function. 
This result is consistent with the findings of other studies (Zhang et al., 2007) in which 
dengue virus type 2 envelope domain III protein was expressed in E. coli and purified by 
chromatography. Hence, an ideal subunit vaccine using envelope protein needs to be 
correctly folded and should be well characterized. This is the first report on the use of a pilot 
scale produced, refolded and purified as well as fully characterized domain III protein which 
has been used for the immunomodulatory studies in combination with adjuvant and detailed 
evaluation of humoral immune response. 
In our earlier studies, we described laboratory scale production and affinity 
chromatography purification under denaturing conditions of rDen 3 EDIII protein for use as 
diagnostic reagent. The domain III of the envelope protein is particularly an important 
antigen for vaccine development. Increase in the production to achieve large biomass as well 
as refolding with further purification to achieve high purity of rDen 3 EDIII protein for 
application in dengue vaccine studies was necessary. Development of pilot scale 
fermentation strategy as well as three steps purification with simultaneous refolding as 
described in this report, made its application more feasible. Further, the rDen 3 EDIII protein 
was reactive with mice sera in ELISA. These results suggest that the product may be used for 
development of human dengue vaccine studies.  
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8.4 CONCLUSIONS 
 We have developed a 100 liter pilot scale fermentation  process for high yield 
production of recombinant dengue virus type 3 envelope domain III protein from E. coli. A 
simple,  three-step  puriﬁcation  strategies  involving  immobilized metal afﬁnity 
chromatography with simultaneous refolding,  salt  based cation  exchange  and  pH  based 
cation exchange chromatography, was used to produce rDen 3 EDIII protein that was highly 
pure, homogeneous and recognized by anti-dengue antibodies. Further, characterization for 
its immunogenicity and ability to induce neutralizing antibodies established its application 
more attractive. These ﬁndings suggest that rDen 3 EDIII protein in combination with 
compatible adjuvant is highly immunogenic and can elicit high titer neutralizing antibodies, 
which proves that refolded and purified rDen 3 EDIII protein can be a potential vaccine 
candidate. The method described here to produce rDen 3 EDIII protein may also be useful in 
producing other viral and bacterial  proteins in E. coli as insoluble form for production at 
pilot scale.  
 
*** 
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CHAPTER 9 
PROCESS DEVELOPMENT FOR PRODUCTION OF RECOMBINANT 
DENGUE VIRUS TYPE 1, 2 AND 4 EDIII PROTEIN AND 
EVALUATION OF DIAGNOSTIC POTENTIAL OF TETRAVALENT 
RECOMBINANT DENGUE VIRUS EDIII PROTEIN 
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ABSTRACT 
 Dengue hemorrhagic fever and dengue shock syndrome are the severe manifestations 
of dengue infection. A definitive identification of dengue infection depends on reliable 
dengue diagnostic tests. There is currently no vaccine to prevent dengue virus infection, 
which is caused by any one of four serotypes, dengue virus 1, 2, 3 and 4. A dengue vaccine 
must be tetravalent, because immunity to a single serotype does not offer cross-protection 
against the other serotypes. To develop diagnostic tests or prophylactic for all dengue virus 
serotypes, production of EDIII protein of all dengue viruses viz. dengue virus type 1-4 is 
necessary. In our previous studies we developed high yield scalable process to produce 
recombinant dengue virus type 3 envelope domain III protein for diagnostic and vaccine 
studies. In the present study recombinant envelope domain III protein of dengue virus type 1, 
2 and 4 was expressed in E. coli. Batch and fed-batch fermentation process was developed 
for dengue virus type 1, 2 and 4 EDIII protein using optimized medium. The proteins were 
purified by immobilized metal affinity chromatography under denaturing conditions. The 
physical mixture of envelope domain III proteins of all serotypes was recognized in ELISA 
with dengue infected human serum samples. These results suggest the EDIII based ELISAs 
may be useful in epidemiological surveillance and vaccine efficacy trials. This production 
system may also be suitable for the high yield production of other recombinant proteins 
expressed in E. coli.  
 9.1 INTRODUCTION 
 Dengue viruses, of which there are four antigenically distinct serotypes (dengue virus 
-1, -2, -3 and -4) are mosquito-borne viruses of the Flaviviridae family (Lindenbach and 
Rice, 2003).  Dengue virus infection threatens approximately half the global population, and 
is endemic to over a hundred countries in the tropical and sub-tropical regions of the world. 
Diagnosis of dengue virus infections, based on clinical presentation, is complicated by its 
similarity to that of a host of other infectious illnesses including measles, influenza, typhoid, 
leptospirosis, chikungunya and malaria (Cuzzubbo et al., 2001; AnandaRao et al., 2006). As 
a result, diagnostic tests are critical in detecting dengue virus infections. For the detection of 
dengue virus specific antibodies, most of the commercial tests use either a mixture of four 
inactivated dengue virus particles or four recombinant envelope (ectodomain) proteins 
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representing four serotypes. Invariably most of these tests fail to differentiate between the 
antibodies generated against various flaviviruses due to the existence of shared antigenic 
determinants among members of the Flaviviridae family such as Japanese encephalitis, tick-
borne encephalitis and yellow fever viruses (Batra et al., 2010).  
Domain III of envelope protein (EDIII) is considered to be a flavivirus species 
specific antigen and has been used as a diagnostic reagent or for vaccine studies (Simmons et 
al., 1998; Ludolf et al., 2002; Beasley et al., 2004; Hapugoda et al., 2007; Guzman et al., 
2010; Tan and Ng, 2010). To detect antibodies against all four serotypes of dengue virus, it is 
necessary to use EDIII from four dengue virus serotypes (Simmons et al., 1998). ELISA is a 
commonly used method for detection of anti dengue IgM and IgG antibodies in dengue 
infected patient serum samples (AnandaRao et al., 2006; Hapugoda et al.., 2007; Tan and Ng, 
2010). Escherichia coli is the most commonly used host for heterologous protein production 
(Sahdev et al., 2007; Huang et al., 2012). Using expression vectors in batch and fed-batch 
cultivations, recombinant proteins have been successfully expressed in E. coli. High-cell-
density culture (HCDC) techniques have been developed for use in E. coli in order to 
improve upon the production of recombinant proteins. In HCDC, maximum cell 
concentrations are most often achieved by using fed-batch processes and various feeding 
strategies (Shiloach and Fass, 2005). There is currently a need for developing cost-effective, 
safe and simple diagnostics with sensitivity and specificity as well as suitable vaccine 
candidate for dengue. In this study, we describe the high yield production and purification of 
rDen 1, 2 and 4 EDIII protein. Further,
 
we present data demonstrating its utility as a 
diagnostic reagent
 
by an in-house ELISA in detection of anti-dengue IgM and IgG antibodies 
in patient serum samples.  
9.2 MATERIALS AND METHODS 
 The materials used for this study are described in chapter 3. The methodologies used 
for this study are described in materials and methods section (chapter 3). 
9.3. RESULTS AND DISCUSSION 
9.3.1 Expression of Recombinant Dengue Virus 1, 2 and 4 EDIII Protein 
 Currently, there is no vaccine to prevent or a drug to treat dengue virus infection. 
Thus, the availability of reliable diagnostic tools assumes great importance in clinical 
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management, surveillance and outbreak investigations. In the present study we have 
produced and purified rDen 1, 2 and 4 EDIII antigens. The major aims of this study were to 
develop batch as well as fed-batch fermentation process and purification strategies to produce 
pure protein with high yield. Further evaluation of mixture of EDIII of all serotypes using 
indirect microwell plate ELISA for detection of both IgG and IgM classes of anti-dengue 
virus antibodies in human sera was also carried out. The rDen 1, 2 and 4 EDIII gene was 
previously cloned into pET30a+ and transformed into BLR (DE3) cells. The cells upon 
induction with IPTG expressed a recombinant protein with a desired molecular weight of 
~11.9 kDa rDen 1 EDIII, ~11.7 kDa rDen 2 EDIII and ~11.6 kDa rDen 4 EDIII proteins 
respectively (Figure 7.1). The appropriate medium for production of these proteins was 
analysed by using shake flask experiments. For this purpose, LB and modified SB media 
were tested. The cultures were induced with 1 mM IPTG for 4 h. Modified SB medium 
resulted more protein yield than LB medium. The final EDIII protein yield at shake flasks 
using modified SB medium was about 16, 116 and 54 mg per liter of culture for dengue virus 
type 1, 2 and 4 respectively. However in LB medium, the protein yield was about 11, 60 and 
25 mg/l for dengue virus type 1, 2 and 4 respectively.  
9.3.2 Production of rDen 1, 2 and 4 EDIII Protein 
 For E. coli or any other cultivation systems, the level of intracellular accumulation of 
a recombinant protein is dependent on the final cell density. Several recombinant proteins 
have been successfully produced in recombinant E. coli by fed-batch cultivation using 
various regimes of nutrient feeding resulting in different biomass and production yields. 
Since the primary goal of fermention research is cost-effective production of recombinant 
products, it is important to develop a cultivation method that allows the maximization of the 
yield of the desired product. Although shake-flask production of these recombinant dengue 
virus envelope domain III proteins was reasonable as mentioned above, the development of a 
fed-batch process for high yield production of rDen 1, 2 and 4 EDIII protein is required for 
further studies as a diagnostic reagent or prophylactic purpose. For maximizing the 
volumetric production, the E. coli cells expressing these proteins were grown in a batch and 
fed-batch cultivation process. Laboratory scale batch fermentation for rDen 2 EDIII protein 
using modified SB medium, the cultures at DCW 3.72 g/l were induced with 1 mM IPTG and 
grown for another 4 h. The batch was terminated at a DCW of 7.10 g/l. Further fed-batch 
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process for rDen 2 EDIII protein production resulted about 21.80 g/l of final DCW at the 
time of harvest. The real time profile of fed-batch fermentation process for production of 
rDen 2 EDIII protein is shown in figure 9.1. For rDen 1 EDIII protein production in modified 
SB medium using batch and fed-batch process the DCW at harvest was about 5 and 16 g/l 
respectively. In case of rDen 4 EDIII protein using terrific broth medium, the final DCW was 
4.56 and 17.34 g/l after batch and fed-batch fermentation respectively. 
 
Figure 9.1. Real time profile of fed-batch fermentation process for production of rDen 2 
EDIII protein. 
Pilot scale fermentation was also carried out to ensure proper scale up from 
laboratory scale (5.0 liter) to pilot scale (100 liter). Large amount of biomass for purification 
of rDen 2 EDIII protein used in vaccine studies was necessary. Before going for the pilot 
scale fermentation, the fermentation conditions and culture medium must be optimized at the 
small scale using shake flask culture and 5 liter fermentor. Under the optimized conditions, 
production of rJEV EDIII protein was carried out using 100 liter working volume fermentor 
with 80 liter modified SB medium. The dry cell weight achieved after batch and fed-batch 
fermentations for production of these proteins are given in table 9.1. This pilot scale 
fermentation process for rDen 2 EDIII protein production continued for nine and half hour 
which comprised of the pre-induction (five and half hour) and post induction (four hour) 
phase. The DCW reached a final value of 7.04 g/l after pilot scale batch process. The DCW 
at induction was 3.74 g/l. The successful production of these proteins in fermentor with a 
high yield was initiated to foster further applications and research with dengue vaccines. The 
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real time profile of a pilot scale batch fermentation process for rDen 2 EDIII protein 
production is shown in figure 9.2.  
Table 9.1. Production characteristics of E. coli expressing rDen 1, 2 and 4 EDIII 
protein. 
Media type         Cultivation mode        Dry cell weight (g/l)      Protein yield (mg/l)   
Modified SB 
*
Batch fermentation
a   
5.16   62   
Modified SB 
*
Fed-batch fermentation
b
  16.30   161  
Modified SB  
#
Batch fermentation
a
   7.10   331  
Modified SB 
#
Batch fermentation
c
   7.04   287  
Modified SB 
#
Fed-batch fermentation
b
  21.80   1040  
Terrific Broth 
$
Batch fermentation
a 
  4.56   66  
Terrific Broth 
#
Fed-batch fermentation
b
  17.34   196  
a
At 5.0 liter scale; 
b
At 10 liter scale; 
c
At 100  liter scale; 
 *
for rDen 1 EDIII protein 
#
for rDen 2 EDIII protein; 
$
for rDen 4 EDIII protein. 
 
Figure 9.2. Real time profile of pilot scale batch fermentation process for production of rDen 
2 EDIII protein. 
9.3.3 Purification and Characterization of rDen 1, 2 and 4 EDIII Protein  
 As the rDen 1, 2 and 4 EDIII protein was insoluble, immobilized metal affinity 
chromatography was used to purify the protein. After cell disruption and centrifugation, 
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analysis of the lysate confirmed the presence of these proteins in SDS-PAGE with ~12 kDa 
protein band (Figure 7.1a). Inclusion bodies were harvested and purified from the induced 
and lysed cell mass. The inclusion bodies were solubilized in 8M urea containing buffers and 
purified by affinity chromatography column under denaturing conditions. The real time 
profile (Time vs OD280) of affinity purification for rDen 2 EDIII protein is shown in figure 
9.3. The pilot scale produced biomass was purified using quick scale (70/55) column 
containing 500 ml Ni-charged streamline chelating AC resin. However lab scale purification 
were carried out using pre-packed Ni-sepharose columns. The final yield of  rDen 1, 2 and 4 
EDIII protein after affinity chromatography is given in table 9.1. 
 
Figure 9.3. Chromatogram showing purification of rDen 2 EDIII protein using IMAC. 
 The SDS-PAGE analysis of purified rDen 1, 2 and 4 EDIII proteins is shown in figure 
9.4. These proteins migrates with molecular weight of ~11.9, ~11.7, ~12.0 and 11.6 kDa on 
denaturing SDS-PAGE gel for rDen 1, 2, 3 and 4 EDIII protein (Figure 9.4).  
 
 
 
 
 
 
Figure 9.4. SDS-PAGE analysis of affinity purified EDIII proteins. Lane M, MW marker 
(kDa); lane 1-4, rDen 1, 2,3 and 4 EDIII protein respectively. 
M         1           2         3          4 
Time (min) 
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 The coomassie stained and silver stained gel of pilot scale produced and purified 
rDen 2 EDIII protein is shown in figure 9.5. From the gel analysis it is evident that purified 
rDen 2 EDIII protein was highly pure. 
 
Figure 9.5. (a) Coomassie stained SDS-PAGE gel. (b) Silver stained SDS-PAGE gel. Lane 1 
and 6, MW marker (kDa); lane 2 and 7, un-induced lysate; lane 3 and 8, induced lysate; lane 
4 and 9, solubilized IBs; lane 5 and 10; AC purified rDen 2 EDIII protein. 
9.3.4 Tetravalent Recombinant Dengue Virus 1-4 EDIII Protein as a Diagnostic 
Reagent 
 The diagnostic potential of an antigen mixture comprising the EDIIIs of the four 
dengue virus serotypes for detection of anti-dengue IgM and IgG antibodies was evaluated. 
For this purpose indirect IgM and IgG microwell plate ELISAs were performed using well 
characterized 40 human serum samples. All the 40 samples were tested by Pan-Bio IgM and 
IgG capture ELISA. The OD450 values determined by Pan-Bio capture ELISAs and OD490 
values determined by in-house ELISA for detection of anti dengue IgM and IgG antibodies 
are given table 9.2 and 9.3. To detect IgM and IgG antibodies for any of the dengue virus 
serotype 1-4, mixture of EDIII proteins (0.4 µg/ 100 µl/ well) of all serotypes (0.1 µg EDIII 
protein of each serotype) was used as antigen in in-house microwell plate ELISA to develop 
diagnostic assay. In IgM ELISA, among 40 samples, 20 samples were positive and 20 
samples were negative by in-house ELISA. Out of 40 samples 25 samples were positive and 
15 samples were negative by Pan-Bio IgM capture assay. In IgG ELISA, among 40 samples, 
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20 samples were positive and 20 samples were negative by in-house ELISA. Out of 40 
samples 22 samples were positive and 18 samples were negative by Pan-Bio IgG capture 
assay.  
Table 9.2. Range of OD450 values in the IgM and IgG capture ELISA for human serum, 
used to evaluate in-house ELISA. 
Capture ELISA OD range
a
  No. of serum samples
b
  No. of serum samples
c
 
0.000–0.099    8    6 
0.100–0.199    7    12 
0.200–0.399   3    2 
0.400–0.599   6    5 
0.600–0.999   12    8 
  ≥1.00    4    7 
   Total   40    40 
a 
ELISA OD450 values of ≥ 0.20 were considered positive at a serum dilution of 1:100 for 
IgM antibodies and of 1:1000 for IgG antibodies. 
b 
No of serum samples in IgM capture ELISA; 
c 
No of serum samples in IgG capture ELISA.  
Table 9.3. Range of OD490 values in the in-house indirect IgM and IgG microwell plate 
ELISA for human serum samples. 
        ELISA OD range
a
  No. of serum samples
b
  No. of serum samples
c
 
0.000–0.149    11    8 
0.150–0.249    9    12 
0.250–0.499   5    3 
0.500–0.799   4    8 
0.800–0.999   8    3 
  ≥1.00    3    6 
   Total   40    40 
a 
ELISA OD490 values of ≥ 0.25 were considered positive at a serum dilution of 1:100 for 
IgM antibodies and of 1:1000 for IgG antibodies. 
b 
No of serum samples in IgM ELISA; 
c 
No of serum samples in IgG ELISA.  
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 The data reveal that, both the sensitivity and specificity of a physical mixture of 4 
monovalent EDIII antigens in detecting anti-dengue antibodies are comparable to those 
obtained using Pan-Bio capture ELISA (Table 9.4). Thus tetravalent EDIII protein could be 
specifically used as a valuable antigen for detection of anti dengue IgM and IgG antibodies in 
ELISA. 
Table 9.4. Comparative evaluation of in-house ELISA with reference toPan-Bio IgM 
and IgG capture ELISA for detection of anti dengue IgG and IgM antibodies. 
Test             n     % Agreement
a           
% Sensitivity
b
      % Specificity
c
 
In-house/ IgG capture ELISA         40       95% (38/40)       90% (20/22)         100% (18/18)        
In-house/ IgM capture ELISA        40       87% (35/40)       80% (20/25)         100% (15/15) 
n, total number of sera tested. 
a 
(Number of samples positive by both method + number of samples negative by both 
methods) /(total number samples) x100. 
b 
True positive/(true positive + false negative) x 100. 
c 
True negative /(true negative + false positive) x 100. 
9.4 DISCUSSION 
 The  immunodominant  epitopes  in  the  recombinant  dengue virus type 1-4 
envelope domain III proteins contribute to a high  degree  of  sensitivity  and  specificity  for  
diagnosis  of dengue  infections  and  to  induce  neutralizing antibodies. Hence, envelope 
domain III protein, an independently folding domain that plays an important role in host 
receptor interaction has become possible diagnostic and vaccine candidate.  In the present 
study, we were able to developed batch and fed-batch process successfully to overexpress 
envelope domain III protein of all the four serotypes. Further EDIII proteins were purified to 
homogeneity by affinity chromatography and the purified proteins were successfully tested 
for the diagnosis of dengue virus infections. Expression of  recombinant  envelope  protein  
in  different expression  systems viz. E. coli, Pichia pastoris, insect cells, transgenic plants  
was  demonstrated  recently (Etemad et al., 2008; Block et al., 2010; Tan and Ng., 2010; 
Chiang et al., 2012). Most of the investigations showed that the yields of recombinant 
envelope protein  have  been  very  low  and  also  difficulties  in  purification of the envelope 
protein, which  limits  its large scale production. Nonetheless, generation of recombinant 
dengue virus EDIII protein from infected tissue culture insect cells is a laborious and costly, 
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subjected to batch-to-batch variation making it difﬁcult for routine large-scale production. 
Production of recombinant EDIII protein in E. coli strains is a much cheaper and a simpler 
procedure (Jaiswal et al., 2004; Zhang et al., 2007; Tripathi et al., 2008; Tan et al., 2010; 
Tripathi et al., 2011). Several recombinant proteins have been successfully produced in E. 
coli by fed-batch cultivation using various regimes of nutrient feeding resulting in different 
biomass and production yields (Lee, 1996; Babu et al., 2000; Khalilzadeh et al., 2004; 
Sahdev et al., 2008; Huang et al., 2012). To enhance the yield, EDIII proteins of dengue virus 
was produced by batch and fed-batch cultivation processes. The final dry cell weight after 
fed-batch process for rDen 2 EDIII protein was 21.80 g/l using modified SB medium. The 
present study demonstrates the feasibility of obtaining pure protein utilizing a single step 
affinity chromatographic. More than 95% purity of proteins as determined by SDS-PAGE 
gels has been achieved following a single step purification strategy. The final protein yield of 
rDen 2 EDIII protein after fed-batch process was 1.04 g/l. The final protein yield of rDen 1 
EDIII and rDen 4 EDIII proteins after fed-batch process was 161 and 196 mg/l. The 
successful production of these EDIII proteins of dengue virus 1, 2, 3 and 4 in fermentor with 
a high yield was initiated to foster further applications and research with dengue diagnostics 
and vaccines. The  envelope domain III protein, that plays an important role in host receptor 
interaction has  become  an  attractive  candidate,  because  of  the  ease  of producing small 
molecules which results in higher yields. In the present study we could successfully 
developed high yield and scalable production process to produce EDIII proteins of all 
serotypes of dengue virus. 
To test the diagnostic potential of tetravalent EDIII antigen, the ELISA reactivity of a 
physical mixture of the four EDIII antigens was compared with commercial test using a panel 
of 40 human sera. A recently reported comparative analysis of several commercial dengue 
antibody ELISAs has shown that most of these suffer from low specificity (Hunsperger et al., 
2009). Therefore, there is a genuine need for a promising test system to detect virus dengue 
infection. To address the issue of false positives, we included in our study a collection of 20 
healthy sera. All these sera were scored as negative samples in both IgM and IgG ELISAs 
using tetravalent EDIII antigen. The level of observed specificity may stem from the EDIII 
epitopes predominantly recognizing the dengue virus complex, thereby reducing cross 
reactivity from antibodies elicited by other non-dengue virus pathogens. In comparison with 
commercial test used in this study, the in-house ELISA showed 100% specificity, more than 
95% accordance and 80% sensitivity. The envelope domain III protein is particularly an 
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important antigen for vaccine development, as it contains multiple serotype specific 
conformation dependent neutralizing epitopes and host cell receptor recognition site 
(Guzman et al., 2010). Increase in the production of EDIII proteins for application in 
diagnostic use as well as for further vaccine studies was necessary. Process development for 
high yield production as described in this report, made its application more feasible. Further, 
the use of tetravalent EDIII protein as an antigen in in-house ELISA resulted in good 
agreement with the findings of commercial capture ELISAs. These results show that the 
product has a promising potential for its use in diagnosis of dengue with comparable 
sensitivity and specificity.  
9.5 CONCLUSIONS 
 We have developed laboratory scale batch and fed-batch fermentation process for 
high yield production of recombinant dengue virus type 1, 2 and 4 envelope domain III 
protein from E. coli. Pilot scale fermentation process was also developed to produce rDen 2 
EDIII protein. A single step affinity chromatographic puriﬁcation was used to purify these 
proteins. Further pilot scale affinity purification was also developed for rDen 2 EDIII protein 
purification. Our  strategy  of  using  a  recombinant  protein  will  obviate  time-consuming  
native  antigen  preparation and  the  associated  biohazard  risk. The sensitivity and 
specificity of tetravalent EDIII protein in detecting antibodies from dengue infected patients 
render a hope that it may be a good candidate for the  development  of  inexpensive  dengue  
diagnostic  tests.  The EDIII based ELISAs may be useful in epidemiological surveillance 
and vaccine efficacy trials. We believe that our approach of producing all four EDIIIs to 
make a tetravalent recombinant antigen has the potential to lead to the development of an 
ideal dengue diagnostic test suitable for use, particularly, in the resource-poor regions of 
dengue endemicity around the globe. This study could also be valuable for the development 
of tetravalent subunit vaccine for prevention of dengue infections. A similar strategy could 
lead to the high yield and scalable production of recombinant envelope domain III proteins of 
other related viruses.  Since the expression system uses E. coli as the heterologous host, the 
process can be employed for inexpensive scale-up.   
 
*** 
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10.1 INTRODUCTION 
 Recent developments in bioprocess engineering involve large scale production of 
recombinant proteins. Now a days demand for recombinant proteins has increased because 
they are being used in therapeutic, prophylactic and diagnostic purposes. The key component 
of the commercial success of any biopharmaceutical product is the ability to achieve large-
scale production. The present challenges for viral diagnostic and vaccine production include 
the need for scale up, minimization of biohazard risk and production costs. The aim of 
bioprocess engineering research is the cost effective production of desired recombinant 
protein by maximizing the productivity. The scale up process of recombinant viral proteins 
production may be performed by replacing commonly used shake flasks to lab scale and pilot 
scale fermentations. Recombinant protein purification using minimum possible steps is 
crucial to meet the required level of purity with low cost. Thus in the present study, lab and 
pilot scale production, refolding and purification as well as diagnostic and prophylactic 
potential has been studied using recombinant envelope domain III proteins of JE and dengue 
viruses. Dengue fever, a mosquito-borne viral disease, has become a major worldwide public 
health problem, with a dramatic expansion in recent decades. Similarly, Japanese encephalitis 
(JE) is a major public health problem in Southeast Asia and Western pacific including India. 
Due to unavailability of effective vaccine or therapeutics, early diagnosis plays a crucial role 
in patient management. Although early efforts to develop dengue and JE vaccines or 
diagnostics have focused on conventional approaches, recent approaches focus 
predominantly on recombinant strategies. The major envelope (E) protein of dengue and JE 
viruses is considered a lead sub-unit vaccine and diagnostic candidate and virtually all 
recombinant dengue and JE vaccine approaches are focused on it. Domain III (DIII) of the 
envelope protein (E) has been identified as the critical region from the perspective of 
diagnostic and vaccine development. Immunization of animals with EDIII proteins has been 
shown to elicit neutralizing antibodies to dengue and JE viruses. Studies also showed the 
diagnostic potential of nonstructural 1 (NS1) protein of dengue and JE viruses. Recent 
developments and success in recombinant subunit protein vaccine for viral diseases like 
Hepatitis B, opened new opportunities in dengue and JE vaccine research. Keeping in view 
of the present scenario of severity and spread of dengue fever and Japanese encephalitis, 
studies on process development for high yield scalable production and evaluation of new 
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candidate recombinant dengue and JE antigens for possible diagnostics and vaccine 
development is the need of the hour. Therefore, in the current research work we intend to 
produce EDIII protein of dengue and JE viruses at large scale and evaluate the diagnostic 
potential and immunogenicity. 
10.2 SUMMARY AND CONCLUSIONS 
 In this work, production, purification and characterization of recombinant envelope 
domain III protein of JE and dengue viruses has been studied. The objective of the present 
work is to develop high yield and scalable production process for recombinant dengue and 
Japanese encephalitis envelope domain III proteins in E. coli, purification process to achieve 
high purity and biologically active protein as well as their characterization for use as 
diagnostic reagent in enzyme linked immunosorbent assay (ELISA) and possible vaccine 
candidate molecule. Expression of EDIII and NS1 proteins of JE and EDIII proteins of 
dengue viruses was carried out in recombinant E. coli. Development of cost effective and 
simple culture media as well as appropriate culture conditions is generally favorable for large 
scale production of recombinant proteins. Optimization of culture media was carried out for 
enhanced production of EDIII and NS1 protein in E. coli. Laboratory scale batch 
fermentation process in E. coli was developed using optimized media and culture conditions. 
Furthermore, fed-batch fermentation process was also developed in optimized medium. For 
diagnostic studies, the protein was purified under denaturing conditions using affinity 
chromatography. The affinity chromatography purified protein was used as an antigen to 
develop enzyme linked immunosorbent assay (ELISA) to detect antibodies in infected serum 
samples. In order to take this vaccine candidate for further studies, recombinant EDIII 
protein was produced employing a pilot scale fermentation process. A three-step purification 
process comprising of on-column refolding with affinity chromatography, ion-exchange 
chromatography (IEX) based on salt, and IEX based on pH was developed. Biological 
function of the refolded and purified EDIII protein was confirmed by their ability to generate 
EDIII-specific antibodies in mice that could neutralize the virus. These findings suggest that 
recombinant EDIII protein is highly immunogenic and elicit high-titer neutralizing 
antibodies. These results establish the application of these proteins to be used for the 
diagnosis of JE and Dengue virus infection or for further studies in vaccine development. 
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This process may also be suitable for the high-yield production of other recombinant viral 
proteins.  
 Following are the brief summary of the conclusions made in the respective chapters. 
10.2.1 Production of rJEV EDIII protein by batch and fed-batch fermentation as well as 
evaluation of its diagnostic potential 
 The Japanese encephalitis virus envelope domain III gene was cloned into pET30a+ 
and transformed into BL21 (DE3) cells. The cells upon induction with 1 mM IPTG expressed 
a recombinant protein with a desired molecular weight of about 13 kDa rJEV EDIII protein. 
Increase in the production of rJEV EDIII protein for application in diagnostic studies was 
necessary. In the shake flask culture, the final cell density and cell concentration was found 
to depend upon the media used. Super broth medium achieved final dry cell weight about 
2.55 g/l. However, LB medium produced 1.30 g/l dry cell weight. For maximizing the 
production, the E. coli cells expressing rJEV EDIII protein were grown in a batch and fed-
batch cultivation process. Production of the maximum amount of rJEV EDIII protein was 
attained after 4 h induction with 1 mM IPTG. The final dry cell weight of about 36.45 g/l was 
attained at ~14 h of cultivation in fed batch mode. In batch cultivation with super broth 
medium, the dry cell weight at induction and harvest was 2.18 g/l and 4.16 g/l respectively. 
From SDS-PAGE, the recombinant protein was found associated with the insoluble inclusion 
body (IBs) fraction. IBs were harvested and purified from the lysed cell mass and solubilized 
in 8 M urea. The protein was purified by Ni based affinity chromatography under denaturing 
conditions. The SDS-PAGE gel analysis showed that more than 95% purity has been 
achieved. The final yield of rJEV EDIII protein was ~910 mg/l, which was increased after 
fed-batch cultivation to about more than thirty six times in comparison with commonly used 
shake flask culture with LB medium. This protein was subjected to Western blot assay and 
revealed that the JEV positive serum sample reacted with rJEV EDIII protein. Evaluation of 
rJEV EDIII protein by in-house ELISA was carried out to develop detection system for 
Japanese encephalitis. Comparison of the in-house ELISA using both commercial assays for 
detection of IgM antibodies to JE revealed comparable sensitivities, specificities and overall 
agreements. These results show that the product has a promising potential for its use in 
diagnosis of JE both in laboratory and field condition with comparable sensitivity and 
specificity. The fed-batch cultivation strategy employed in this study is probably one of the 
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cost-effective means to enhance cell mass and proteins production. Large quantity of 
antigenically active recombinant protein, produced by these methods may possibly be used 
for diagnosis as well as for further studies of immunoprophylaxis in JE virus infection.  
10.2.2 Development of a pilot scale production process for rJEV EDIII protein and 
characterization for its vaccine potential 
 To conduct vaccine studies with rJEV EDIII antigen, large amount of pure, refolded 
and biologically active protein was required. Pilot scale fermentations were carried out to 
produce large amounts of biomass for vaccine studies using modified SB medium. This 
fermentation process continued for nine and half hours, which comprised of the pre-induction 
(five and half hour) and post induction (four hour) phase. After fermentation dry cell weight 
and OD600 reached a final value of 6.31 g/l and 19.80 respectively. The DCW at induction 
was 2.70 g/l. The pilot scale fermentation yielded approximately 2 kg cell paste. 
Recombinant JEV EDIII protein was refolded by on-column refolding protocol in the 
presence of glycerol. Three step purification processes comprising of affinity 
chromatography, ion-exchange chromatography (IEX) based on salt and IEX based on pH 
was developed. Processing  of  biomass  from   pilot scale batch  fermentation  yielded  ~124 
mg  of  highly  pure, refolded rJEV EDIII protein from 100 g wet biomass. Pilot scale 
produced and purified rJEV EDIII protein was characterized for its purity and reactivity 
using SDS-PAGE and Western blot analysis respectively. SDS-PAGE analysis of refolded 
and IEX purified rJEV EDIII protein showed greater than 98% purity. The western blot with 
hyper immune sera raised in mice revealed that the sera reacted with rJEV EDIII protein and 
confirmed its usefulness. Refolded, purified and characterized rJEV EDIII protein was 
formulated with FCA adjuvant and used to immunize mice. Sera collected from mice were 
serially diluted and tested for recognition of rJEV EDIII protein by ELISA. The rJEV EDIII 
antigen specific antibody titer was found to be more than 2, 56,000. The result shows that 
rJEV EDIII protein is able to elicit EDIII-specific antibody responses. The neutralization 
effect of polyclonal antibodies raised against rJEV EDIII protein on the JE virus was 
evaluated by PRNT in Vero cells. Complete neutralization of JE virus by anti-EDIII 
antibodies was observed up to a dilution of around 1:16 and high neutralization effect 
remained up to a dilution of 1:64. These ﬁndings suggest that rJEV EDIII protein in 
combination with compatible adjuvant is highly immunogenic and can elicit high titer 
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neutralizing antibodies, which proves that pilot scale produced, refolded and purified rJEV 
EDIII protein can be a potential vaccine candidate.  
10.2.3 Production, purification and diagnostic potential of rJEV NS1 protein  
 The JEV NS1 coding sequence was cloned into pQE30UA and, transformation of the 
E. coli SG13009 strain was carried out. The expressed proteins, following 4 h incubation in 
the presence of 1 mM IPTG, were monitored by SDS-PAGE. These protein bands with 
molecular mass of about 44 kDa in the insoluble protein extracts of the recombinant strain 
corresponded to the predicted mass of JEV NS1 protein. The appropriate medium for rJEV 
NS1 protein production was analysed by using shake flask experiments. Maximum protein 
yield was obtained in modified SB medium (2.14 g/l) followed by super broth medium (1.77 
g/l). The development of a batch and fed-batch process for high yield production of rJEV 
NS1 protein is required for further studies as a diagnostic reagent or prophylactic purpose. 
Batch cultivation with modified SB medium (6.25 g/l) resulted in more DCW in comparison 
with SB medium (4.30 g/l). For further increasing the production of rJEV NS1 protein per 
unit volume, fed-batch cultivation using modified SB medium was carried out. The final 
DCW of about 17.78 g/l was obtained at ~13 h of growth in fed-batch mode. In an effort to 
obtain target protein in host E. coli strain, IBs formation is still considered as a convenient 
and effective way in recombinant protein production. After cell disruption and centrifugation, 
IBs were purified. The IBs were solubilized and purified by affinity chromatography under 
denaturing conditions. From SDS-PAGE profile of protein, more than 90% purity was found 
to be achieved. Improvement in product yield of more than eight times for fed-batch process 
as compared to shake flask culture was achieved using modified SB medium. The final rJEV 
NS1 protein yield after fed-batch cultivation was ~142.16 mg/l. The purified rJEV NS1 
protein was tested with mice sera raised against rJEV NS1 protein using Western blot. This 
revealed that the rJEV NS1 protein could react with anti-JEV NS1 antibody. The usefulness 
of purified rJEV NS1 protein for the detection of anti-JEV IgM antibodies in human sera and 
CSF samples was carried out by in-house developed ELISA. The use of this protein as an 
antigen in ELISA avoids costly and tedious production of viral antigen as well as the inherent 
biosafety issues. In this study, the high cell density fed-batch cultivation was adopted to 
increase the protein yield.  A simple, one step puriﬁcation strategy involving metal afﬁnity 
chromatography was devised to produce rJEV NS1 protein with high purity. The purified 
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rJEV NS1 protein thus produced has a potential application for detection of anti-JEV IgM 
antibody. This approach of creating recombinant antigens coupled to over-expression in E. 
coli and simple purification offers a promising alternative option to JE diagnosis with the 
potential to circumvent the drawbacks of the whole virus antigen based assays.  
10.2.4 Production of rDen 3 EDIII protein by batch and fed-batch batch fermentation as 
well as evaluation of its diagnostic potential  
 To produce rDen 3 EDIII protein in E. coli, EDIII gene was cloned into pET30a+ and 
transformed into BLR (DE3) cells. The cells upon induction with IPTG expressed a 
recombinant protein with a desired molecular weight of 12 kDa protein. It was found that 1 
mM IPTG and 4 h of post induction time were optimal for the highest expression of this 
protein. The different culture media resulted in different final OD value and dry cell weight 
(DCW). Media optimization using batch cultivations resulted in the DCW about 2.10, 2.96 
and 4.50 g/l in LB, SOB and SB medium respectively. Further the recombinant cells were 
cultivated in a fed-batch mode using optimized medium. The DCW at induction and harvest 
was 15.10 g/l
 
and 22.80 g/l respectively. The final DCW after fed-batch process was found to 
increase more than seventeen times when compared with that of shake flask culture with LB 
medium and about nine times more with SB medium. From the localization experiments it 
was inferred that the recombinant proteins were found associated with the insoluble inclusion 
body fraction, hence the recombinant proteins were purified under denaturing conditions by 
Ni-NTA affinity chromatography. The batch cultivation yielded 176 mg/l of rDen 3 EDIII 
protein using optimized medium. The final rDen 3 EDIII protein yield after fed-batch 
cultivation was 649.24 mg/l. From SDS-PAGE profile of protein, more than 95% purity was 
found to be achieved. The result of Western blot analysis clearly establishes the use of this 
protein in the sero-diagnosis of dengue infection. The purified rDen 3 EDIII protein was used 
for detection of anti-dengue virus antibodies in human sera. A total of 90 serum samples 
tested for detection of anti-dengue virus IgM and IgG antibodies by both in-house ELISA 
and Pan-Bio IC test. Agreement, sensitivity and specificity of in-house test with reference to 
Pan-Bio rapid IC test were 98%, 98% and 100% for detection of anti-dengue virus IgM, and 
97%, 100% and 94% for anti-dengue virus IgG antibodies respectively. Large quantity of 
antigenically active recombinant protein, produced by these methods may possibly be used 
for diagnosis as well as for further studies of immunoprophylaxis in dengue virus infection.  
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10.2.5 Development of a pilot scale production process for rDen 3 EDIII protein and 
characterization for its vaccine potential  
 Increase in the production to achieve large biomass as well as refolding with further 
purification to achieve high purity of rDen 3 EDIII protein is required to conduct vaccine 
studies. Although lab scale production of rDen 3 EDIII protein yielded significant protein 
levels, the potential requirement for this protein in larger quantity led to its production in 
pilot scale fermentor. The pilot scale batch fermentation process for production of rDen 3 
EDIII protein was carried out using modified SB medium. This fermentation process 
continued for nine and half hours, comprising the pre-induction (five and half hour) and post-
induction (four hour) phase. The DCW and OD600 increased continuously and reached a final 
value of 6.82 g/l and 21.15 respectively. We  developed  a puriﬁcation  process  for  this 
protein to obtain a high quality  protein  suitable  for  development of human  dengue vaccine 
studies.  The immobilized  metal afﬁnity  chromatography with simultaneous refolding  and  
cation exchange chromatography based on salt followed  by  pH   was  used  to  obtain highly  
pure  rDen 3 EDIII protein.  Processing  of  biomass  from   batch  fermentation  yielded  35 
mg  of  highly  pure, refolded rDen 3 EDIII protein per liter culture. To investigate whether 
the produced recombinant dengue protein could induce an antibody response specific for the 
rDen 3 EDIII protein, a group of mice were immunized with refolded and purified protein 
(25 g protein/dose) formulated with FCA adjuvant.  Sera were collected prior to start of 
immunization and after final immunization from all mice. Mice sera were tested for 
recognition of rDen 3 EDIII protein by ELISA. Formulations of rDen 3 EDIII protein with 
FCA were highly immunogenic and yielded about 5,12,000 ELISA titers. The neutralization 
effects of polyclonal antibodies raised against rDen 3 EDIII proteins on the dengue virus type 
3 was evaluated by PRNT in LLC-MK2 cells. Complete neutralization of Dengue virus type 
3 by anti-EDIII antibodies was observed up to a dilution of around 1:16 and high 
neutralization effect remained up to a dilution of 1:32. These results established the potential 
of pilot scale produced, refolded and purified rDen 3 EDIII protein in dengue vaccine 
development.  
10.2.6 Process development for production of rDen 1, 2 and 4 EDIII protein and 
evaluation of diagnostic potential of tetravalent rDen EDIII protein. 
 To develop diagnostic tests or prophylactic for all dengue virus serotypes, production 
of EDIII protein of all dengue viruses viz. dengue virus type 1-4 is necessary. The rDen 1, 2 
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and 4 EDIII gene was cloned into pET30a+ and transformed into BLR (DE3) cells. The cells 
upon induction with IPTG expressed a recombinant protein with a desired molecular weight 
of ~11.9 kDa rDen 1 EDIII, ~11.7 kDa rDen 2 EDIII and ~11.6 kDa rDen 4 EDIII proteins. 
From the localization experiments it was inferred that the recombinant proteins were found 
associated with the insoluble inclusion body fraction, hence the recombinant proteins were 
purified under denaturing conditions. Recombinant protein production in a laboratory scale is 
generally performed using complex medium such as LB. However, for producing protein in 
bioreactor, trials with different media are necessary. High-cell densities were attained with 
medium enriched in yeast extract and glycerol. For maximizing the volumetric production, 
the E. coli cells expressing EDIII proteins were grown in a fed-batch cultivation process. 
Shake flask culture, laboratory scale batch and fed-batch fermentation process was developed 
for dengue virus type 1, 2 and 4 EDIII protein using optimized medium. Further pilot scale 
batch fermentation was also developed for a dengue virus type 2 domain III protein in 
optimized medium. After cell disruption, IBs were harvested and purified from the lysed cell 
mass and solubilized in 8M urea. The proteins were purified by immobilized metal affinity 
chromatography under denaturing conditions. The SDS-PAGE gel analysis showed that more 
than 95% purity has been achieved. Reactivity of these proteins was also confirmed using 
Western blot assay. The final protein yield was 116, 331, 287 and 1040 mg/l
 
after shake flask 
culture, lab scale and pilot scale batch process and lab scale fed-batch process respectively 
for rDen 2 EDIII protein. The final protein yield was 161 and 196 mg/l for rDen 1 EDIII and 
rDen 4 EDIII protein respectively after fed-batch process. To detect any of the dengue virus 
serotype 1-4, mixture of envelope domain III proteins of all serotypes was used as an antigen 
in in-house ELISA to develop diagnostic assay. Comparison of the in-house ELISA using 
this protein with Pan-Bio IgM and IgG capture ELISA for detection of IgM and IgG 
antibodies to dengue virus revealed 80%, 90% sensitivities and 100%, 100% specificities 
respectively. The EDIII based ELISAs may be useful in epidemiological surveillance and 
vaccine efficacy trials. 
 The conclusions and recommendations of the present study are  
 1. We have produced and purified biologically functional recombinant envelope 
domain III protein of the JE and Dengue viruses with high yields. A similar 
strategy could lead to the production of envelope domain III proteins of other 
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related viruses. Since the expression system uses E. coli as the heterologous 
host, the process is amenable to inexpensive scale-up. This could be valuable 
for the development of sub-unit vaccine candidates for prevention of JE and 
dengue virus infections. 
 2. The composition of media affected the yield of envelope domain III and NS1 
protein production which made its application more feasible. Further batch 
fermentation process using optimized medium resulted in better yield in 
comparison to shake flask culture.   
 3. The fed-batch fermentation strategy employed in this work is probably one of 
the cost effective means to enhance cell mass and protein production. Taking 
advantage of high yields obtained by fed batch cultivation, large amount of 
protein was produced. 
 4. Pilot scale fermentation process was developed for envelope domain III 
proteins to produce large amount of biomass for vaccine studies. 
 5. Laboratory and pilot scale purification process developed to achieve high 
purity of proteins suitable for diagnostic and vaccine studies. Single step 
affinity chromatography used for that protein, used as diagnostic antigens and 
three step purification strategies, for that protein, used for vaccine studies. 
 6. Further, the use of envelope domain III proteins of JE and Dengue virus and 
NS1 protein of JE virus as an antigen in microwell plate and dipstick ELISA 
resulted in excellent agreement with the findings of commercial tests. These 
results show that the product has a promising potential for its use in diagnosis 
of JE and dengue both in laboratory and field conditions. 
 7. For vaccine studies, envelope domain III proteins expressed in E. coli were 
successfully refolded in vitro conditions. Characterizations of refolded 
proteins were carried out to demonstrate the biological activity of the protein.  
 8. The high neutralizing antibody titers observed in mice immunized with the 
ED III proteins of JE and dengue virus indicate that the recombinant EDIII 
protein deserves further study as a potential subunit JE and Dengue vaccine 
candidate. 
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 9. Envelope domain III proteins formulated with FCA adjuvant was found to be 
highly immunogenic yielding high titers of neutralizing antibodies.  
To summarize, the results of the present study has contributed to the greater 
understanding of the high yield production of JE and Dengue virus EDIII as well as JEV NS1 
protein in E. coli. The large scale fermentation and purification strategy may be valuable for 
developing inexpensive diagnostic test systems and vaccines. Further the ability of envelope 
domain III protein to induce high titers of neutralizing antibodies with adjuvant pave the way 
for development of a Japanese encephalitis and dengue vaccine in future. The similar strategy 
could open up the avenues for development of diagnostic/prophylactic for other related viral 
disease. 
10.3 FUTURE SCOPE OF THE WORK 
 From the above results it can be concluded that envelope domain III proteins 
produced at large scale has potential for the use as a diagnostic agent for dengue and 
Japanese encephalitis. Further studies are required to fully establish the envelope domain III 
proteins as a JE and dengue vaccine candidate for human use. The followings are the 
recommendations for the future work. 
 Evaluation of recombinant JEV and tetravalent dengue virus 1-4 envelope 
domain III and JEV NS1 proteins based ELISA with large number of 
suspected serum/ CSF samples in field conditions. 
 Development of rapid immunochromatography (IC) test for JE and dengue 
using these recombinant proteins. 
 Studies on vaccine potential of tetravalent envelope domain III protein of 
dengue virus serotype 1-4 and JE virus in monkey model. 
 
*** 
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